Prognostic Factors for Overall Survival in Patients With Treated With Vascular Endothelial Growth Factor–Ta Multicenter Study

Journal of Clinical Oncology 27, 5794-5799 DOI: 10.1200/jco.2008.21.4809

Citation Report

#	Article	IF	CITATIONS
1	Targeted therapy for advanced renal cell carcinoma. The Cochrane Library, 2011, 2011, CD006017.	2.8	64
2	Deep Brain Stimulation Improves Performance of Complex Instrumental Paradigms. European Neurology, 2008, 60, 32-36.	1.4	3
3	Prognostic factors for cases with metastatic renal cell carcinoma in the era of targeted medicine. International Journal of Urology, 2009, 16, 855-861.	1.0	5
5	Factors affecting outcome in renal cell carcinoma. Current Opinion in Urology, 2010, 20, 355-360.	1.8	7
6	Serum IgG against Candida predict survival in patients with metastatic renal cell carcinoma. Cancer Immunology, Immunotherapy, 2010, 59, 1141-1147.	4.2	2
7	Prognostic factors in renal cell carcinoma. World Journal of Urology, 2010, 28, 319-327.	2.2	155
8	Defining risk status in the first-line treatment of metastatic renal cell carcinoma. Journal of Cancer Research and Clinical Oncology, 2010, 136, 961-968.	2.5	6
9	Perspectives in drug development for metastatic renal cell cancer. Targeted Oncology, 2010, 5, 139-156.	3.6	9
10	Updated recommendations from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma. Cancer and Metastasis Reviews, 2010, 29, 1-10.	5.9	3
11	Vascular endothelial growth factorâ€ŧargeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma. Cancer, 2010, 116, 5219-5225.	4.1	121
12	Pazopanib and anti-VEGF therapy. Research and Reports in Urology, 0, Volume 2, 35-40.	1.0	3
13	VEGF and Pleiotrophin Modulate the Immune Profile of Breast Cancer. Cancers, 2010, 2, 970-988.	3.7	20
14	Rationale for targeted therapies and potential role of pazopanib in advanced renal cell carcinoma. Biologics: Targets and Therapy, 2010, 4, 187.	3.2	2
15	Management of metastatic renal cell carcinoma in patients with poor prognosis. Cancer Management and Research, 2010, , 123.	1.9	5
16	Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2010, 21, v137-v139.	1.2	85
17	Breaking through a Plateau in Renal Cell Carcinoma Therapeutics: Development and Incorporation of Biomarkers. Molecular Cancer Therapeutics, 2010, 9, 3115-3125.	4.1	24
18	Review: Updates on novel therapies for metastatic renal cell carcinoma. Therapeutic Advances in Medical Oncology, 2010, 2, 209-219.	3.2	21
19	Another Step Toward the Cure of Metastatic Renal Cell Carcinoma?. Journal of Clinical Oncology, 2010, 28, 5017-5019.	1.6	14

TATION REDO

#	Article	IF	CITATIONS
20	Bevacizumab for metastatic renal cell carcinoma: a monoclonal antibody in a sea of small molecules. Expert Opinion on Biological Therapy, 2010, 10, 1517-1520.	3.1	2
23	Clinical Outcome in Metastatic Renal Cell Carcinoma Patients After Failure of Initial Vascular Endothelial Growth Factor-Targeted Therapy. Urology, 2010, 76, 430-434.	1.0	75
24	Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncology, The, 2010, 11, 1172-1183.	10.7	290
25	Long-term management of patients with metastatic renal cell carcinoma on targeted agents. Expert Review of Anticancer Therapy, 2010, 10, 1883-1889.	2.4	9
26	Potential of imaging biomarkers for characterization of renal masses. Expert Review of Anticancer Therapy, 2010, 10, 781-786.	2.4	3
27	Laparoscopic Adrenalectomy for Metachronous Metastases After Ipsilateral Nephrectomy for Renal-Cell Carcinoma. Journal of Endourology, 2011, 25, 1323-1327.	2.1	13
28	The Value of Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma in the Era of Targeted Therapy. Journal of Urology, 2011, 185, 54-59.	0.4	65
29	Metastasectomy After Targeted Therapy in Patients With Advanced Renal Cell Carcinoma. Journal of Urology, 2011, 185, 439-444.	0.4	113
30	The Impact of Cytoreductive Nephrectomy on Survival of Patients With Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor Targeted Therapy. Journal of Urology, 2011, 185, 60-66.	0.4	322
31	Systemic Therapies for Metastatic Renal Cell Carcinoma in Older Adults. Drugs and Aging, 2011, 28, 635-649.	2.7	16
32	The Role of Surgery in Advanced Renal Cell Carcinoma: Cytoreductive Nephrectomy and Metastasectomy. Hematology/Oncology Clinics of North America, 2011, 25, 753-764.	2.2	22
33	Future Directions in Renal Cell Carcinoma: 2011 and Beyond. Hematology/Oncology Clinics of North America, 2011, 25, 917-935.	2.2	18
34	Clinical and Molecular Prognostic Factors in Renal Cell Carcinoma: What We Know So Far. Hematology/Oncology Clinics of North America, 2011, 25, 871-891.	2.2	27
35	Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: A retrospective examination. European Journal of Cancer, 2011, 47, 1955-1961.	2.8	111
36	Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncology, The, 2011, 12, 1143-1150.	10.7	217
37	Early Primary Tumor Size Reduction Is an Independent Predictor of Improved Overall Survival in Metastatic Renal Cell Carcinoma Patients Treated With Sunitinib. European Urology, 2011, 60, 1273-1279.	1.9	69
38	Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet, The, 2011, 378, 1931-1939.	13.7	1,663
39	Low initial PSA levels links to lower risk of prostate cancer death. British Journal of Hospital Medicine (London, England: 2005), 2011, 72, 190-190.	0.5	0

#	Article	IF	CITATIONS
40	Targeted therapy for metastatic renal cell cancer in older patients. British Journal of Hospital Medicine (London, England: 2005), 2011, 72, 190-190.	0.5	0
41	Biomarkers of Renal Cancer. , 2011, , 313-350.		4
42	Critical appraisal of pazopanib as treatment for patients with advanced metastatic renal cell carcinoma. Cancer Management and Research, 2011, , 273.	1.9	5
43	Renal Cell Cancer: What Can We Learn from Pre-Operative Studies?. Frontiers in Oncology, 2011, 1, 51.	2.8	Ο
44	Surgery and Target Agents for Renal Cell Carcinoma Treatment: The Path between Proper Interaction. Urologia, 2011, 78, 9-15.	0.7	0
46	Update on targeted therapies for clear cell renal cell carcinoma. Current Opinion in Oncology, 2011, 23, 283-289.	2.4	56
47	A new patientâ€focused approach to the treatment of metastatic renal cell carcinoma: establishing customized treatment options. BJU International, 2011, 107, 1190-1199.	2.5	21
48	Role of preoperative platelet level in clinical and pathological outcomes after surgery for renal cortical malignancies. BJU International, 2011, 108, 73-79.	2.5	9
49	Management of metastatic renal cell carcinoma in the era of targeted therapies. Internal Medicine Journal, 2011, 41, 594-605.	0.8	6
50	Phaseâ€II trial of combination treatment of interferonâ€Î±, cimetidine, cyclooxygenaseâ€2 inhibitor and reninâ€angiotensinâ€system inhibitor (lâ€CCA therapy) for advanced renal cell carcinoma. Cancer Science, 2011, 102, 137-143.	3.9	33
51	Biomarkers to predict response to sunitinib therapy and prognosis in metastatic renal cell cancer. Cancer Science, 2011, 102, 1949-1957.	3.9	37
52	Sunitinib and other targeted therapies for renal cell carcinoma. British Journal of Cancer, 2011, 104, 741-745.	6.4	47
53	Prognostic Factors and Predictive Models in Renal Cell Carcinoma: A Contemporary Review. European Urology, 2011, 60, 644-661.	1.9	272
54	Sequence Therapy in Patients with Metastatic Renal Cell Carcinoma: Comparison of Common Targeted Treatment Options Following Failure of Receptor Tyrosine Kinase Inhibitors. European Urology, 2011, 60, 1163-1170.	1.9	43
56	Biomarkers in Renal Cell Carcinoma: What Next?. Current Oncology Reports, 2011, 13, 87-89.	4.0	2
57	The impact of tumor burden characteristics in patients with metastatic renal cell carcinoma treated with sunitinib. Cancer, 2011, 117, 1183-1189.	4.1	23
58	Progressionâ€free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy. Cancer, 2011, 117, 2637-2642.	4.1	74
59	VEGF Inhibitors in Metastatic Renal Cell Carcinoma: Current Therapies and Future Perspectives. Current Clinical Pharmacology, 2011, 6, 164-168.	0.6	16

# 60	ARTICLE Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. Annals of	IF 1.2	Citations
61	Oncology, 2011, 22, 295-300. The role of metastasectomy in metastatic renal cell carcinoma. Nature Reviews Urology, 2011, 8, 180-181.	3.8	20
63	Boning up on prognostic factors in advanced renal cell carcinoma. Annals of Oncology, 2011, 22, 751-753.	1.2	1
64	Kidney cancer: Does hypothyroidism predict clinical outcome?. Nature Reviews Urology, 2011, 8, 10-11.	3.8	4
65	Sequential FDG-PET/CT as a Biomarker of Response to Sunitinib in Metastatic Clear Cell Renal Cancer. Clinical Cancer Research, 2011, 17, 6021-6028.	7.0	123
66	Visceral Fat Area as a New Independent Predictive Factor of Survival in Patients with Metastatic Renal Cell Carcinoma Treated with Antiangiogenic Agents. Oncologist, 2011, 16, 71-81.	3.7	98
67	Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib. Journal of the National Cancer Institute, 2011, 103, 763-773.	6.3	526
68	Impact of Body Composition on Clinical Outcomes in Metastatic Renal Cell Cancer. Oncologist, 2011, 16, 1484-1486.	3.7	15
69	The sequence of cytoreductive nephrectomy: glass half empty or glass half full?. Annals of Oncology, 2011, 22, 1691.	1.2	1
70	Sunitinib for Asian Patients with Advanced Renal Cell Carcinoma: A Comparable Efficacy with Different Toxicity Profiles. Oncology, 2011, 80, 395-405.	1.9	48
71	Tumor Biology and Prognostic Factors in Renal Cell Carcinoma. Oncologist, 2011, 16, 4-13.	3.7	106
72	Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy. Annals of Oncology, 2011, 22, 1048-1053.	1.2	52
73	Prognostic Model for Survival in Patients with Metastatic Renal Cell Carcinoma: Results from the International Kidney Cancer Working Group. Clinical Cancer Research, 2011, 17, 5443-5450.	7.0	164
74	Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies. British Journal of Cancer, 2011, 105, 1635-1639.	6.4	29
75	Pazopanib Efficacy in Renal Cell Carcinoma: Evidence for Predictive Genetic Markers in Angiogenesis-Related and Exposure-Related Genes. Journal of Clinical Oncology, 2011, 29, 2557-2564.	1.6	152
76	Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings. Annals of Oncology, 2011, 22, 1812-1823.	1.2	124
77	Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib. Annals of Oncology, 2011, 22, 794-800.	1.2	116
78	Biomarkers in Advanced Colorectal Cancer: Challenges in Translating Clinical Research into Practice. Cancers, 2011, 3, 1844-1860.	3.7	1

#	Article	IF	CITATIONS
79	Clinical Outcome and Prognostic Factors of Sorafenib in Japanese Patients with Advanced Renal Cell Carcinoma in General Clinical Practice. Japanese Journal of Clinical Oncology, 2011, 41, 1265-1270.	1.3	27
80	Better Late than Early: FDG-PET Imaging in Metastatic Renal Cell Carcinoma. Clinical Cancer Research, 2011, 17, 5841-5843.	7.0	8
81	Optimizing further treatment choices in short- and long-term responders to first-line therapy for patients with advanced renal cell carcinoma. Expert Review of Anticancer Therapy, 2012, 12, 1089-1096.	2.4	5
82	Dissecting responsive phenotypes through cytokine and angiogenic factor analysis. Annals of Oncology, 2012, 23, 6-7.	1.2	49
83	Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinoma. Annals of Oncology, 2012, 23, 2108-2114.	1.2	82
84	Predictive models for the practical management of renal cell carcinoma. Nature Reviews Urology, 2012, 9, 73-84.	3.8	13
85	Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy. Annals of Oncology, 2012, 23, 1549-1555.	1.2	121
86	Selecting patients for cytoreductive nephrectomy in advanced renal cell carcinoma: who and when. Expert Review of Anticancer Therapy, 2012, 12, 787-797.	2.4	11
88	Prognostic factors for survival in patients with metastatic renal cell carcinoma treated with targeted therapies. British Journal of Cancer, 2012, 107, 1227-1232.	6.4	18
89	Association between treatment effects on disease progression end points and overall survival in clinical studies of patients with metastatic renal cell carcinoma. British Journal of Cancer, 2012, 107, 1059-1068.	6.4	33
90	Comparative Efficacy of Sunitinib versus Sorafenib as First-Line Treatment for Patients with Metastatic Renal Cell Carcinoma. Chemotherapy, 2012, 58, 468-474.	1.6	38
91	Observation as a treatment strategy for advanced renal cell carcinoma—a call for prospective validation. Frontiers in Oncology, 2012, 2, 155.	2.8	21
92	Randomized Phase II Trial of Sunitinib on an Intermittent Versus Continuous Dosing Schedule As First-Line Therapy for Advanced Renal Cell Carcinoma. Journal of Clinical Oncology, 2012, 30, 1371-1377.	1.6	254
95	Impact of hyponatremia on survival of patients with metastatic renal cell carcinoma treated with molecular targeted therapy. International Journal of Urology, 2012, 19, 1050-1057.	1.0	27
96	Randomized Study of Autologous Cytokine-Induced Killer Cell Immunotherapy in Metastatic Renal Carcinoma. Clinical Cancer Research, 2012, 18, 1751-1759.	7.0	134
97	Conditional survival in patients treated with vascular endothelial growth factor-targeted therapy for advanced renal cell carcinoma. Journal of Cancer Research and Clinical Oncology, 2012, 138, 1901-1907.	2.5	2
98	Management of Favorable-Risk Patients With Metastatic Renal Cell Carcinoma: When to Start and When to Stop Targeted Therapy. Clinical Genitourinary Cancer, 2012, 10, 213-218.	1.9	9
99	Validation of Serum Amyloid α as an Independent Biomarker for Progression-Free and Overall Survival in Metastatic Renal Cell Cancer Patients. European Urology, 2012, 62, 685-695.	1.9	21

#	Article	IF	CITATIONS
100	A Phase 2 Trial of Sunitinib in Patients with Advanced Non–clear Cell Renal Cell Carcinoma. European Urology, 2012, 62, 1013-1019.	1.9	139
101	The Effect of Sunitinib on Primary Renal Cell Carcinoma and Facilitation of Subsequent Surgery. Journal of Urology, 2012, 187, 1548-1554.	0.4	79
102	Defining an Individualized Treatment Strategy for Metastatic Renal Cancer. Urologic Clinics of North America, 2012, 39, 233-249.	1.8	11
103	Improvement in Overall Survival of Patients with Advanced Renal Cell Carcinoma: Prognostic Factor Trend Analysis from an International Data Set of Clinical Trials. Journal of Urology, 2012, 188, 2095-2100.	0.4	35
104	Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2012, 23, vii65-vii71.	1.2	216
105	De impact van comorbiditeit op complicaties na (partiële) tumornefrectomie. Tijdschrift Voor Urologie, 2012, 2, 122-128.	0.1	0
106	Concepts in Advanced Renal Carcinoma. Seminars in Oncology Nursing, 2012, 28, 170-179.	1.5	6
107	Evaluation of patients with metastatic renal cell carcinoma after failure of first-line treatment. Cancer and Metastasis Reviews, 2012, 31, 3-9.	5.9	7
108	Constitutional genetic variants as predictors of antiangiogenic therapy outcome in renal cell carcinoma. Pharmacogenomics, 2012, 13, 1621-1633.	1.3	11
109	Biomarkers: the next therapeutic hurdle in metastatic renal cell carcinoma. British Journal of Cancer, 2012, 107, 1009-1016.	6.4	31
110	Brain metastases from renal cell carcinoma. Should we change the current standard?. Cancer Treatment Reviews, 2012, 38, 249-257.	7.7	27
111	The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma. European Journal of Cancer, 2012, 48, 202-208.	2.8	170
112	Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma. European Journal of Cancer, 2012, 48, 1023-1030.	2.8	46
113	Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma. European Journal of Cancer, 2012, 48, 1031-1037.	2.8	49
114	Current status of pharmacotherapy against metastatic renal cell carcinoma in Japan. International Journal of Urology, 2012, 19, 284-295.	1.0	17
115	Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma. BJU International, 2012, 110, 1747-1753.	2.5	60
116	Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Lancet Oncology, The, 2012, 13, 827-837.	10.7	240
117	Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. Lancet Oncology, The, 2012, 13, 927-935.	10.7	112

	CHARON		
#	Article	IF	CITATIONS
118	Difficulty in predicting survival in metastatic renal cancer. Lancet Oncology, The, 2012, 13, 859-860.	10.7	9
119	Treatment selection in metastatic renal cell carcinoma: expert consensus. Nature Reviews Clinical Oncology, 2012, 9, 327-337.	27.6	121
120	Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-line VEGF TKI. Medical Oncology, 2012, 29, 3291-3297.	2.5	40
121	Neoadjuvant and adjuvant treatment of renal cell carcinoma. Expert Review of Anticancer Therapy, 2012, 12, 765-776.	2.4	16
122	New perspectives in the treatment of metastatic renal cell carcinoma. Critical Reviews in Oncology/Hematology, 2012, 84, e16-e23.	4.4	1
124	Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nature Medicine, 2012, 18, 1254-1261.	30.7	721
125	Combination of targeted agents in metastatic renal cell carcinoma. Cancer, 2012, 118, 1744-1746.	4.1	8
126	Cessation of vascular endothelial growth factor–targeted therapy in patients with metastatic renal cell carcinoma. Cancer, 2012, 118, 3277-3282.	4.1	19
127	O ⁶ â€methylguanineâ€DNA methyltransferase (MGMT) promoter methylation and low MGMTâ€encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide. Cancer, 2012, 118, 4545-4554.	4.1	79
128	Circulating Biomarkers in Advanced Renal Cell Carcinoma: Clinical Applications. Current Oncology Reports, 2012, 14, 221-229.	4.0	27
129	Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features. Journal of Cancer Research and Clinical Oncology, 2012, 138, 687-693.	2.5	22
130	Outcome Assessment of Patients With Metastatic Renal Cell Carcinoma Under Systemic Therapy Using Artificial Neural Networks. Clinical Genitourinary Cancer, 2012, 10, 37-42.	1.9	18
131	Sequencing of Agents for Metastatic Renal Cell Carcinoma: Can We Customize Therapy?. European Urology, 2012, 61, 307-316.	1.9	52
132	A Review of Integrated Staging Systems for Renal Cell Carcinoma. European Urology, 2012, 62, 303-314.	1.9	108
133	Biomarkers predicting tumor response and evasion to anti-angiogenic therapy. Biochimica Et Biophysica Acta: Reviews on Cancer, 2012, 1825, 86-100.	7.4	17
134	Câ€reactive protein as a prognostic marker for advanced renal cell carcinoma treated with sunitinib. International Journal of Urology, 2012, 19, 908-913.	1.0	44
135	Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib. BJU International, 2012, 109, 1349-1354.	2.5	20
136	Impact of pathological tumour characteristics in patients with sarcomatoid renal cell carcinoma. BJU International, 2012, 109, 1600-1606.	2.5	76

#	Article	IF	CITATIONS
137	Impact of comorbidity on complications after nephrectomy: use of the Clavien Classification of Surgical Complications. BJU International, 2012, 110, 682-687.	2.5	32
138	Recent advances in the treatment of advanced renal cell carcinoma: towards multidisciplinary personalized care. BJU International, 2012, 110, 1289-1300.	2.5	12
139	The impact of kidney function on the outcome of metastatic renal cell carcinoma patients treated with vascular endothelial growth factorâ€ŧargeted therapy. Cancer, 2012, 118, 365-370.	4.1	21
140	Role of Cytoreductive Nephrectomy in the Era of Targeted Therapy for Renal Cell Carcinoma. Current Urology Reports, 2012, 13, 38-46.	2.2	19
141	Targeted Therapies in Metastatic Renal Cell Carcinoma: Overview of the Past Year. Current Urology Reports, 2012, 13, 16-23.	2.2	17
142	Limited impact of prognostic factors in patients with recurrent glioblastoma multiforme treated with a bevacizumab-based regimen. Journal of Neuro-Oncology, 2013, 114, 191-198.	2.9	29
143	Cabozantinib as a Novel Therapy for Renal Cell Carcinoma. Current Oncology Reports, 2013, 15, 76-82.	4.0	46
144	Prognostic factors of metastatic renal cell carcinoma with extensive sarcomatoid component. Journal of Cancer Research and Clinical Oncology, 2013, 139, 817-827.	2.5	19
145	The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients. Targeted Oncology, 2013, 8, 203-209.	3.6	47
146	Does preoperative platelet count and thrombocytosis play a prognostic role in patients undergoing nephrectomy for renal cell carcinoma? Results of a comprehensive retrospective series. World Journal of Urology, 2013, 31, 1309-1316.	2.2	21
147	Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial. Lancet Oncology, The, 2013, 14, 1233-1242.	10.7	215
148	Does a reasonable treatment approach beyond second-line exist?. European Journal of Cancer, Supplement, 2013, 11, 169-171.	2.2	0
149	Beyond the Maths of Biology: Long-term Spontaneous Tumoral Regression After Sunitinib Withdrawal. Clinical Genitourinary Cancer, 2013, 11, 198-200.	1.9	1
150	Adjuvant Treatment for Resected Renal Cell Carcinoma: Are All Strategies Equally Negative? Potential Implications for Trial Design With Targeted Agents. Clinical Genitourinary Cancer, 2013, 11, 471-476.	1.9	22
151	A prognostic model for metastatic renal-cell carcinoma. Lancet Oncology, The, 2013, 14, 102-103.	10.7	11
152	"Real World―Treatment of Metastatic Renal Cell Carcinoma in a Joint Community-Academic Cohort: Progression-Free Survival Over Three Lines of Therapy. Clinical Genitourinary Cancer, 2013, 11, 441-450.	1.9	29
153	Individualising treatment choices in a crowded treatment algorithm. European Journal of Cancer, Supplement, 2013, 11, 160-168.	2.2	2
154	Utilizing pre-therapy clinical schema and initial CT changes to predict progression-free survival in patients with metastatic renal cell carcinoma on VEGF-targeted therapy: A preliminary analysis. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 1283-1291.	1.6	23

#	Article	IF	CITATIONS
155	Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma. British Journal of Cancer, 2013, 109, 1755-1759.	6.4	79
156	mTOR inhibitors in advanced renal cell carcinomas: From biology to clinical practice. Critical Reviews in Oncology/Hematology, 2013, 88, 42-56.	4.4	19
157	First Experience of Active Surveillance Before Systemic Target Therapy in Patients With Metastatic Renal Cell Carcinoma. Urology, 2013, 82, 118-123.	1.0	24
158	Prognostic Factors of Patients With Metastatic Renal Cell Carcinoma With Removed Metastases: A Multicenter Study of 556 Patients. Urology, 2013, 82, 846-851.	1.0	61
160	Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. Lancet Oncology, The, 2013, 14, 1287-1294.	10.7	357
161	A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG. Annals of Oncology, 2013, 24, 679-687.	1.2	39
162	Emerging antiangiogenics for renal cancer. Expert Opinion on Emerging Drugs, 2013, 18, 495-511.	2.4	15
163	Metastatic non–clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria. Cancer, 2013, 119, 2999-3006.	4.1	189
164	Major response with sorafenib in advanced renal cell carcinoma after 14 years of follow-up. World Journal of Surgical Oncology, 2013, 11, 243.	1.9	4
165	Is the Pretreatment Neutrophil to Lymphocyte Ratio an Important Prognostic Parameter in Patients with Metastatic Renal Cell Carcinoma?. Clinical Genitourinary Cancer, 2013, 11, 141-148.	1.9	41
166	Development of Accurate Models for Individualized Prediction of Survival After Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma. European Urology, 2013, 63, 947-952.	1.9	67
167	Prognostic Factors of Survival for Patients With Metastatic Renal Cell Carcinoma With Brain Metastases Treated With Targeted Therapy: Results From the International Metastatic Renal Cell Carcinoma Database Consortium. Clinical Genitourinary Cancer, 2013, 11, 311-315.	1.9	64
168	Impact of age on treatment trends and clinical outcome in patients with metastatic renal cell carcinoma. Journal of Geriatric Oncology, 2013, 4, 128-133.	1.0	11
169	External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncology, The, 2013, 14, 141-148.	10.7	808
170	Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: Results from a large patient cohort. European Journal of Cancer, 2013, 49, 2134-2142.	2.8	60
171	A Gap in Disease-Specific Survival Between Younger and Older Adults With De Novo Metastatic Renal Cell Carcinoma: Results of a SEER Database Analysis. Clinical Genitourinary Cancer, 2013, 11, 303-310.	1.9	9
172	A Phase II Study of Bevacizumab and Everolimus as Treatment for Refractory Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2013, 11, 100-106.	1.9	25
173	Quality of Life in Patients With Metastatic Renal Cell Carcinoma: Assessment of Long-Term Survivors. Clinical Genitourinary Cancer, 2013, 11, 149-154.	1.9	14

#	Article	IF	CITATIONS
174	Retrospective Comparison of Triple-sequence Therapies in Metastatic Renal Cell Carcinoma. European Urology, 2013, 64, 62-70.	1.9	23
175	Second line treatment of metastatic renal cell carcinoma: The Institut Gustave Roussy experience with targeted therapies in 251 consecutive patients. European Journal of Cancer, 2013, 49, 1898-1904.	2.8	42
176	Current and future systemic treatments for renal cell carcinoma. Seminars in Cancer Biology, 2013, 23, 38-45.	9.6	100
177	Combination of Zoledronic Acid and Targeted Therapy Is Active But May Induce Osteonecrosis of the Jaw in Patients With Metastatic Renal Cell Carcinoma. Journal of Oral and Maxillofacial Surgery, 2013, 71, 1532-1540.	1.2	57
178	Systemic Treatment Options for Untreated Patients With Metastatic Clear Cell Renal Cancer. Seminars in Oncology, 2013, 40, 436-443.	2.2	20
179	Refining the Use of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma. Seminars in Oncology, 2013, 40, 429-435.	2.2	6
180	Predictive Markers in Advanced Renal Cell Carcinoma. Seminars in Oncology, 2013, 40, 459-464.	2.2	13
181	Sequencing Therapy in Metastatic Renal Cell Cancer. Seminars in Oncology, 2013, 40, 465-471.	2.2	10
182	Platelet volume as a parameter for platelet activation in patients with endometrial cancer. Journal of Obstetrics and Gynaecology, 2013, 33, 301-304.	0.9	32
183	Integrating metastasectomy and stereotactic radiosurgery in the treatment of metastatic renal cell carcinoma. European Journal of Cancer, Supplement, 2013, 11, 192-203.	2.2	4
184	Commentary on "Detailed analysis of morbidity following nephrectomy for renal cell carcinoma in octogenarians.―Berger J, Fardoun T, Brassart E, Capon G, Bigot P, Bernhard JC, Rigaud J, Patard JJ, Descazeaud A, Department of Urology, Dupuytren University Hospital, Limoges, France. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 128-129.	1.6	0
185	Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. Lancet Oncology, The, 2013, 14, 159-167.	10.7	383
187	Clinical outcome in patients receiving systemic therapy for metastatic sarcomatoid renal cell carcinoma: A retrospective analysisâ~†. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 1826-1831.	1.6	19
188	VEGF-targeted therapy: A population-based study.―Harshman LC, Xie W, Bjarnason GA, Knox JJ, MacKenzie M, Wood L, Srinivas S, Vaishampayan UN, Tan MH, Rha SY, Donskov F, Agarwal N, Kollmannsberger C, North S, Rini BI, Heng DY, Choueiri TK, Stanford Cancer Institute, Stanford University School of Medicine, Stanford CA, Urologic Oncology: Seminars and Original	1.6	6
189	Reply from Authors re: Camillo Porta, Chiara Paglino. Experience Gathered from Retrospective Series on Renal Cell Carcinoma Is Useful, But Now It Is Time for a Global Claim for Academically Driven Prospective Studies. Eur Urol 2013;64:71–2. European Urology, 2013, 64, 72-73.	1.9	1
190	The progression free survival-plateau with vascular endothelial growth factor receptor inhibitors – Is there more to come?. European Journal of Cancer, 2013, 49, 2504-2511.	2.8	10
191	Immunomonitoring and prognostic relevance of neutrophils in clinical trials. Seminars in Cancer Biology, 2013, 23, 200-207.	9.6	250
192	New Insights into the Management of Renal Cell Cancer. Oncology, 2013, 84, 22-31.	1.9	16

#	Article	IF	CITATIONS
193	Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib. British Journal of Cancer, 2013, 108, 887-900.	6.4	88
194	Prognostic Factors in Advanced Renal Cell Carcinoma. , 2013, , 249-255.		0
195	Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial. British Journal of Cancer, 2013, 108, 1571-1578.	6.4	56
196	Validation of the pre-treatment neutrophil–lymphocyte ratio as a prognostic factor in a large European cohort of renal cell carcinoma patients. British Journal of Cancer, 2013, 108, 901-907.	6.4	227
197	Response Evaluation Criteria in Solid Tumors Response of the Primary Lesion in Metastatic Renal Cell Carcinomas Treated With Sunitinib: Does the Primary Lesion Have to Be Regarded as a Target Lesion?. Clinical Genitourinary Cancer, 2013, 11, 276-282.	1.9	2
198	Prognostic Models and Factors for Patients with Renal-Cell Carcinoma: A Survey on Their Use Among Urologists. Journal of Endourology, 2013, 27, 790-799.	2.1	3
199	Markers of systemic inflammation predict survival in patients with advanced renal cell cancer. British Journal of Cancer, 2013, 109, 147-153.	6.4	130
200	Changes in peripheral blood immune cells: their prognostic significance in metastatic renal cell carcinoma patients treated with molecular targeted therapy. Medical Oncology, 2013, 30, 556.	2.5	47
201	Management of metastatic renal cell carcinoma patients with poor-risk features: current status and future perspectives. Expert Review of Anticancer Therapy, 2013, 13, 697-709.	2.4	12
202	Optimal Management of Metastatic Renal Cell Carcinoma: Current Status. Drugs, 2013, 73, 427-438.	10.9	95
203	Impact of primary tumour resection on survival of patients with colorectal cancer and synchronous metastases treated by chemotherapy: Results from the multicenter, randomised trial Fédération Francophone de Cancérologie Digestive 9601. European Journal of Cancer, 2013, 49, 90-97.	2.8	94
204	Validation of the MSKCC and Heng Risk Criteria Models for Predicting Survival in Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib. Annals of Surgical Oncology, 2013, 20, 4397-4404.	1.5	34
205	Prognostic impact of pretreatment C-reactive protein for patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. International Journal of Clinical Oncology, 2013, 18, 884-889.	2.2	41
206	Rechallenge with mTOR Inhibitors in Metastatic Renal Cell Carcinoma Patients Who Progressed on Previous mTOR Inhibitor Therapy. Oncology, 2013, 85, 8-13.	1.9	14
208	Renal Cell Carcinoma – How Can We Predict its Outcomes in Clinical Practice?. Acta Chirurgica Latviensis, 2013, 13, 63-70.	0.2	0
209	Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma. British Journal of Cancer, 2013, 108, 2470-2477.	6.4	121
210	Prognostic Factors Associated with the Response to Sunitinib in Patients with Metastatic Renal Cell Carcinoma. Current Oncology, 2013, 20, 546-553.	2.2	12
211	A New Age for Vaccine Therapy in Renal Cell Carcinoma. Cancer Journal (Sudbury, Mass), 2013, 19, 365-370.	2.0	18

#	Article	IF	CITATIONS
212	Targeting the Hepatocyte Growth Factor/c-Met Signaling Pathway in Renal Cell Carcinoma. Cancer Journal (Sudbury, Mass), 2013, 19, 316-323.	2.0	45
213	Phase II trial of everolimus for the treatment of nonclear-cell renal cell carcinoma. Annals of Oncology, 2013, 24, 1026-1031.	1.2	70
214	Chemotherapy in metastatic renal cell carcinoma today? A systematic review. Anti-Cancer Drugs, 2013, 24, 535-554.	1.4	77
215	A Phase II Study of Bevacizumab and High-dose Interleukin-2 in Patients With Metastatic Renal Cell Carcinoma. Journal of Immunotherapy, 2013, 36, 490-495.	2.4	25
216	Management of Advanced Kidney Cancer – Canadian Kidney Cancer Forum Consensus Update. Canadian Urological Association Journal, 2013, 7, 238.	0.6	7
217	Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies. Cancer, 2013, 119, 3377-3384.	4.1	170
218	Characteristics and Clinical Impacts of the Immune Environments in Colorectal and Renal Cell Carcinoma Lung Metastases: Influence of Tumor Origin. Clinical Cancer Research, 2013, 19, 4079-4091.	7.0	301
219	Tumour shrinkage measured with first treatment evaluation under VEGF-targeted therapy as prognostic marker in metastatic renal cell carcinoma (mRCC). British Journal of Cancer, 2013, 109, 2998-3004.	6.4	22
220	Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study. British Journal of Cancer, 2013, 109, 121-130.	6.4	19
221	Development and validation of a prognostic model in patients with metastatic renal cell carcinoma treated with sunitinib: a European collaboration. British Journal of Cancer, 2013, 109, 332-341.	6.4	26
222	Time to recurrence is a significant predictor of cancerâ€specific survival after recurrence in patients with recurrent renal cell carcinoma – results from a comprehensive multiâ€centre database (<scp>CORONA</scp> / <scp>SATURN</scp> â€ <scp>P</scp> roject). BJU International, 2013, 112, 909-916.	2.5	69
223	Clinical Treatment Decisions for Advanced Renal Cell Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 694-697.	4.9	16
224	Prognostic biomarkers for patients with advanced renal cell carcinoma treated with VEGF-targeted tyrosine kinase inhibitors. OncoTargets and Therapy, 2013, 6, 679.	2.0	6
225	Laparoscopic adrenalectomy for metachronous ipsilateral metastasis following nephrectomy for renal cell carcinoma. Wideochirurgia I Inne Techniki Maloinwazyjne, 2013, 3, 221-225.	0.7	5
226	Prise en charge du cancer du rein de stade avancé : Mise à jour 2013 des lignes directrices consensuelles du Forum canadien sur le cancer du rein. Canadian Urological Association Journal, 2013, 7, .	0.6	0
227	Metastatic renal cell carcinoma: update on epidemiology, genetics, and therapeutic modalities. ImmunoTargets and Therapy, 2013, 2, 73.	5.8	28
228	EphA2 protein expression in metastatic renal cell carcinoma treated with VEGF-inhibitors is predictive of patient survival. Journal of Solid Tumors, 2013, 3, .	0.1	0
229	Treating the Two Extremes in Renal Cell Carcinoma: Management of Small Renal Masses and Cytoreductive Nephrectomy in Metastatic Disease. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e214-e221.	3.8	5

#	Article	IF	CITATIONS
230	Surgical management of renal cell carcinoma: Canadian Kidney Cancer Forum Consensus. Canadian Urological Association Journal, 2014, 8, 398.	0.6	28
231	Prognostic factors for overall survival with targeted therapy in Chinese patients with metastatic renal cell carcinoma. Canadian Urological Association Journal, 2014, 8, 821.	0.6	8
232	Predictive role of vascular endothelial growth factor polymorphisms in the survival of renal cell carcinoma patients. Genetics and Molecular Research, 2014, 13, 5011-5017.	0.2	15
233	Optimal first-line and second-line treatments for metastatic renal cell carcinoma: current evidence. International Journal of Nephrology and Renovascular Disease, 2014, 7, 401.	1.8	30
234	Activity and safety of sunitinib in poor risk metastatic renal cell carcinoma patients. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2014, 40, 835-841.	1.5	3
235	Predicting efficacy of sunitinib in metastatic renal cell carcinoma. Current Biomarker Findings, 2014, , 43.	0.4	0
236	Erfolge und Grenzen zielgerichteter Therapien beim Nierenzellkarzinom. Karger Kompass Onkologie, 2014, 1, 66-74.	0.0	0
239	First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC. British Journal of Cancer, 2014, 110, 1917-1922.	6.4	64
240	Anti-VEGF therapy in mRCC: differences between Asian and non-Asian patients. British Journal of Cancer, 2014, 110, 1433-1437.	6.4	18
241	Successes and Limitations of Targeted Therapies in Renal Cell Carcinoma. Progress in Tumor Research, 2014, 41, 98-112.	0.1	8
242	Prognostic factors in patients with advanced renal cell carcinoma treated with VEGF-targeted agents. Expert Review of Anticancer Therapy, 2014, 14, 523-542.	2.4	11
243	First line treatment of metastatic renal cell carcinoma. Cancer Biology and Therapy, 2014, 15, 19-21.	3.4	7
244	Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2014, 25, iii49-iii56.	1.2	1,039
245	Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. Annals of Oncology, 2014, 25, 149-154.	1.2	121
246	Study of the effectiveness of first-line treatment in renal cell carcinoma. Molecular and Clinical Oncology, 2014, 2, 1167-1171.	1.0	1
247	Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib. Acta OncolÃ ³ gica, 2014, 53, 1413-1422.	1.8	30
248	Comparative Effectiveness of Second-Line Targeted Therapies for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis of Real-World Observational Studies. PLoS ONE, 2014, 9, e114264.	2.5	35
249	Cytoreductive nephrectomy: past, present and future. Expert Review of Anticancer Therapy, 2014, 14, 271-277.	2.4	3

#	Article	IF	CITATIONS
250	Clinical implications of body composition assessment by computed tomography in metastatic renal cell carcinoma. Expert Review of Anticancer Therapy, 2014, 14, 279-288.	2.4	16
251	Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting. Future Oncology, 2014, 10, 1741-1750.	2.4	12
252	Pharmacotherapy options for advanced renal cell carcinoma. Expert Opinion on Orphan Drugs, 2014, 2, 643-652.	0.8	0
253	Prognostic impact of baseline serum <scp>C</scp> â€reactive protein in patients with metastatic renal cell carcinoma (<scp>RCC</scp>) treated with sunitinib. BJU International, 2014, 114, 81-89.	2.5	68
254	Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with firstâ€line sunitinib: a medical chart review across ten centers in five European countries. Cancer Medicine, 2014, 3, 1517-1526.	2.8	53
255	Impact of surgery on the prognosis of metastatic renal cell carcinoma with IVC thrombus received TKI therapy. Journal of Surgical Oncology, 2014, 110, 145-150.	1.7	14
256	SEOM clinical guidelines for the treatment of renal cell carcinoma. Clinical and Translational Oncology, 2014, 16, 1043-1050.	2.4	29
257	Current management and future perspectives of metastatic renal cell carcinoma. International Journal of Urology, 2014, 21, 847-855.	1.0	27
258	Management of metastatic kidney cancer in the era of personalized medicine. Critical Reviews in Clinical Laboratory Sciences, 2014, 51, 85-97.	6.1	6
259	Tumor signatures of <i>PTHLH</i> overexpression, high serum calcium, and poor prognosis were observed exclusively in clear cell but not non clear cell renal carcinomas. Cancer Medicine, 2014, 3, 845-854.	2.8	10
260	Role of natural and adaptive immunity in renal cell carcinoma response to VEGFRâ€TKIs and mTOR inhibitor. International Journal of Cancer, 2014, 134, 2772-2777.	5.1	57
261	Overall survival after immunotherapy, tyrosine kinase inhibitors and surgery in treatment of metastatic renal cell cancer: outcome of 143 consecutive patients from a single centre. Scandinavian Journal of Urology, 2014, 48, 379-386.	1.0	9
262	Real-World Outcomes in Metastatic Renal Cell Carcinoma: Insights From a Joint Community-Academic Registry. Journal of Oncology Practice, 2014, 10, e63-e72.	2.5	25
263	Implementation of an Interleukin-2 National Registry: an opportunity to improve cancer outcomes. , 2014, 2, 20.		4
264	VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib – a multicentric retrospective analysis. Acta Oncológica, 2014, 53, 103-112.	1.8	45
265	Management of Metastatic Renal Cell Carcinoma Progressed After Sunitinib or Another Antiangiogenic Treatment. American Journal of Clinical Oncology: Cancer Clinical Trials, 2014, 37, 611-615.	1.3	11
266	Protein kinase inhibitors in renal cell carcinoma. Expert Opinion on Pharmacotherapy, 2014, 15, 337-351.	1.8	8
267	Retrospective Analysis of the Safety and Efficacy of High-dose Interleukin-2 After Prior Tyrosine Kinase Inhibitor Therapy in Patients With Advanced Renal Cell Carcinoma. Journal of Immunotherapy, 2014, 37, 360-365.	2.4	12

#	Article	IF	CITATIONS
268	Factors affecting survival in 267 consecutive patients undergoing surgery for spinal metastasis from renal cell carcinoma. Journal of Neurosurgery: Spine, 2014, 20, 108-116.	1.7	42
269	Immunomodulatory Effects of Everolimus in a Long Responsive Patient With Metastatic Renal Cell Carcinoma. Journal of Immunotherapy, 2014, 37, 51-54.	2.4	10
270	Systematic Evaluation of the Prognostic Impact and Intratumour Heterogeneity of Clear Cell Renal Cell Carcinoma Biomarkers. European Urology, 2014, 66, 936-948.	1.9	141
271	Treatment Algorithm for Metastatic Renal Cell Carcinoma - Recommendations Based on Evidence and Clinical Practice. Oncology Research and Treatment, 2014, 37, 136-141.	1.2	13
272	A Phase II trial of dosage escalation of sorafenib in Asian patients with metastatic renal cell carcinoma. Future Oncology, 2014, 10, 1941-1951.	2.4	11
273	Regression of Metastatic Clear Cell Kidney Cancer With Interleukin-2 Treatment Following Nivolumab (Anti-PD-1) Treatment. Journal of Immunotherapy, 2014, 37, 187-191.	2.4	7
274	Clinical Outcomes for Patients with Metastatic Renal Cell Carcinoma Treated with Alternative Sunitinib Schedules. Journal of Urology, 2014, 191, 611-618.	0.4	122
275	Categories of response to first line vascular endothelial growth factor receptor targeted therapy and overall survival in patients with metastatic renal cell carcinoma. European Journal of Cancer, 2014, 50, 563-569.	2.8	20
276	Efficacy of Targeted Therapy for Metastatic Renal Cell Carcinoma in the Elderly Patient Population. Clinical Genitourinary Cancer, 2014, 12, 354-358.	1.9	26
278	Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokines. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 488-495.	1.6	11
279	Improved overall survival after implementation of targeted therapy for patients with metastatic renal cell carcinoma: Results from the Danish Renal Cancer Group (DARENCA) study-2. European Journal of Cancer, 2014, 50, 553-562.	2.8	69
280	Lymphopenia and clinical outcome of elderly patients treated with sunitinib for metastatic renal cell cancer. Journal of Geriatric Oncology, 2014, 5, 156-163.	1.0	22
281	Pharmacological Regulation of Platelet Factors That Influence Tumor Angiogenesis. Seminars in Oncology, 2014, 41, 370-377.	2.2	29
282	Population-based analysis of factors associated with survival in patients undergoing cytoreductive nephrectomy in the targeted therapy era. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 561-568.	1.6	28
283	Standard vs Adapted Sunitinib Regimen in Elderly Patients With Metastatic Renal Cell Cancer: Results From a Large Retrospective Analysis. Clinical Genitourinary Cancer, 2014, 12, 182-189.	1.9	23
284	Improvement of prognosis in patients with metastatic renal cell carcinoma and Memorial Sloan-Kettering Cancer Center intermediate risk features by modern strategy including molecular-targeted therapy in clinical practice. International Journal of Clinical Oncology, 2014, 19, 505.515	2.2	9
285	Do targeted agents offer clinical benefit as presurgical therapy?. World Journal of Urology, 2014, 32, 3-8.	2.2	16
286	Sequential therapy with targeted agents in metastatic renal cell carcinoma: beyond second-line and overcoming drug resistance. World Journal of Urology, 2014, 32, 19-29.	2.2	10

#	Article	IF	CITATIONS
287	Clinical prognostic factors associated with outcome in patients with renal cell cancer with prior tyrosine kinase inhibitors or immunotherapy treated with everolimus. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 345-354.	1.6	22
288	Prognostic significance of serum albumin in patients with metastatic renal cell carcinoma. Medical Oncology, 2014, 31, 841.	2.5	44
289	A systematic review of predictive and prognostic biomarkers for VEGF-targeted therapy in renal cell carcinoma. Cancer Treatment Reviews, 2014, 40, 533-547.	7.7	61
290	Impact of Bone and Liver Metastases on Patients with Renal Cell Carcinoma Treated with Targeted Therapy. European Urology, 2014, 65, 577-584.	1.9	207
291	Tumor Growth Rate Provides Useful Information to Evaluate Sorafenib and Everolimus Treatment in Metastatic Renal Cell Carcinoma Patients: An Integrated Analysis of the TARGET and RECORD Phase 3 Trial Data. European Urology, 2014, 65, 713-720.	1.9	71
292	Sarcomatoid Dedifferentiation in Metastatic Clear Cell Renal Cell Carcinoma and Outcome on Treatment With Anti–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors: A Retrospective Analysis. Clinical Genitourinary Cancer, 2014, 12, e205-e214.	1.9	33
293	Recommendations for the clinical and radiological evaluation of response to treatment in metastatic renal cell cancer. Targeted Oncology, 2014, 9, 9-24.	3.6	5
294	Sunitinib objective response in metastatic renal cell carcinoma: Analysis of 1059 patients treated on clinical trials. European Journal of Cancer, 2014, 50, 351-358.	2.8	113
295	Precision medicine for metastatic renal cell carcinoma I I Disclosures: Guru Sonpavde, MD: Research support from Novartis, Pfizer, and speaker or advisory board for Novartis, Pfizer, and GSK. Toni K. Choueiri, MD: Research support from Pfizer. Advisory board: Pfizer, Novartis, Aveo, GSK, Bayer/Onyx, and Genentech. No speakers bureau Urologic Oncology: Seminars and Original Investigations, 2014,	1.6	16
296	32, 5-15. Dosing Patterns, Toxicity, and Outcomes in Patients Treated With First-Line Sunitinib for Advanced Renal Cell Carcinoma in Community-Based Practices. Clinical Genitourinary Cancer, 2014, 12, 413-421.	1.9	15
297	Efficacy of sorafenib in advanced renal cell carcinoma independent of prior treatment, histology or prognostic group. Asia-Pacific Journal of Clinical Oncology, 2014, 10, 60-65.	1.1	11
298	Cytoreductive nephrectomy in patients with metastatic nonâ€clearâ€cell renal cell carcinoma (<scp>RCC</scp>). BJU International, 2014, 113, E67-74.	2.5	62
299	Renal cell carcinoma. BMJ, The, 2014, 349, g4797-g4797.	6.0	509
300	Local treatments for metastases of renal cell carcinoma: a systematic review. Lancet Oncology, The, 2014, 15, e549-e561.	10.7	265
301	Active Smoking May Negatively Affect Response Rate, Progression-Free Survival, and Overall Survival of Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib. Oncologist, 2014, 19, 51-60.	3.7	57
302	Reconciling the Use of Cytoreductive Nephrectomy in the Targeted Therapy Era. European Urology, 2014, 66, 711-712.	1.9	1
303	The early response of renal cell carcinoma to tyrosine kinase inhibitors evaluated by FDG PET/CT was not influenced by metastatic organ. BMC Cancer, 2014, 14, 390.	2.6	26
304	Volumetric FDG-PET predicts overall and progression- free survival after 14Âdays of targeted therapy in metastatic renal cell carcinoma. BMC Cancer, 2014, 14, 408.	2.6	29

#	Article	IF	CITATIONS
305	Granulocyteâ€ŧoâ€dendritic cellâ€ŧatio as marker for the immune monitoring in patients with renal cell carcinoma. Clinical and Translational Medicine, 2014, 3, 13.	4.0	5
306	The Judgment of Paris: Treatment Dilemmas in Advanced Renal Cell Carcinoma. Journal of Clinical Oncology, 2014, 32, 729-734.	1.6	11
307	Impact of everolimus blood concentration on its anti-cancer activity in patients with metastatic renal cell carcinoma. Cancer Chemotherapy and Pharmacology, 2014, 73, 999-1007.	2.3	31
308	Surgical management of metastatic renal cell carcinoma in the era of targeted therapies. World Journal of Urology, 2014, 32, 615-622.	2.2	18
309	Role of metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy. World Journal of Urology, 2014, 32, 631-642.	2.2	45
310	Active surveillance for metastatic or recurrent renal cell carcinoma. Journal of Cancer Research and Clinical Oncology, 2014, 140, 1421-1428.	2.5	39
311	Association between hemoglobin, calcium, and lactate dehydrogenase variability and mortality among metastatic renal cell carcinoma. International Urology and Nephrology, 2014, 46, 1081-1087.	1.4	19
312	Antagonism of Sorafenib and Regorafenib actions by platelet factors in hepatocellular carcinoma cell lines. BMC Cancer, 2014, 14, 351.	2.6	35
313	Lactate Dehydrogenase A is a potential prognostic marker in clear cell renal cell carcinoma. Molecular Cancer, 2014, 13, 101.	19.2	141
314	Cytoreductive Nephrectomy in Patients with Synchronous Metastases from Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. European Urology, 2014, 66, 704-710.	1.9	382
315	A cohort study investigating aspirin use and survival in men with prostate cancer. Annals of Oncology, 2014, 25, 154-159.	1.2	47
316	Landmarks in the diagnosis and treatment of renal cell carcinoma. Nature Reviews Urology, 2014, 11, 517-525.	3.8	176
317	The Effect of Targeted Therapy on Overall Survival in Advanced Renal Cancer: A Study of the National Surveillance Epidemiology and End Results Registry Database. Clinical Genitourinary Cancer, 2014, 12, 124-129.	1.9	55
318	First-Line Mammalian Target of Rapamycin Inhibition in Metastatic Renal Cell Carcinoma: An Analysis of Practice Patterns From the International Metastatic Renal Cell Carcinoma Database Consortium. Clinical Genitourinary Cancer, 2014, 12, 335-340.	1.9	9
319	Prognostic Significance of Cytoreductive Nephrectomy in Patients With Synchronous Metastases From Renal Cell Carcinoma Treated With First-Line Sunitinib: A European Multiinstitutional Study. Clinical Genitourinary Cancer, 2014, 12, 373-383.	1.9	39
320	Sarcomatoid features, necrosis, and grade are prognostic factors in metastatic clear cell renal cell carcinoma with vascular endothelial growth factor–targeted therapy. Human Pathology, 2014, 45, 1437-1444.	2.0	22
321	The Impact of Low Serum Sodium on Treatment Outcome of Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Cancer Database Consortium. European Urology, 2014, 65, 723-730.	1.9	69
322	A Population-Based Overview of Sequences of Targeted Therapy in Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2014, 12, e127-e131.	1.9	25

#	Article	IF	CITATIONS
323	Prognostic Impact of the Neutrophil-to-Lymphocyte Ratio in Men With Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer, 2014, 12, 317-324.	1.9	60
324	C-kit overexpression is not associated with KIT gene mutations in chromophobe renal cell carcinoma or renal oncocytoma. Pathology Research and Practice, 2014, 210, 521-525.	2.3	14
325	Sarcomatoid Renal Cell Carcinoma: Clinical Outcome and Survival After Treatment With Sunitinib. Clinical Genitourinary Cancer, 2014, 12, 251-255.	1.9	25
326	Computed Tomography Characteristics of Unresectable Primary Renal Cell Carcinoma Treated With Neoadjuvant Sunitinib. Clinical Genitourinary Cancer, 2014, 12, 117-123.	1.9	2
328	Clinical Outcome of Stereotactic Radiosurgery for Central Nervous System Metastases From Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2014, 12, 111-116.	1.9	19
329	Survival Outcome and Treatment Response of Patients with Late Relapse from Renal Cell Carcinoma in the Era of Targeted Therapy. European Urology, 2014, 65, 1086-1092.	1.9	71
330	Pazopanib after sunitinib failure in patients with metastatic renal cell carcinoma. Acta Oncológica, 2014, 53, 113-118.	1.8	17
331	Renal cell carcinoma: An update for the practicing urologist. Asian Journal of Urology, 2015, 2, 19-25.	1.2	10
333	Nutritional screening is strongly associated with overall survival in patients treated with targeted agents for metastatic renal cell carcinoma. Journal of Cachexia, Sarcopenia and Muscle, 2015, 6, 222-230.	7.3	61
334	Prognosis of J apanese patients with previously untreated metastatic renal cell carcinoma in the era of molecularâ€ŧargeted therapy. Cancer Science, 2015, 106, 618-626.	3.9	24
335	Prognostic factors and risk classifications for patients with metastatic renal cell carcinoma. International Journal of Urology, 2015, 22, 888-897.	1.0	26
337	Prognostic outcome in patients treated with tyrosine kinase inhibitors as first-line molecular-targeted therapy for metastatic renal cell carcinoma: Experience in real-world clinical practice in Japan. Molecular and Clinical Oncology, 2015, 3, 601-606.	1.0	13
338	Re: Cytoreductive Nephrectomy in Patients with Synchronous Metastases from Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. European Urology, 2015, 68, 737.	1.9	0
339	Platelet to lymphocyte ratio as a new prognostic for patients with metastatic renal cell cancer. Asia-Pacific Journal of Clinical Oncology, 2015, 11, 288-292.	1.1	50
340	Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poorâ€risk metastatic renal cell carcinoma. Cancer, 2015, 121, 3435-3443.	4.1	64
341	Is observation a valid strategy in metastatic renal cell carcinoma?. Current Opinion in Urology, 2015, 25, 390-394.	1.8	8
342	Role of cytoreductive nephrectomy for Japanese patients with primary renal cell carcinoma in the cytokine and targeted therapy era. International Journal of Urology, 2015, 22, 736-740.	1.0	18
343	Baseline chronic kidney disease is associated with toxicity and survival in patients treated with targeted therapies for metastatic renal cell carcinoma. Anti-Cancer Drugs, 2015, 26, 866-871.	1.4	11

		15	2
#		IF	CITATIONS
344	Role of metastasectomy in metastatic renal cell carcinoma. Current Opinion in Urology, 2015, 25, 381-389.	1.8	21
345	Emerging Role for Novel Immunotherapy Agents in Metastatic Renal Cell Carcinoma: From Bench to Bedside. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e291-e297.	3.8	4
346	Management of cancer of the kidney. , 0, , 293-303.		0
347	Co-occurring Adverse Events Enable Early Prediction of Progression-free Survival in Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib: A Hypothesis-generating Study. Tumori, 2015, 101, 555-559.	1.1	16
348	Current management and future directions in the treatment of advanced renal cell carcinoma-a latin american perspective: 10 years in review. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2015, 41, 835-843.	1.5	12
349	Prognostic analysis of Chinese patients with metastasis renal cell cancer receiving sorafenib: results from a multicenter long-term follow-up retrospective study. OncoTargets and Therapy, 2015, 8, 1581.	2.0	5
350	Bone metastases affect prognosis but not effectiveness of third-line targeted therapies in patients with metastatic renal cell carcinoma. Canadian Urological Association Journal, 2015, 9, 263.	0.6	6
351	Assessment of survival of patients with metastatic clear cell renal cell carcinoma after radical cytoreductive nephrectomy versus no surgery: a SEER analysis. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2015, 41, 288-295.	1.5	15
352	Prognostic Value of Components of Body Composition in Patients Treated with Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Case Series. PLoS ONE, 2015, 10, e0118022.	2.5	32
353	Cardiovascular Toxicity of Multi-Tyrosine Kinase Inhibitors in Advanced Solid Tumors: A Population-Based Observational Study. PLoS ONE, 2015, 10, e0122735.	2.5	14
354	The Association of Platelet Count with Clinicopathological Significance and Prognosis in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. PLoS ONE, 2015, 10, e0125538.	2.5	36
355	Clinical outcomes model in renal cell cancer patients treated with modified vaccinia Ankara plus tumor-associated antigen 5T4. International Journal of Biological Markers, 2015, 30, 111-121.	1.8	2
356	Challenging the Treatment Paradigm for Advanced Renal Cell Carcinoma: A Review of Systemic and Localized Therapies. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e239-e247.	3.8	9
357	Management of advanced kidney cancer: Canadian Kidney Cancer Forum consensus update. Canadian Urological Association Journal, 2015, 9, 164.	0.6	18
358	Analysis of pre-operative variables for identifying patients who might benefit from upfront cytoreductive nephrectomy for metastatic renal cell carcinoma in the targeted therapy era. Japanese Journal of Clinical Oncology, 2015, 45, 96-102.	1.3	34
359	Quantitative tumour necrosis is an independent predictor of overall survival in clear cell renal cell carcinoma. Pathology, 2015, 47, 34-37.	0.6	14
362	The Impact of PBRM1 Expression as a Prognostic and Predictive Marker in Metastatic Renal Cell Carcinoma. Journal of Urology, 2015, 194, 1112-1119.	0.4	19
363	Sites of disease as predictors of outcome in metastatic renal cell carcinoma patients treated with first-line sunitinib or sorafenib. Therapeutic Advances in Urology, 2015, 7, 59-68.	2.0	2

#	Article	IF	CITATIONS
364	Triple jejuno-jejunal intussusception due to metastatic renal cell carcinoma. Journal of Surgical Case Reports, 2015, 2015, rjv047-rjv047.	0.4	4
366	Percutaneous biopsy for risk stratification of renal masses. Therapeutic Advances in Urology, 2015, 7, 265-274.	2.0	30
367	Cytoreductive nephrectomy and its role in the present-day period of targeted therapy. Therapeutic Advances in Urology, 2015, 7, 275-285.	2.0	12
368	Editorial Comment to Role of cytoreductive nephrectomy for Japanese patients with primary renal cell carcinoma in the cytokine and targeted therapy era. International Journal of Urology, 2015, 22, 740-741.	1.0	0
369	Surgical considerations for patients with metastatic renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 528-537.	1.6	23
370	Real-world use of sunitinib in Japanese patients with advanced renal cell carcinoma: efficacy, safety and biomarker analyses in 1689 consecutive patients. Japanese Journal of Clinical Oncology, 2015, 45, 576-583.	1.3	41
371	RANK/OPG ratio of expression in primary clear-cell renal cell carcinoma is associated with bone metastasis and prognosis in patients treated with anti-VEGFR-TKIs. British Journal of Cancer, 2015, 113, 1313-1322.	6.4	19
372	UNC-51-like kinase 1 expression in radical nephrectomy specimens as a predicting factor of progression-free survival in patients with metastatic renal cell carcinoma treated with mammalian target of rapamycin inhibitors. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 506.e1-506.e7.	1.6	3
373	Development and Validation of a Prognostic Nomogram for Progression-Free Survival in Patients with Advanced Renal Cell Carcinoma Treated with Pazopanib. Oncology, 2015, 89, 235-241.	1.9	9
375	Pazopanib as Third Line Therapy for Metastatic Renal Cell Carcinoma: Clinical Efficacy and Temporal Analysis of Cytokine Profile. Journal of Urology, 2015, 193, 1114-1121.	0.4	25
376	Clinical Significance of Thrombocytosis Before Preoperative Chemoradiotherapy in Rectal Cancer: Predicting Pathologic Tumor Response and Oncologic Outcome. Annals of Surgical Oncology, 2015, 22, 513-519.	1.5	42
377	Prognostic Factors in Patients Receiving Third Line Targeted Therapy for Metastatic Renal Cell Carcinoma. Journal of Urology, 2015, 193, 1905-1910.	0.4	11
378	Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?. Journal of Experimental and Clinical Cancer Research, 2015, 34, 10.	8.6	65
380	Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis. Annals of Oncology, 2015, 26, 2107-2113.	1.2	85
381	Osteonecrosis of the Jaw in Patients With Metastatic Renal Cell Cancer Treated With Bisphosphonates and Targeted Agents: Results of an Italian Multicenter Study and Review of the Literature. Clinical Genitourinary Cancer, 2015, 13, 287-294.	1.9	40
382	Outcome of Patients With Metastatic Sarcomatoid Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium. Clinical Genitourinary Cancer, 2015, 13, e79-e85.	1.9	78
384	IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma. British Journal of Cancer, 2015, 112, 1190-1198.	6.4	35
385	Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma. British Journal of Cancer, 2015, 113, 12-19.	6.4	157

#	Article	IF	CITATIONS
386	Clinical significance of prognosis using the neutrophil–lymphocyte ratio and erythrocyte sedimentation rate in patients undergoing radical nephroureterectomy for upper urinary tract urothelial carcinoma. BJU International, 2015, 115, 587-594.	2.5	26
387	Time from Nephrectomy as a Prognostic Factor in Metastatic Renal Cell Carcinoma Patients Receiving Targeted Therapies: Overall Results from a Large Cohort of Patients. Oncology, 2015, 88, 133-138.	1.9	4
388	Biomarkers for evaluating racial disparities in clinical outcome in patients with renal cell carcinoma. Molecular Aspects of Medicine, 2015, 45, 47-54.	6.4	6
389	Personalized immunotherapy (AGS-003) when combined with sunitinib for the treatment of metastatic renal cell carcinoma. Expert Opinion on Biological Therapy, 2015, 15, 1241-1248.	3.1	17
390	Relationship of Pathologic Factors to Efficacy of Sorafenib Treatment in Patients With Metastatic Clear Cell Renal Cell Carcinoma. American Journal of Clinical Pathology, 2015, 143, 492-499.	0.7	3
391	Comparison of Two Prognostic Models in Patients with Metastatic Renal Cancer Treated with Sunitinib: a Retrospective, Registry-Based Study. Targeted Oncology, 2015, 10, 557-563.	3.6	9
392	Survival with AGS-003, an autologous dendritic cell–based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results. , 2015, 3, 14.		160
393	Tratamiento del cáncer de riñón metastásico. EMC - UrologÃa, 2015, 47, 1-13.	0.0	0
394	Vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) rechallenge for patients with metastatic renal cell carcinoma after treatment failure using both VEGFR-TKI and mTOR inhibitor. Cancer Chemotherapy and Pharmacology, 2015, 75, 1025-1035.	2.3	6
395	Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy. Targeted Oncology, 2015, 10, 517-522.	3.6	49
396	New Challenges in Kidney Cancer Management: Integration of Surgery and Novel Therapies. Current Treatment Options in Oncology, 2015, 16, 337.	3.0	4
397	Axitinib in metastatic renal cell carcinoma. Expert Review of Anticancer Therapy, 2015, 15, 499-507.	2.4	13
398	Clinical outcome of patients with pancreatic metastases from renal cell cancer. BMC Cancer, 2015, 15, 46.	2.6	31
399	Deferred Systemic Therapy in Patients With Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2015, 13, e159-e166.	1.9	17
400	Efficacy of Targeted Treatment Beyond Third-Line Therapy in Metastatic Kidney Cancer: Retrospective Analysis From a Large-Volume Cancer Center. Clinical Genitourinary Cancer, 2015, 13, e145-e152.	1.9	16
401	VHL and HIF in Clear Cell Renal Cell Carcinoma: Molecular Abnormalities and Potential Clinical Applications. , 2015, , 57-110.		0
403	Prognostic accuracy in second-line renal cancer therapy. Lancet Oncology, The, 2015, 16, 240-241.	10.7	0
404	The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a	10.7	299

ARTICLE IF CITATIONS # Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated with Sunitinib Response in the 405 7.0 250 Metastatic Setting. Clinical Cancer Research, 2015, 21, 1329-1339. CYP3A5 and ABCB1 Polymorphisms as Predictors for Sunitinib Outcome in Metastatic Renal Cell 406 Carcinoma. European Urology, 2015, 68, 621-629. Complete remission with sunitinib in a poor-risk patient with metastatic renal cell carcinoma. 407 1.4 1 Anti-Cancer Drugs, 2015, 26, 469-473. Surgical Management of Local Retroperitoneal Recurrence of Renal Cell Carcinoma after Radical 408 49 Nephrectomy. Journal of Urology, 2015, 194, 316-322. Safety and activity of temsirolimus and bevacizumab in patients with advanced renal cell carcinoma previously treated with tyrosine kinase inhibitors: a phase 2 consortium study. Cancer Chemotherapy 409 2.3 14 and Pharmacology, 2015, 75, 485-493. Prognostic factors for survival following initiation of second-line treatment with everolimus for metastatic renal cell carcinoma: evidence from a nationwide sample of clinical practice in the United 1.8 States. Expert Opinion on Pharmacotherapy, 2015, 16, 805-819. Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET/CT. Annals of 412 2.2 152 Nuclear Medicine, 2015, 29, 877-882. The use of prognostic factors in metastatic renal cell carcinoma. Urologic Oncology: Seminars and 1.6 Original Investigations, 2015, 33, 509-516. Clinical experience with temsirolimus in the treatment of advanced renal cell carcinoma. Therapeutic 414 2.0 27 Advances in Urology, 2015, 7, 152-161. Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell 6.4 carcinoma patients. British Journal of Cancer, 2015, 113, 1571-1580. Algorithms in the Firstâ€Line Treatment of Metastatic Clear Cell Renal Cell Carcinomaâ€"Analysis Using 416 3.7 23 Diagnostic Nodes. Oncologist, 2015, 20, 1028-1035. miR-200c Targets CDK2 and Suppresses Tumorigenesis in Renal Cell Carcinoma. Molecular Cancer 3.4 36 Research, 2015, 13, 1567-1577 Lymphopenia is an independent predictor of inferior outcome in papillary renal cell carcinoma. 418 1.6 36 Úrologic Oncology: Seminars and Original Investigations, 2015, 33, 388.e19-388.e25. miR-221/222 Are Involved in Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma. 8.2 Molecular Therapy, 2015, 23, 1748-1758. Trends in Metastatic Kidney Cancer Survival From the Cytokine to the Targeted Therapy Era. Urology, 420 1.0 31 2015, 86, 262-268. Everolimus and Temsirolimus Are Not the Same Second-Line in Metastatic Renal Cell Carcinoma. A 421 28 Systematic Review and Meta-Analysis of Literature Data. Clinical Genitourinary Cancer, 2015, 13, 137-141. Emerging tyrosine kinase inhibitors for the treatment of renal cancer. Expert Opinion on Emerging 422 2.4 3 Drugs, 2015, 20, 379-392. Characterizing the Impact of Lymph Node Metastases on the Survival Outcome for Metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapies. European Urology, 2015, 68, 506-515.

#	Article	IF	CITATIONS
424	Efficacy and Safety of Sequential Use of Everolimus in Patients With Metastatic Renal Cell Carcinoma Previously Treated With Bevacizumab With or Without Interferon Therapy: Results From the European AVATOR Study. Clinical Genitourinary Cancer, 2015, 13, 231-238.	1.9	6
425	ls Late Recurrence a Predictive Clinical Marker for Better Sunitinib Response in Metastatic Renal Cell Carcinoma Patients?. Clinical Genitourinary Cancer, 2015, 13, 548-554.	1.9	10
426	Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma. European Journal of Cancer, 2015, 51, 2580-2586.	2.8	79
427	Diagnosis of Renal Cell Carcinoma. Surgical Pathology Clinics, 2015, 8, 657-662.	1.7	7
428	Kidney cancer and 2014: is innovation really over?. Future Oncology, 2015, 11, 1437-1449.	2.4	1
429	Characteristics of Long-Term and Short-Term Survivors of Metastatic Renal Cell Carcinoma Treated With Targeted Therapies: Results From the International mRCC Database Consortium. Clinical Genitourinary Cancer, 2015, 13, 150-155.	1.9	10
430	Direct Visualization of the Antiangiogenic Effects of Sunitinib During the Treatment of Metastatic Clear Cell Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2015, 13, e407-e410.	1.9	1
431	Sarcopenia as a predictor of overall survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 339.e17-339.e23.	1.6	91
432	Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma. Therapeutic Advances in Urology, 2015, 7, 365-377.	2.0	103
433	Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma. European Journal of Clinical Pharmacology, 2015, 71, 1477-1484.	1.9	19
434	Evidence and Clinical Relevance of Tumor Flare in Patients Who Discontinue Tyrosine Kinase Inhibitors for Treatment of Metastatic Renal Cell Carcinoma. European Urology, 2015, 68, 154-160.	1.9	53
436	Pharmacogenomic biomarkers for personalized cancer treatment. Journal of Internal Medicine, 2015, 277, 201-217.	6.0	57
437	Resistance to sunitinib in renal cell carcinoma: From molecular mechanisms to predictive markers and future perspectives. Biochimica Et Biophysica Acta: Reviews on Cancer, 2015, 1855, 1-16.	7.4	73
438	Predictive role of tissue-based molecular markers in patients treated with sunitinib for metastatic renal cell carcinoma. World Journal of Urology, 2015, 33, 111-118.	2.2	13
439	Hyponatremia as a powerful prognostic predictor for Japanese patients with clear cell renal cell carcinoma treated with a tyrosine kinase inhibitor. International Journal of Clinical Oncology, 2015, 20, 351-357.	2.2	10
440	Impact of Cytoreductive Nephrectomy on Survival in Patients with Metastatic Renal Cell Carcinoma Treated by Targeted Therapy. Chinese Medical Journal, 2016, 129, 530-535.	2.3	8
441	Prognostic relevance of sunitinib toxicities and comparison of continuous vs. intermittent sunitinib dosing schedule in metastatic renal cell cancer patients. Wspolczesna Onkologia, 2016, 2, 147-152.	1.4	0
442	Contemporary treatment of metastatic renal cell carcinoma. Oncology Reviews, 2016, 10, 295.	1.8	32

#	ARTICLE	IF	CITATIONS
443	First-line treatment options in metastatic renal cell cancer. Canadian Urological Association Journal, 2016, 10, 236.	0.6	9
444	Treatment, Outcome and Prognostic Factors in Renal Cell Carcinoma - A Single Center Study (2000-2010). Journal of Cancer, 2016, 7, 921-927.	2.5	11
445	Everolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapy. Core Evidence, 2016, Volume 11, 23-36.	4.7	45
446	Is there a "Trial Effect" on Outcome of Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib?. Cancer Research and Treatment, 2016, 48, 281-287.	3.0	9
447	Cancer subtypes classification using long non-coding RNA. Oncotarget, 2016, 7, 54082-54093.	1.8	38
448	Sunitinib side effects as surrogate biomarkers of efficacy. Canadian Urological Association Journal, 2016, 10, 245.	0.6	11
449	Prognostic and Predictive Values of Subcellular Localisation of RET in Renal Clear-Cell Carcinoma. Disease Markers, 2016, 2016, 1-8.	1.3	4
450	Basic Parameters of Blood Count as Prognostic Factors for Renal Cell Carcinoma. BioMed Research International, 2016, 2016, 1-7.	1.9	14
451	Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Oncotarget, 2016, 7, 54564-54571.	1.8	116
452	Axitinib in the treatment of renal cell carcinoma: patient selection and perspectives. International Journal of Nephrology and Renovascular Disease, 2016, 9, 65.	1.8	4
453	Clinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selection. OncoTargets and Therapy, 2016, Volume 9, 5825-5837.	2.0	25
454	Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis. Oncotarget, 2016, 7, 27044-27054.	1.8	28
455	Clinical Impact of Pancreatic Metastases from Renal Cell Carcinoma: A Multicenter Retrospective Analysis. PLoS ONE, 2016, 11, e0151662.	2.5	56
456	Serum levels of HMGB1 have a diagnostic role in metastatic renal cell cancer. Cancer Biomarkers, 2016, 17, 17-20.	1.7	9
457	Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases. BJU International, 2016, 117, 761-765.	2.5	56
458	Prognostic value of pathological features of primary lesion in metastatic renal cell carcinoma treated with sorafenib. Future Oncology, 2016, 12, 1783-1793.	2.4	0
459	Prognostic value of pretherapy platelet elevation in oropharyngeal cancer patients treated with chemoradiation. International Journal of Cancer, 2016, 138, 1290-1297.	5.1	17
460	Management of poor-risk metastatic renal cell carcinoma: current approaches, the role of temsirolimus and future directions. Future Oncology, 2016, 12, 533-549.	2.4	8

#	Article	IF	CITATIONS
461	A retrospective study of predictive factors for unexpectedly prolonged or shortened progression-free survival and overall survival among patients with metastatic renal cell carcinoma who received first-line targeted therapy. BMC Cancer, 2016, 16, 577.	2.6	4
462	Case Discussion: Systemic Therapy for Metastatic Renal Cell Carcinoma. European Urology Focus, 2016, 2, 579-581.	3.1	1
463	Prognostic significance of platelet–lymphocyte ratio in patients receiving first-line tyrosine kinase inhibitors for metastatic renal cell cancer. SpringerPlus, 2016, 5, 1889.	1.2	23
464	Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma. , 2016, 4, 81.		79
466	Impact of Second-Line Targeted Therapy Dose Intensity on Patients With Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2016, 14, e575-e583.	1.9	10
467	Prescribing Preferences in the First-Line Treatment for Patients With Metastatic Renal Cell Carcinoma in the United States. Clinical Genitourinary Cancer, 2016, 14, e479-e487.	1.9	4
468	Tyrosine Kinase Signaling in Clear Cell and Papillary Renal Cell Carcinoma Revealed by Mass Spectrometry–Based Phosphotyrosine Proteomics. Clinical Cancer Research, 2016, 22, 5605-5616.	7.0	19
469	Skin manifestations associated with kidney cancer. Seminars in Oncology, 2016, 43, 408-412.	2.2	8
470	Fuhrman Grade and Neutrophil-To-Lymphocyte Ratio Influence on Survival in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors. Clinical Genitourinary Cancer, 2016, 14, 457-464.	1.9	30
471	Survival in Patients With Primary Metastatic Renal Cell Carcinoma Treated With Sunitinib With or Without Previous Cytoreductive Nephrectomy: Results From a Population-based Registry. Urology, 2016, 95, 121-127.	1.0	34
472	Local salvage therapy for late (≥2 years) metastatic and local relapse of renal cell cancer is a potentially curative treatment irrespective of the site of recurrence. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 238.e9-238.e17.	1.6	7
473	Does the onset of bone metastasis in sunitinib-treated renal cell carcinoma patients impact the overall survival?. World Journal of Urology, 2016, 34, 909-915.	2.2	5
474	Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)–tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma. Annals of Oncology, 2016, 27, 1304-1311.	1.2	66
475	The safety and efficacy of nivolumab for the treatment of advanced renal cell carcinoma. Expert Review of Anticancer Therapy, 2016, 16, 577-584.	2.4	12
476	The †̃nivolution' in renal cell carcinoma: behind the scenes of clinical trials. Future Oncology, 2016, 12, 2061-2063.	2.4	2
477	Therapeutic Strategies for Patients With Metastatic Renal Cell Carcinoma in Whom First-Line Vascular Endothelial Growth Factor Receptor–Directed Therapies Fail. Journal of Oncology Practice, 2016, 12, 412-420.	2.5	11
478	The Wide Experience of the Sequential Therapy for Patients with Metastatic Renal Cell Carcinoma. Current Oncology Reports, 2016, 18, 66.	4.0	6
479	Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations. Journal of Clinical Oncology, 2016, 34, 3655-3663.	1.6	174

#	Article	IF	CITATIONS
480	GLI2 expression levels in radical nephrectomy specimens as a predictor of disease progression in patients with metastatic clear cell renal cell carcinoma following treatment with sunitinib. Molecular and Clinical Oncology, 2016, 5, 186-192.	1.0	9
481	Key predictive factors for efficacy of axitinib in first-line metastatic renal cell carcinoma: subgroup analysis in Japanese patients from a randomized, double-blind phase II study. Japanese Journal of Clinical Oncology, 2016, 46, 1031-1041.	1.3	20
482	IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncology, The, 2016, 17, 1599-1611.	10.7	181
483	Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma. Cancer Immunology, Immunotherapy, 2016, 65, 1533-1544.	4.2	89
484	Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2016, 27, v58-v68.	1.2	413
485	Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy. Cancer Treatment Reviews, 2016, 50, 109-117.	7.7	64
486	Target molecule expression profiles in metastatic renal cell carcinoma: Development of individual targeted therapy. Tissue Engineering and Regenerative Medicine, 2016, 13, 416-427.	3.7	4
487	The prospect of precision therapy for renal cell carcinoma. Cancer Treatment Reviews, 2016, 49, 37-44.	7.7	46
488	Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. Lancet Oncology, The, 2016, 17, 1317-1324.	10.7	200
489	First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. European Journal of Cancer, 2016, 65, 102-108.	2.8	60
490	Immunotherapy of advanced renal cell carcinoma: Current and future therapies. Human Vaccines and Immunotherapeutics, 2016, 12, 2997-3004.	3.3	12
491	Metastatic clear cell renal cell carcinoma: Circulating biomarkers to guide antiangiogenic and immune therapies. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 510-518.	1.6	18
492	Risk factors for recurrence after surgery in nonâ€metastatic <scp>RCC</scp> with thrombus: a contemporary multicentre analysis. BJU International, 2016, 117, E87-94.	2.5	39
493	Medical treatment of renal cancer: new horizons. British Journal of Cancer, 2016, 115, 505-516.	6.4	83
494	Renal cell cancer: overview of the current therapeutic landscape. Expert Review of Anticancer Therapy, 2016, 16, 955-968.	2.4	20
495	Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors. Journal of Clinical Oncology, 2016, 34, 3562-3569.	1.6	175
496	Efficacy and safety of axitinib in elderly patients with metastatic renal cell carcinoma. Medical Oncology, 2016, 33, 95.	2.5	11
497	Metastasectomy for metastatic renal cell carcinoma in the era of modern systemic treatment: Câ€reactive protein is an independent predictor of overall survival. International Journal of Urology, 2016, 23, 916-921	1.0	12

#	Article	IF	CITATIONS
498	Impact of resection and systemic therapy on the survival of patients with brain metastasis of metastatic renal cell carcinoma. Journal of Neuro-Oncology, 2016, 130, 221-228.	2.9	26
499	Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated With Sunitinib. Oncologist, 2016, 21, 1212-1217.	3.7	17
500	Benefit from cytoreductive nephrectomy and the prognostic role of neutrophilâ€toâ€lymphocyte ratio in patients with metastatic renal cell carcinoma. Internal Medicine Journal, 2016, 46, 1291-1297.	0.8	15
501	Pharmacokinetics, pharmacodynamics and clinical efficacy of nivolumab in the treatment of metastatic renal cell carcinoma. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 1089-1096.	3.3	17
502	Prognostic Value of SETD2 Expression in Patients with Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors. Journal of Urology, 2016, 196, 1363-1370.	0.4	42
503	Pazopanib as a second-line treatment for non-cytokine-treated metastatic renal cell carcinoma: a meta-analysis of the effect of treatment. BMC Urology, 2016, 16, 34.	1.4	7
504	Validation of <scp>VEGFR</scp> 1 rs9582036 as predictive biomarker in metastatic clearâ€cell renal cell carcinoma patients treated with sunitinib. BJU International, 2016, 118, 890-901.	2.5	23
505	A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinoma. BMC Urology, 2016, 16, 46.	1.4	14
506	Predictive and prognostic biomarkers of targeted agents and modern immunotherapy in renal cell carcinoma. ESMO Open, 2016, 1, e000013.	4.5	36
507	Sunitinib in the treatment of metastatic renal cell carcinoma. Therapeutic Advances in Urology, 2016, 8, 348-371.	2.0	41
508	The effects of RNA interference mediated VEGF gene silencing on biological behavior of renal cell carcinoma and transplanted renal tumor in nude mice. Cancer Biomarkers, 2016, 16, 1-9.	1.7	5
509	Overall prognostic impact of C-reactive protein level in patients with metastatic renal cell carcinoma treated with sorafenib. Anti-Cancer Drugs, 2016, 27, 1028-1032.	1.4	9
510	Angiotensin system inhibitors and survival in patients with metastatic renal cell carcinoma treated with VEGF-targeted therapy: A pooled secondary analysis of clinical trials. International Journal of Cancer, 2016, 138, 2293-2299.	5.1	20
511	Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma. European Urology, 2016, 70, 1006-1015.	1.9	23
512	Rapalogs Efficacy Relies on the Modulation of Antitumor T-cell Immunity. Cancer Research, 2016, 76, 4100-4112.	0.9	42
513	Survival Analyses of Patients With Metastatic Renal Cancer Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy: A National Cancer Data Base Study. Journal of Clinical Oncology, 2016, 34, 3267-3275.	1.6	185
514	Pazopanib versus sunitinib for the treatment of metastatic renal cell carcinoma patients with poor-risk features. Cancer Chemotherapy and Pharmacology, 2016, 78, 325-332.	2.3	18
515	Insights into the Genetic Basis of the Renal Cell Carcinomas from The Cancer Genome Atlas. Molecular Cancer Research, 2016, 14, 589-598.	3.4	29

#	Article	IF	CITATIONS
516	Survival and prognostic factors of patients with renal cell cancer with bone metastasis in the era of targeted therapy: A single-institution analysis. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 433.e1-433.e8.	1.6	21
517	Metformin Use and Outcome of Sunitinib Treatment in Patients With Diabetes and Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2016, 14, 420-425.	1.9	19
518	Using Interferon Alfa Before Tyrosine Kinase Inhibitors May Increase Survival in Patients With Metastatic Renal Cell Carcinoma: A Turkish Oncology Group (TOG) Study. Clinical Genitourinary Cancer, 2016, 14, e347-e353.	1.9	6
519	External Validation of the MSKCC and IMDC Risk Models in Patients Treated with Targeted Therapy as a First-line and Subsequent Second-line Treatment: A Japanese Multi-institutional Study. European Urology Focus, 2016, 2, 303-309.	3.1	21
520	Risk factors of proteinuria in renal cell carcinoma patients treated with VEGF inhibitors: a secondary analysis of pooled clinical trial data. British Journal of Cancer, 2016, 114, 1313-1317.	6.4	45
521	Efficacy of fourth-line targeted therapy in patients with metastatic renal cell carcinoma: a retrospective analysis. World Journal of Urology, 2016, 34, 1147-1154.	2.2	7
522	Elevated preoperative neutrophil-to-lymphocyte ratio may be associated with decreased overall survival in patients with metastatic clear cell renal cell carcinoma undergoing cytoreductive nephrectomy. Asian Journal of Urology, 2016, 3, 20-25.	1.2	24
524	Effect of reclassification of the IMDC model in patients with metastatic renal cell carcinoma treated with targeted therapy in the first-line and second-line settings. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 293.e17-293.e25.	1.6	4
525	Response to post-axitinib treatment in patients with metastatic renal cell carcinoma. BMC Cancer, 2016, 16, 254.	2.6	1
526	The best objective response of target lesions and the incidence of treatment-related hypertension are associated with the survival of patients with metastatic renal cell carcinoma treated with sunitinib: a Japanese retrospective study. BMC Research Notes, 2016, 9, 79.	1.4	15
527	Prognostic Significance of Early Tumor Shrinkage Under Second-Line Targeted Therapy for Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Study in Japan. Molecular Diagnosis and Therapy, 2016, 20, 385-392.	3.8	8
528	Outcomes of unselected patients with metastatic clear-cell renal cell carcinoma treated with first-line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors: a sin. BJU International, 2016, 118, 264-271.	2.5	17
529	Body mass index and age are additional prognostic factors in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 258.e15-258.e22.	1.6	8
530	Prognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-Analysis. Targeted Oncology, 2016, 11, 143-148.	3.6	152
531	Expert Recommendations for First-Line Management of Metastatic Renal Cell Carcinoma in Special Subpopulations. Targeted Oncology, 2016, 11, 129-141.	3.6	3
532	Favorable prognostic influence of T-box transcription factor Eomesodermin in metastatic renal cell cancer patients. Cancer Immunology, Immunotherapy, 2016, 65, 181-192.	4.2	27
533	Evaluation of polymorphisms in angiogenesis-related genes as predictive and prognostic markers for sunitinib-treated metastatic renal cell carcinoma patients. Journal of Cancer Research and Clinical Oncology, 2016, 142, 1171-1182.	2.5	23
534	Correlation Between Molecular Subclassifications of Clear Cell Renal Cell Carcinoma and Targeted Therapy Response. European Urology Focus, 2016, 2, 204-209.	3.1	40

#	Article	IF	CITATIONS
535	Role of dose exposure and inflammatory status in a single center, real-world analysis of sunitinib in patients with metastatic renal cell carcinoma. Future Oncology, 2016, 12, 909-919.	2.4	4
536	Micro <scp>RNA</scp> â€194 is a Marker for Good Prognosis in Clear Cell Renal Cell Carcinoma. Cancer Medicine, 2016, 5, 656-664.	2.8	50
537	Prognostic tissue biomarker exploration for patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors. Tumor Biology, 2016, 37, 4919-4927.	1.8	6
539	Absence of Significant Correlation of Adverse Events Between First- and Second-Line Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2016, 14, e19-e24.	1.9	3
540	Patients with ClearCode34-identified molecular subtypes of clear cell renal cell carcinoma represent unique populations with distinct comorbidities. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 122.e1-122.e7.	1.6	23
541	Comparison of pre-treatment MSKCC and IMDC prognostic risk models in patients with synchronous metastatic renal cell carcinoma treated in the era of targeted therapy. World Journal of Urology, 2016, 34, 1067-1072.	2.2	21
542	Significance and therapeutic implications of endothelial progenitor cells in angiogenic-mediated tumour metastasis. Critical Reviews in Oncology/Hematology, 2016, 100, 177-189.	4.4	19
543	A prospective risk-stratified follow-up programme for radically treated renal cell carcinoma patients: evaluation after eight years of clinical use. World Journal of Urology, 2016, 34, 1087-1099.	2.2	40
544	Change in Neutrophil-to-lymphocyte Ratio in Response to Targeted Therapy for Metastatic Renal Cell Carcinoma as a Prognosticator and Biomarker of Efficacy. European Urology, 2016, 70, 358-364.	1.9	133
545	Comprehensive analysis and validation of contemporary survival prognosticators in Korean patients with metastatic renal cell carcinoma treated with targeted therapy: prognostic impact of pretreatment neutrophil-to-lymphocyte ratio. International Urology and Nephrology, 2016, 48, 985-992.	1.4	10
546	First-Line Treatments for Poor-Prognosis Metastatic Renal Cell Carcinoma: Experts' Prescribing Practices and Systematic Literature Review. Clinical Drug Investigation, 2016, 36, 389-399.	2.2	6
547	Long-term survival correlates with immunological responses in renal cell carcinoma patients treated with mRNA-based immunotherapy. Oncolmmunology, 2016, 5, e1108511.	4.6	41
548	Long-term outcomes of tyrosine kinase inhibitor discontinuation in patients with metastatic renal cell carcinoma. Cancer Chemotherapy and Pharmacology, 2016, 77, 339-347.	2.3	4
549	A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel. Annals of Oncology, 2016, 27, 454-460.	1.2	142
550	Validation of the International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) prognostic model for first-line pazopanib in metastatic renal carcinoma: the Spanish Oncologic Genitourinary Group (SOGUG) SPAZO study. Annals of Oncology, 2016, 27, 706-711.	1.2	30
551	Optimal treatment of poor-risk renal cell carcinoma patients with mTOR inhibitors and anti-VEGFR agents. Expert Review of Anticancer Therapy, 2016, 16, 33-43.	2.4	3
552	The radiogenomic risk score stratifies outcomes in a renal cell cancer phase 2 clinical trial. European Radiology, 2016, 26, 2798-2807.	4.5	33
553	Efficacy of sorafenib correlates with Memorial Sloan-Kettering Cancer Center (MSKCC) risk classification and bone metastasis in Chinese patients with metastatic renal cell carcinoma. Cellular Oncology (Dordrecht), 2016, 39, 15-21.	4.4	2

#	Article	IF	CITATIONS
554	Prognostic Significance of Sarcopenia in Patients with Metastatic Renal Cell Carcinoma. Journal of Urology, 2016, 195, 26-32.	0.4	102
555	A five-factor biomarker profile obtained week 4–12 of treatment for improved prognostication in metastatic renal cell carcinoma: Results from DARENCA study 2. Acta Oncológica, 2016, 55, 341-348.	1.8	15
556	Pretreatment neutrophil-to-lymphocyte ratio predicts prognosis in patients with metastatic renal cell carcinoma receiving targeted therapy. International Journal of Clinical Oncology, 2016, 21, 373-378.	2.2	23
557	Early Tumor Shrinkage Under Treatment with First-line Tyrosine Kinase Inhibitors as a Predictor of Overall Survival in Patients with Metastatic Renal Cell Carcinoma: a Retrospective Multi-Institutional Study in Japan. Targeted Oncology, 2016, 11, 175-182.	3.6	20
558	Predictive biomarker candidates to delineate efficacy of antiangiogenic treatment in renal cell carcinoma. Clinical and Translational Oncology, 2016, 18, 1-8.	2.4	8
559	Renal cancer. Lancet, The, 2016, 387, 894-906.	13.7	762
560	Sunitinibâ€induced hypertension, neutropaenia and thrombocytopaenia as predictors of good prognosis in patients with metastatic renal cell carcinoma. BJU International, 2016, 117, 110-117.	2.5	47
561	Sunitinib-induced hypertension in CYP3A4 rs4646437 A-allele carriers with metastatic renal cell carcinoma. Pharmacogenomics Journal, 2017, 17, 42-46.	2.0	21
562	Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. European Urology, 2017, 71, 204-209.	1.9	65
563	Intrinsic resistance to sunitinib in patients with metastatic renal cell carcinoma. Asia-Pacific Journal of Clinical Oncology, 2017, 13, 61-67.	1.1	18
564	Therapeutic approaches in clear cell and non-clear cell renal cell carcinoma. Acta Clinica Belgica, 2017, 72, 12-18.	1.2	25
565	Real-World Survival Outcomes and Prognostic Factors Among Patients Receiving First Targeted Therapy for Advanced Renal Cell Carcinoma: A SEER–Medicare Database Analysis. Clinical Genitourinary Cancer, 2017, 15, e573-e582.	1.9	53
566	Immunomodulatory Activity of VEGF in Cancer. International Review of Cell and Molecular Biology, 2017, 330, 295-342.	3.2	153
567	First-Line PAzopanib in NOn–clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study. Clinical Genitourinary Cancer, 2017, 15, e609-e614.	1.9	42
568	Patterns of Care and Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma—Results From a Tertiary Cancer Center in India. Clinical Genitourinary Cancer, 2017, 15, e345-e355.	1.9	6
569	Angiotensin Inhibitors as Treatment of Sunitinib/Pazopanib-induced Hypertension inÂMetastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2017, 15, 384-390.e3.	1.9	14
570	Checkpoint inhibition: new treatment options in urologic cancer. Acta Clinica Belgica, 2017, 72, 24-28.	1.2	13
571	Cytoreductive Surgery in the Management of Renal Tumours: Rationale, Current Evidence and Future Perspectives. Indian Journal of Surgical Oncology, 2017, 8, 33-38.	0.7	2

#	Article	IF	CITATIONS
572	Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib. Scientific Reports, 2017, 7, 41371.	3.3	3
573	Systemic Therapy for Metastatic Renal-Cell Carcinoma. New England Journal of Medicine, 2017, 376, 354-366.	27.0	940
574	A Phase II Study of Intermittent Sunitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology, 2017, 35, 1764-1769.	1.6	36
575	Pretreatment Serum Prealbumin as an Independent Prognostic Indicator in Patients With Metastatic Renal Cell Carcinoma Using Tyrosine Kinase Inhibitors as First-Line Target Therapy. Clinical Genitourinary Cancer, 2017, 15, e437-e446.	1.9	27
576	Predictive and Prognostic Markers in Metastatic Renal Cell Carcinoma. , 2017, , 237-251.		0
577	Impact of baseline visceral fat accumulation on prognosis in patients with metastatic renal cell carcinoma treated with systemic therapy. Medical Oncology, 2017, 34, 47.	2.5	20
578	Outcomes and Drug Costs of Sunitinib Regimens for Metastatic Renal Cell Carcinoma: A Provincial Population-Based Study. Clinical Genitourinary Cancer, 2017, 15, e397-e404.	1.9	16
579	Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model. Oncologist, 2017, 22, 286-292.	3.7	54
580	Prediction of Everolimus Toxicity and Prognostic Value of Skeletal Muscle Index in Patients With Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2017, 15, 350-355.	1.9	26
581	Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma in the Era of Targeted Therapy: Scientifically Relevant or Natural Selection?. Journal of Clinical Oncology, 2017, 35, 1265-1266.	1.6	5
582	Renal Cell Carcinoma With Pulmonary Metastasis and Metachronous Non-Small Cell Lung Cancer. Clinical Genitourinary Cancer, 2017, 15, e675-e680.	1.9	5
583	Tumoral cubilin is a predictive marker for treatment of renal cancer patients with sunitinib and sorafenib. Journal of Cancer Research and Clinical Oncology, 2017, 143, 961-970.	2.5	5
584	Renal cell carcinoma. Nature Reviews Disease Primers, 2017, 3, 17009.	30.5	1,727
585	The prognostic value of the neutrophil-lymphocyte ratio in renal oncology: A review. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 135-141.	1.6	79
586	FDA Approval Summary: Nivolumab in Advanced Renal Cell Carcinoma After Anti-Angiogenic Therapy and Exploratory Predictive Biomarker Analysis. Oncologist, 2017, 22, 311-317.	3.7	75
587	The independent oncological role for cytoreductive nephrectomy in metastatic renal cell carcinoma: Prognostic features in the era of targeted therapies. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 152.e13-152.e22.	1.6	2
588	Expression pattern of immune checkpoint–associated molecules in radical nephrectomy specimens as a prognosticator in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 363-369.	1.6	15
589	Correlation of c-Met Expression and Outcome in Patients With Renal Cell Carcinoma Treated With Sunitinib. Clinical Genitourinary Cancer, 2017, 15, 487-494.	1.9	16

#	Article	IF	CITATIONS
590	CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma. European Urology, 2017, 72, 962-971.	1.9	199
591	Safety and Efficacy of Stereotactic Ablative Radiation Therapy for Renal Cell Carcinoma Extracranial Metastases. International Journal of Radiation Oncology Biology Physics, 2017, 98, 91-100.	0.8	67
592	Description of the EuroTARGET cohort: A European collaborative project on TArgeted therapy in renal cell cancer—GEnetic- and tumor-related biomarkers for response and toxicity. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 529.e9-529.e16.	1.6	9
593	Genomic alterations as predictors of survival among patients within a combined cohort with clear cell renal cell carcinoma undergoing cytoreductive nephrectomy. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 532.e7-532.e13.	1.6	25
594	Retrospective Analysis of Fifth-Line Targeted Therapy Efficacy in Patients with Metastatic Renal Cell Carcinoma. Urologia Internationalis, 2017, 98, 184-190.	1.3	4
595	Characterizing the outcomes of metastatic papillary renal cell carcinoma. Cancer Medicine, 2017, 6, 902-909.	2.8	37
596	Delayed Cytoreductive Nephrectomy Following Three Years of Targeted Therapy for Metastatic Renal Cell Carcinoma. Current Urology, 2017, 9, 202-208.	0.6	0
597	Immunotherapy for metastatic renal cell carcinoma. The Cochrane Library, 2017, 2017, CD011673.	2.8	31
598	Axitinib in metastatic renal cell carcinoma: patient characteristics and treatment patterns in US community oncology centers. Future Oncology, 2017, 13, 1323-1332.	2.4	3
599	A case of metastatic Xp11.2 translocation renal cell carcinoma successfully managed by cytoreductive nephrectomy followed by axitinib therapy. Molecular and Clinical Oncology, 2017, 6, 362-364.	1.0	5
600	Evaluation of KDR rs34231037 as a predictor of sunitinib efficacy in patients with metastatic renal cell carcinoma. Pharmacogenetics and Genomics, 2017, 27, 227-231.	1.5	5
601	Renal Cell Carcinoma Biomarkers in Circulation. , 2017, , 303-324.		0
602	Overall survival in Swedish patients with renal cell carcinoma treated in the period 2002 to 2012: Update of the RENCOMP study with subgroup analysis of the synchronous metastatic and elderly populations. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 541.e15-541.e22.	1.6	21
603	Time-dependent effects of prognostic biomarkers of systemic inflammation in patients with metastatic renal cell carcinoma. Tumor Biology, 2017, 39, 101042831770551.	1.8	13
604	Predictive value of the modified Glasgow Prognostic Score for the therapeutic effects of molecular-targeted drugs on advanced renal cell carcinoma. Molecular and Clinical Oncology, 2017, 6, 669-675.	1.0	17
605	Systematic review of renal carcinoma prognostic factors. Actas Urológicas Españolas (English) Tj ETQq1 1 0.7	84314 rgl 0.2	BT /Overlock
606	The clinicopathological and prognostic role of thrombocytosis in patients with cancer: A meta-analysis. Oncology Letters, 2017, 13, 5002-5008.	1.8	14
607	Overall survival of firstâ€line axitinib in metastatic renal cell carcinoma: Japanese subgroup analysis from phase II study. Cancer Science, 2017, 108, 1231-1239.	3.9	21

#	Article	IF	CITATIONS
608	Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti–Vascular Endothelial Growth Factor–Targeted Agents. Clinical Nuclear Medicine, 2017, 42, e235-e241.	1.3	22
609	Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 541.e7-541.e13.	1.6	10
610	Current management of metastatic renal cell carcinoma: evolving new therapies. Current Opinion in Supportive and Palliative Care, 2017, 11, 231-237.	1.3	12
611	Prognostic factors for overall survival after lung metastasectomy in renal cell cancer patients: A systematic review and meta-analysis. International Journal of Surgery, 2017, 41, 70-77.	2.7	47
612	ls Change in Hemoglobin Level a Predictive Biomarker of Tyrosine Kinase Efficacy in Metastatic Renal Cell Carcinoma? A Turkish Oncology Group Study. Cancer Investigation, 2017, 35, 248-255.	1.3	3
615	Biomarkers to predict prognosis and response to checkpoint inhibitors. International Journal of Clinical Oncology, 2017, 22, 629-634.	2.2	57
616	Alternating Treatment With Pazopanib and Everolimus vs Continuous Pazopanib to Delay Disease Progression in Patients With Metastatic Clear Cell Renal Cell Cancer. JAMA Oncology, 2017, 3, 501.	7.1	23
617	Determinants and prognostic implications of malignant ascites in metastatic papillary renal cancer. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 114.e9-114.e14.	1.6	7
618	Biomarkers of Renal Cancer. , 2017, , 421-467.		1
619	Thrombocytopenia and the outcomes of hepatectomy for hepatocellular carcinoma: a meta-analysis. Journal of Surgical Research, 2017, 210, 99-107.	1.6	19
620	Treatment of renal cell carcinoma: Current status and future directions. Ca-A Cancer Journal for Clinicians, 2017, 67, 507-524.	329.8	583
621	Multimodal treatment of advanced renal cancer in 2017. Expert Review of Clinical Pharmacology, 2017, 10, 1395-1402.	3.1	23
622	Immune checkpoint inhibitors in renal cell carcinoma. Clinical Science, 2017, 131, 2627-2642.	4.3	62
623	Risk models for patients with localized renal cell carcinoma. Actas Urológicas Españolas (English) Tj ETQq1 1 0.	784314 rg	gBT /Overlo
624	Clinical Trials for Specific Renal Cancer Subtypes—The Time Will Come!. European Urology Supplements, 2017, 16, 241-252.	0.1	2
625	Outcome of Patients with Renal Cell Carcinoma and Multiple Glandular Metastases Treated with Targeted Agents. Oncology, 2017, 92, 269-275.	1.9	5
626	Significance of preoperative prognostic nutrition index as prognostic predictors in patients with metastatic renal cell carcinoma with tyrosine kinase inhibitors as first-line target therapy. International Urology and Nephrology, 2017, 49, 1955-1963.	1.4	20
627	Baseline risk stratification or duration of prior therapy predicts prognosis in patients with metastatic renal cell carcinoma treated with axitinib. Japanese Journal of Clinical Oncology, 2017, 47, 1170-1174.	1.3	2

#	Article	IF	Citations
628	Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 804-834.	4.9	443
629	Clinical correlates and prognostic value of different metastatic sites in metastatic renal cell carcinoma. Future Oncology, 2017, 13, 1967-1980.	2.4	36
630	Cancer vaccines: Enhanced immunogenic modulation through therapeutic combinations. Human Vaccines and Immunotherapeutics, 2017, 13, 2561-2574.	3.3	91
631	In Reply. Oncologist, 2017, 22, 1561-1561.	3.7	0
632	When to Perform Preoperative Bone Scintigraphy for Kidney Cancer Staging. Urology, 2017, 110, 114-120.	1.0	5
633	Survival of metastatic renal cell carcinoma patients continues to improve over time, even in targeted therapy era. International Urology and Nephrology, 2017, 49, 2143-2149.	1.4	36
634	Expression of long non-coding RNA MFI2-AS1 is a strong predictor of recurrence in sporadic localized clear-cell renal cell carcinoma. Scientific Reports, 2017, 7, 8540.	3.3	21
635	The effect of kinetics of C-reactive protein in the prediction of overall survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 662.e1-662.e7.	1.6	22
636	Blood Platelet Volume Represents a Novel Prognostic Factor in Patients with Nonmetastatic Renal Cell Carcinoma and Improves the Predictive Ability of Established Prognostic Scores. Journal of Urology, 2017, 198, 1247-1252.	0.4	25
637	Hilar fat infiltration: A new prognostic factor in metastatic clear cell renal cell carcinoma with first-line sunitinib treatment. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 603.e7-603.e14.	1.6	0
638	Early response of C-reactive protein as a predictor of survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. International Journal of Clinical Oncology, 2017, 22, 1081-1086.	2.2	25
639	Modelos de riesgo en pacientes con carcinoma de células renales localizado. Actas Urológicas Españolas, 2017, 41, 564-570.	0.7	3
640	Immune Check Point Inhibition in Sarcomatoid Renal Cell Carcinoma: A New Treatment Paradigm. Clinical Genitourinary Cancer, 2017, 15, e897-e901.	1.9	12
641	Sunitinib in the treatment of renal cell carcinoma: an update on recent evidence. Therapeutic Advances in Urology, 2017, 9, 195-207.	2.0	47
642	Optimal Surveillance Strategies After Surgery for Renal Cell Carcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 835-840.	4.9	21
643	Current management of renal cell cancer. Trends in Urology & Men's Health, 2017, 8, 21-25.	0.4	2
644	Metastases of Renal Cell Carcinoma to the Contralateral Adrenal Gland Managed by Laparoscopic Adrenalectomy. Indian Journal of Surgical Oncology, 2017, 8, 326-330.	0.7	4
645	Progression-free survival of first-line treatment with molecular-targeted therapy may be a meaningful intermediate endpoint for overall survival in patients with metastatic renal cell carcinoma. Molecular and Clinical Oncology, 2017, 7, 454-460.	1.0	0

#	Article	IF	CITATIONS
646	Prognostic and Predictive Markers, and Stratifications Tables, for the Detection and Treatment of Renal Cell Carcinoma. , 2017, , 1-17.		1
647	Cytoreductive nephrectomy in patients with metastatic renal cell carcinoma in the era of targeted therapy: a bibliographic review. World Journal of Urology, 2017, 35, 1807-1816.	2.2	8
648	Prognostic role of the cumulative toxicity in patients affected by metastatic renal cells carcinoma and treated with first-line tyrosine kinase inhibitors. Anti-Cancer Drugs, 2017, 28, 206-212.	1.4	9
649	Integrating cytokines and angiogenic factors and tumour bulk with selected clinical criteria improves determination of prognosis in advanced renal cell carcinoma. British Journal of Cancer, 2017, 117, 478-484.	6.4	12
651	Overcoming intratumoural heterogeneity for reproducible molecular risk stratification: a case study in advanced kidney cancer. BMC Medicine, 2017, 15, 118.	5.5	8
652	Prognostic value of CC-chemokine receptor seven expression in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor. BMC Cancer, 2017, 17, 70.	2.6	10
653	Haemoglobin level increase as an efficacy biomarker during axitinib treatment for metastatic renal cell carcinoma: a retrospective study. BMC Cancer, 2017, 17, 355.	2.6	7
654	Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers: a first-in-human study in unfavourable risk patients with metastatic renal cell carcinoma. , 2017, 5, 52.		42
655	Association of post-treatment hypoalbuminemia and survival in Chinese patients with metastatic renal cell carcinoma. Chinese Journal of Cancer, 2017, 36, 47.	4.9	8
656	Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. European Urology, 2017, 71, 970-978.	1.9	12
657	Long-Term Outcomes of 98 Surgically Resected Metastatic Tumors in the Pancreas. Annals of Surgical Oncology, 2017, 24, 801-807.	1.5	20
658	Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma. Oncologist, 2017, 22, 41-52. Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma	3.7	61
659	treated with first-line and subsequent second-line targeted therapy: A proposal of the modified-IMDC risk model11Dr. Mizuno reports grants from The Japan Agency for Medical Research and Development (AMED), personal fees from Pfizer, grants and personal fees from Novartis, during the conduct of the study. Dr. Mikami reports grants from The Japan Agency for Medical Research and Development (AMED)	1.6	24
660	during the con. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 39.e19-39.e28. Paratesticular Metastasis of a Clear-Cell Renal-Cell Carcinoma With Renal Vein Thrombus Mimicking Primary Testicular Cancer. Clinical Genitourinary Cancer, 2017, 15, e123-e126.	1.9	4
661	Renal fossa recurrence after nephrectomy for renal cell carcinoma: prognostic features and oncological outcomes. BJU International, 2017, 119, 116-127.	2.5	33
662	Assessment of Efficacy, Safety, and Quality of Life of 124 Patients Treated With Axitinib as Second-Line Therapy for Metastatic Renal-Cell Carcinoma: Experience in Real-World Clinical Practice in Japan. Clinical Genitourinary Cancer, 2017, 15, 122-128.	1.9	26
663	Long-term response to sunitinib: everolimus treatment in metastatic clear cell renal cell carcinoma. Future Oncology, 2017, 13, 31-49.	2.4	19
664	Postoperative Changes in Skeletal Muscle Mass Predict Survival of Patients With Metastatic Renal Cell Carcinoma Undergoing Cytoreductive Nephrectomy. Clinical Genitourinary Cancer, 2017, 15, e229-e238.	1.9	32
#	Article	IF	CITATIONS
-----	---	------	-----------
665	Revisión sistemática de los factores pronósticos del carcinoma renal. Actas Urológicas Españolas, 2017, 41, 215-225.	0.7	11
666	Clinical Effect of Dose Escalation After Disease Progression in Patients With Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2017, 15, e275-e280.	1.9	19
667	How Did We Obtain Complete Remission in Patients Who Had Metastatic Renal Cancer in the Era of Targeted Therapies?. Annals of Surgical Oncology, 2017, 24, 369-374.	1.5	7
668	Metastatic Tumor Burden Does Not Predict Overall Survival Following Cytoreductive Nephrectomy for Renal Cell Carcinoma: a Novel 3-Dimensional Volumetric Analysis. Urology, 2017, 100, 139-144.	1.0	5
669	Heterogeneity of Patients With Intermediate-Prognosis Metastatic Renal Cell Carcinoma Treated With Sunitinib. Clinical Genitourinary Cancer, 2017, 15, 291-299.e1.	1.9	36
670	Expression and prognostic significance of VEGF and mTOR pathway proteins in metastatic renal cell carcinoma patients: a prognostic immunohistochemical profile for kidney cancer patients. World Journal of Urology, 2017, 35, 411-419.	2.2	20
671	Synchronous Metastatic Clear-Cell Renal Cell Carcinoma: A Distinct Morphologic, Immunohistochemical, and Molecular Phenotype. Clinical Genitourinary Cancer, 2017, 15, e1-e7.	1.9	20
673	Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. Journal of Clinical Oncology, 2017, 35, 591-597.	1.6	584
674	Survival of Patients With Advanced or Metastatic Renal Cell Carcinoma in Routine Practice Differs From That in Clinical Trials—Analyses From the German Clinical RCC Registry. Clinical Genitourinary Cancer, 2017, 15, e209-e215.	1.9	46
675	Association of Circulating Tumor DNA (ctDNA) Detection in Metastatic Renal Cell Carcinoma (mRCC) with Tumor Burden. Kidney Cancer, 2017, 1, 65-70.	0.4	36
676	Metastatic Surgery in Advanced Renal Cell Carcinoma. , 2017, , 1-26.		0
677	Neutrophils in cancer: prognostic role and therapeutic strategies. Molecular Cancer, 2017, 16, 137.	19.2	295
678	Treatment of Advanced Renal Cell Carcinoma: Recent Advances and Current Role of Immunotherapy, Surgery, and Cryotherapy. Tumori, 2017, 103, 15-21.	1.1	8
680	Sequential Treatment with Pazopanib and Everolimus in Metastatic Renal Cell Carcinoma. Frontiers in Pharmacology, 2017, 8, 484.	3.5	4
681	The Inverse Association between the Baseline Renal Function and Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with Molecular-Targeted Agents. Current Urology, 2017, 10, 186-192.	0.6	1
682	Clinical outcomes of the sequential use of pazopanib followed by everolimus for the treatment of metastatic renal cell carcinoma: A multicentre study in Korea. Canadian Urological Association Journal, 2017, 12, E15-20.	0.6	2
683	Primary Tumor Characteristics Are Important Prognostic Factors for Sorafenib-Treated Patients with Metastatic Renal Cell Carcinoma: A Retrospective Multicenter Study. BioMed Research International, 2017, 2017, 1-13.	1.9	4
684	Case: Secondary polycythemia due to pazopanib in patients with metastatic renal cell carcinoma. Canadian Urological Association Journal, 2017, 11, E449-50.	0.6	8

	C	ITATION REPORT	
#	Article	IF	CITATIONS
685	Current management options in metastatic renal cell cancer. Oncology Reviews, 2017, 11, 339.	1.8	13
686	Neutrophil-lymphocyte ratio as a predictive biomarker for response to high dose interleukin-2 in patients with renal cell carcinoma. BMC Urology, 2017, 17, 1.	1.4	42
687	Feature selection through validation and un-censoring of endovascular repair survival data for predicting the risk of re-intervention. BMC Medical Informatics and Decision Making, 2017, 17, 115.	3.0	26
688	Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy. , 2017, 5, 82.		77
689	Comparison of efficacy, safety, and quality of life between sorafenib and sunitinib as first-line therapy for Chinese patients with metastatic renal cell carcinoma. Chinese Journal of Cancer, 2017, 36, 64.	/ 4.9	18
690	Outcomes of Metastatic Chromophobe Renal Cell Carcinoma (chrRCC) in the Targeted Therapy Era: Results from the International Metastatic Renal Cell Cancer Database Consortium (IMDC). Kidney Cancer, 2017, 1, 41-47.	0.4	13
691	Renal cell carcinoma: the search for a reliable biomarker. Translational Cancer Research, 2017, 6, 620-632.	1.0	78
692	Real-world experience of everolimus as second-line treatment in metastatic renal cell cancer after failure of pazopanib. OncoTargets and Therapy, 2017, Volume 10, 4885-4893.	2.0	6
693	Overall survival in renal cell carcinoma after introduction of targeted therapies: a Norwegian population-based study. OncoTargets and Therapy, 2017, Volume 10, 371-385.	2.0	26
694	Tumoral ANXA1 Is a Predictive Marker for Sunitinib Treatment of Renal Cancer Patients. Journal of Cancer, 2017, 8, 3975-3983.	2.5	9
695	Management of advanced kidney cancer: Canadian Kidney Cancer Forum (CKCF) consensus update 2 Canadian Urological Association Journal, 2017, 11, 310-320.	2017. 0.6	6
696	Too Much or Just Enough of a Good Thing: Vascular Endothelial Growth Factor Inhibition in Renal Cell Carcinoma?. Journal of Clinical Oncology, 2017, 35, 1755-1757.	1.6	0
697	Reply to C. Buttigliero et al and B. Biswas et al. Journal of Clinical Oncology, 2017, 35, 1266-1267.	1.6	0
698	Hypertension and Survival in Renal Cell Carcinoma Treated with anti-VEGFR Agents: A Systematic Review and Meta-Analysis. Journal of Onco-Nephrology, 2017, 1, 120-126.	0.6	1
699	Renal Medullary Carcinoma. Journal of Oncology Practice, 2017, 13, 422-423.	2.5	2
700	Patient-specific molecular alterations are associated with metastatic clear cell renal cell cancer progressing under tyrosine kinase inhibitor therapy. Oncotarget, 2017, 8, 74049-74057.	1.8	14
701	Renovascular Safety of Sunitinib in Renal Cell Carcinoma: The Prognostic Value of Hypertension and Proteinuria. Journal of Onco-Nephrology, 2017, 1, 213-219.	0.6	0
702	Online tools for patient counseling in bladder and kidney cancer—ready for prime time?. Translation Andrology and Urology, 2017, 6, 1123-1131.	nal 1.4	2

#	Article	IF	CITATIONS
703	Molecular Subtypes of Clear-cell Renal Cell Carcinoma are Prognostic for Outcome After Complete Metastasectomy. European Urology, 2018, 74, 474-480.	1.9	72
704	Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials. British Journal of Cancer, 2018, 118, 763-769.	6.4	28
705	Neutrophil-to-lymphocyte Ratio, Platelet-to-lymphocyte Ratio, and C-reactive Protein as New and Simple Prognostic Factors in Patients With Metastatic Renal Cell Cancer Treated With Tyrosine Kinase Inhibitors: AÂSystemic Review and Meta-analysis. Clinical Genitourinary Cancer, 2018, 16, e685-e693.	1.9	60
706	Pattern of Care Study in Metastatic Renal-Cell Carcinoma in the Preimmunotherapy Era in Switzerland. Clinical Genitourinary Cancer, 2018, 16, e711-e718.	1.9	1
707	Targeting the Tumor Microenvironment with Immunotherapy for Genitourinary Malignancies. Current Treatment Options in Oncology, 2018, 19, 16.	3.0	5
708	Cabozantinib Versus Standard-of-Care Comparators in the Treatment of Advanced/Metastatic Renal Cell Carcinoma in Treatment-naÃ ⁻ ve Patients: a Systematic Review and Network Meta-Analysis. Targeted Oncology, 2018, 13, 205-216.	3.6	9
709	A Genetic Polymorphism in <i>CTLA-4</i> Is Associated with Overall Survival in Sunitinib-Treated Patients with Clear Cell Metastatic Renal Cell Carcinoma. Clinical Cancer Research, 2018, 24, 2350-2356.	7.0	7
710	Prognostic Value of Baseline Serum C-Reactive Protein Level in Intermediate-Risk Group Patients With Metastatic Renal-Cell Carcinoma Treated by First-Line Vascular Endothelial Growth Factor–Targeted Therapy. Clinical Genitourinary Cancer, 2018, 16, e927-e933.	1.9	19
711	Platelet-to-lymphocyte ratio in advanced Cancer: Review and meta-analysis. Clinica Chimica Acta, 2018, 483, 48-56.	1.1	130
712	Role of metastasisâ€directed treatment in kidney cancer. Cancer, 2018, 124, 3641-3655.	4.1	38
713	Predictors of Long-Term Response With Pazopanib in Patients With Advanced Renal-Cell Carcinoma. Clinical Genitourinary Cancer, 2018, 16, 293-297.	1.9	6
714	Cabozantinib in the treatment of advanced renal cell carcinoma in adults following prior vascular endothelial growth factor targeted therapy: clinical trial evidence and experience. Therapeutic Advances in Urology, 2018, 10, 109-123.	2.0	27
715	Association of Expression Levels or Activation Status of STAT3 with Treatment Outcomes of Sunitinib in Patients with Renal Cell Carcinoma. Targeted Oncology, 2018, 13, 371-378.	3.6	7
716	The Platelet Lifeline to Cancer: Challenges and Opportunities. Cancer Cell, 2018, 33, 965-983.	16.8	390
717	Prognostic significance of nephrectomy in metastatic renal cell carcinoma treated with systemic cytokine or targeted therapy: A 16-year retrospective analysis. Scientific Reports, 2018, 8, 2974.	3.3	4
719	The prognostic and predictive value of vascular response parameters measured by dynamic contrast-enhanced-CT, -MRI and -US in patients with metastatic renal cell carcinoma receiving sunitinib. European Radiology, 2018, 28, 2281-2290.	4.5	28
720	Circulating tumor cells in genitourinary tumors. Therapeutic Advances in Urology, 2018, 10, 65-77.	2.0	14
721	Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial. Lancet Oncology, The, 2018, 19, 405-415	10.7	305

#	Article	IF	CITATIONS
722	CXCR1 expression predicts benefit from tyrosine kinase inhibitors therapy in patients with metastatic renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 242.e15-242.e21.	1.6	2
723	Prognostic and clinicopathological significance of PD-L1 in patients with renal cell carcinoma: a meta-analysis based on 1863 individuals. Clinical and Experimental Medicine, 2018, 18, 165-175.	3.6	41
724	Indications, complications, and outcomes following surgical management of locally advanced and metastatic renal cell carcinoma. Expert Review of Anticancer Therapy, 2018, 18, 237-250.	2.4	9
725	Treatments, Outcomes, and Validity of Prognostic Scores in Patients With Sarcomatoid Renal Cell Carcinoma: A 20-Year Single-Institution Experience. Clinical Genitourinary Cancer, 2018, 16, e577-e586.	1.9	15
726	PD-1 Blockade in Renal Cell Carcinoma. , 2018, , 345-355.		0
727	Prognostic effect of cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma: a comparative study using inverse probability of treatment weighting. World Journal of Urology, 2018, 36, 417-425.	2.2	24
728	Sunitinib in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to International Metastatic Renal Cell Carcinoma Database Consortium Risk Group. Clinical Genitourinary Cancer, 2018, 16, 298-304.	1.9	41
729	Up-regulation of SR-BI promotes progression and serves as a prognostic biomarker in clear cell renal cell carcinoma. BMC Cancer, 2018, 18, 88.	2.6	36
730	Prognostic factors and prognostic models for renal cell carcinoma: a literature review. World Journal of Urology, 2018, 36, 1943-1952.	2.2	162
731	Real-world evidence in metastatic renal cell carcinoma. Tumori, 2018, 104, 76-82.	1.1	11
732	Comparative Survival following Initial Cytoreductive Nephrectomy versus Initial Targeted Therapy for Metastatic Renal Cell Carcinoma. Journal of Urology, 2018, 200, 528-534.	0.4	59
733	Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 2018, 378, 1277-1290.	27.0	3,334
734	Prognostic and Predictive Factors for Renal Cell Carcinoma. Targeted Oncology, 2018, 13, 309-331.	3.6	5
735	Clinical Relevance of Gene Copy Number Variation in Metastatic Clear Cell Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2018, 16, e795-e805.	1.9	13
736	Effect of treatment dose reductions in the setting of hand-foot syndrome on survival outcomes in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor receptor inhibitors. Journal of Oncology Pharmacy Practice, 2018, 24, 190-197.	0.9	0
737	Stereotactic Ablative Radiotherapy (SABR) for Large Renal Tumors. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 568-575.	1.3	27
738	Systemic therapy following metastasectomy for renal cell carcinoma: Using insights from other clinical settings to address unanswered questions. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 17-22.	1.6	13
739	Long-Term Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma: A Pooled Analysis of Clinical Trials. Clinical Genitourinary Cancer, 2018, 16, 6-12.e4.	1.9	11

#	Article	IF	CITATIONS
740	Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature. European Urology Focus, 2018, 4, 442-454.	3.1	10
741	Sunitinib dose-escalation after disease progression in metastatic renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 12.e1-12.e6.	1.6	11
742	Expression of tyrosine kinase receptor AXL is associated with worse outcome of metastatic renal cell carcinomas treated with sunitinib. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 11.e13-11.e21.	1.6	24
743	Characterization of Patients With Poor-Risk Metastatic Renal-Cell Carcinoma: Results From aÂPooled Clinical Trials Database. Clinical Genitourinary Cancer, 2018, 16, 13-20.e3.	1.9	1
744	HLA class I expression predicts prognosis and therapeutic benefits from tyrosine kinase inhibitors in metastatic renal-cell carcinoma patients. Cancer Immunology, Immunotherapy, 2018, 67, 79-87.	4.2	7
745	Pro-angiogenic gene expression is associated with better outcome on sunitinib in metastatic clear-cell renal cell carcinoma. Acta Oncológica, 2018, 57, 498-508.	1.8	41
746	Comparative Effectiveness of Initial Surgery vs Initial Systemic Therapy for Metastatic Kidney Cancer in the Targeted Therapy Era: Analysis of a Population-based Cohort. Urology, 2018, 113, 146-152.	1.0	15
747	Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated With Outcome During Pazopanib Therapy in the Metastatic Setting. Clinical Genitourinary Cancer, 2018, 16, e605-e612.	1.9	37
748	SEOM clinical guideline for treatment of kidney cancer (2017). Clinical and Translational Oncology, 2018, 20, 47-56.	2.4	15
749	Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (<scp>HIV</scp>)â€protease inhibitors lopinavir or nelfinavir. BJU International, 2018, 121, 600-609.	2.5	11
750	Phase I Study of Dalteparin in Combination With Sunitinib in Patients With Metastatic Clear Cell Renal Carcinoma. Clinical Genitourinary Cancer, 2018, 16, e1-e9.	1.9	11
751	Reconciling the Role of Vascular Endothelial Growth Factor-Targeted Therapies in Adjuvant Renal Cell Carcinoma Treatment. Kidney Cancer, 2018, 2, 95-102.	0.4	0
752	Prognostication in Kidney Cancer: Recent Advances and Future Directions. Journal of Clinical Oncology, 2018, 36, 3567-3573.	1.6	49
753	Personalized Management of Advanced Kidney Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 330-341.	3.8	25
754	Surgical Management of Advanced Kidney Cancer: The Role of Cytoreductive Nephrectomy and Lymphadenectomy. Journal of Clinical Oncology, 2018, 36, 3601-3607.	1.6	16
755	Evolving Systemic Treatment Landscape for Patients With Advanced Renal Cell Carcinoma. Journal of Clinical Oncology, 2018, 36, 3615-3623.	1.6	65
756	Progress in Kidney Cancer Outcomes Through Collaboration, Innovation, and Discovery. Journal of Clinical Oncology, 2018, 36, 3529-3532.	1.6	0
757	Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of cytoreductive nephrectomy for patients with metastatic renal cell carcinoma. Canadian Urological Association Journal, 2018, 13, 166-174.	0.6	10

#	Article	IF	CITATIONS
758	The De Ritis and Neutrophil-to-Lymphocyte Ratios May Aid in the Risk Assessment of Patients with Metastatic Renal Cell Carcinoma. Journal of Oncology, 2018, 2018, 1-8.	1.3	9
759	Early tumor shrinkage as a predictive factor of metastatic renal cell carcinoma in molecular targeted therapy: A single institutional study. Molecular and Clinical Oncology, 2018, 10, 125-131.	1.0	3
760	Surgery for metastases of renal cell carcinoma: outcome of treatments and preliminary assessment of Leuven-Udine prognostic groups in the targeted therapy era. Scandinavian Journal of Urology, 2018, 52, 419-426.	1.0	16
762	Immunoscore System for Predicting Clinical Outcome of Metastatic Renal Cell Carcinoma Patients Treated with Tyrosine Kinase Inhibitors. Journal of Cancer, 2018, 9, 4099-4107.	2.5	7
763	Prognostic role of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in prostate cancer: A meta-analysis of results from multivariate analysis. International Journal of Surgery, 2018, 60, 216-223.	2.7	43
764	Sunitinib Treatment Modification in First-Line Metastatic Renal Cell Carcinoma: Analysis of the STAR-TOR Registry. Anticancer Research, 2018, 38, 6413-6422.	1.1	19
765	Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study. Lancet Oncology, The, 2018, 19, 1688-1698.	10.7	119
766	Incorporating Neutrophil-to-lymphocyte Ratio and Platelet-to-lymphocyte Ratio in Place of Neutrophil Count and Platelet Count Improves Prognostic Accuracy of the International Metastatic Renal Cell Carcinoma Database Consortium Model. Cancer Research and Treatment, 2018, 50, 103-110.	3.0	29
767	Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analyses. BMC Cancer, 2018, 18, 1271.	2.6	7
768	Activity of cabozantinib in radioresistant brain metastases from renal cell carcinoma: two case reports. Journal of Medical Case Reports, 2018, 12, 351.	0.8	23
769	Current Landscape and the Potential Role of Hypoxia-Inducible Factors and Selenium in Clear Cell Renal Cell Carcinoma Treatment. International Journal of Molecular Sciences, 2018, 19, 3834.	4.1	31
770	Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma. BMC Pharmacology & Toxicology, 2018, 19, 77.	2.4	19
771	Checkpoint molecule PD-1-assisted CD8 ⁺ T lymphocyte count in tumor microenvironment predicts overall survival of patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. Cancer Management and Research, 2018, Volume 10, 3419-3431.	1.9	47
773	Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Cancer, 2018, 124, 3677-3683.	4.1	53
774	Predictive role of changes in the tumor burden and International Metastatic Renal Cell Carcinoma Database Consortium class during active surveillance for metastatic renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 526.e13-526.e18.	1.6	10
776	Effect of Changes in Skeletal Muscle Mass on Oncological Outcomes During First-Line Sunitinib Therapy for Metastatic Renal Cell Carcinoma. Targeted Oncology, 2018, 13, 745-755.	3.6	14
777	Contemporary treatment of metastatic renal cell carcinoma. Medical Oncology, 2018, 35, 156.	2.5	40
778	Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab. , 2018, 6, 107.		52

#	Article	IF	CITATIONS
779	Genitourinary Pathology Reporting Parameters Most Relevant to the Medical Oncologist. Surgical Pathology Clinics, 2018, 11, 877-891.	1.7	0
780	Risk prediction models for cancer-specific survival following cytoreductive nephrectomy in the contemporary era. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 499.e1-499.e7.	1.6	6
781	Immune Checkpoint Inhibitors: Toward New Paradigms in Renal Cell Carcinoma. Drugs, 2018, 78, 1443-1457.	10.9	70
782	Renal cancer: new models and approach for personalizing therapy. Journal of Experimental and Clinical Cancer Research, 2018, 37, 217.	8.6	17
783	miR-9-5p in Nephrectomy Specimens is a Potential Predictor of Primary Resistance to First-Line Treatment with Tyrosine Kinase Inhibitors in Patients with Metastatic Renal Cell Carcinoma. Cancers, 2018, 10, 321.	3.7	18
784	Efficacy of Axitinib as Second-line Treatment in Locally Advanced and Metastatic Renal Cell Carcinoma. Anticancer Research, 2018, 38, 5387-5392.	1.1	11
785	Incidence and Outcomes of Delayed Targeted Therapy After Cytoreductive Nephrectomy for Metastatic Renal-Cell Carcinoma: A Nationwide Cancer Registry Study. Clinical Genitourinary Cancer, 2018, 16, e1221-e1235.	1.9	14
786	Re: Sunitinib Alone or after Nephrectomy in Metastatic Renal-cell Carcinoma. European Urology, 2018, 74, 842-843.	1.9	6
787	Modulating BET Bromodomain Inhibitor ZENâ€3694 and Enzalutamide Combination Dosing in a Metastatic Prostate Cancer Patient Using CURATE.AI, an Artificial Intelligence Platform. Advanced Therapeutics, 2018, 1, 1800104.	3.2	76
788	Advances in the Treatment of Metastatic Renal Cell Carcinoma. Cancer Treatment and Research, 2018, 175, 127-137.	0.5	6
789	Pazopanib-Induced Cutaneous Leukocytoclastic Vasculitis: An Exclusion Diagnosis of a Multidisciplinary Approach. Case Reports in Oncology, 2018, 10, 1041-1049.	0.7	5
790	Updates to the Management of Kidney Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 639-641.	4.9	29
791	Effect of African-American race on cancer specific mortality differs according to clear cell vs. non-clear cell histologic subtype in metastatic renal cell carcinoma. Cancer Epidemiology, 2018, 54, 112-118.	1.9	13
792	The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma. British Journal of Cancer, 2018, 119, 160-163.	6.4	39
793	Is It Possible to Improve Prognostic Classification in Patients Affected by Metastatic Renal Cell Carcinoma With an Intermediate or PoorÂPrognosis?. Clinical Genitourinary Cancer, 2018, 16, 355-359.e1.	1.9	31
794	Molecular targeted therapies of renal cell carcinoma considering life stage of the patient: Two case reports. Experimental and Therapeutic Medicine, 2018, 15, 3976-3980.	1.8	3
795	Significance of Age in Japanese Patients Receiving Sunitinib as First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: Comparative Assessment of Efficacy and Safety between Patients Aged <75 and ≥75 Years. Anticancer Research, 2018, 38, 3593-3599.	1.1	4
796	Changes in Treatment Reality and Survival of Patients With Advanced Clear Cell Renal Cell Carcinoma – Analyses From the German Clinical RCC-Registry. Clinical Genitourinary Cancer, 2018, 16, e1101-e1115.	1.9	16

#	Article	IF	CITATIONS
797	Effect of Targeted Therapies on Prognostic Factors, Patterns of Care, and Survival in Patients With Renal Cell Carcinoma and Brain Metastases. International Journal of Radiation Oncology Biology Physics, 2018, 101, 845-853.	0.8	22
798	Changeable Conditional Survival Rates and Associated Prognosticators in Patients with Metastatic Renal Cell Carcinoma Receiving First Line Targeted Therapy. Journal of Urology, 2018, 200, 989-995.	0.4	16
799	Durable response after discontinuation of nivolumab therapy in patients with metastatic renal cell carcinoma. Japanese Journal of Clinical Oncology, 2018, 48, 860-863.	1.3	14
800	llixadencel – an Allogeneic Cell-Based Anticancer Immune Primer for Intratumoral Administration. Pharmaceutical Research, 2018, 35, 156.	3.5	16
801	Cytoreductive nephrectomy: questions remain after CARMENA. Nature Reviews Urology, 2018, 15, 530-532.	3.8	5
802	The neutrophil-to-lymphocyte ratio makes the Heng risk model improve better the prediction of overall survival in metastatic renal cell cancer patients. Japanese Journal of Clinical Oncology, 2018, 48, 835-840.	1.3	8
803	The Additional Costs per Month of Progression-Free Survival and Overall Survival: An Economic Model Comparing Everolimus with Cabozantinib, Nivolumab, and Axitinib for Second-Line Treatment of Metastatic Renal Cell Carcinoma. Journal of Managed Care & Specialty Pharmacy, 2018, 24, 335-343.	0.9	14
804	Role of radiotherapy in improving activity of immune-modulating drugs in advanced renal cancer: Biological rationale and clinical evidences. Cancer Treatment Reviews, 2018, 69, 215-223.	7.7	19
805	External validation of a predictive model of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. World Journal of Urology, 2018, 36, 1973-1980.	2.2	10
807	Epigenetic modifiers: activities in renal cell carcinoma. Nature Reviews Urology, 2018, 15, 599-614.	3.8	68
808	Re: Fabio Conforti, Laura Pala, Vincenzo Bagnardi, et al. Cancer Immunotherapy Efficacy and Patients' Sex: A Systematic Review and Meta-analysis. Lancet Oncol 2018;19:737–46. European Urology, 2018, 74, e139-e140.	1.9	12
809	Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma. , 2018, 6, 5.		200
810	A prospective phase I dose-escalation trial of stereotactic ablative radiotherapy (SABR) as an alternative to cytoreductive nephrectomy for inoperable patients with metastatic renal cell carcinoma. Radiation Oncology, 2018, 13, 47.	2.7	23
811	Local therapy of stage IV renal cell cancer: a case report. Memo - Magazine of European Medical Oncology, 2018, 11, 38-42.	0.5	1
812	Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program. Clinical Genitourinary Cancer, 2018, 16, e945-e951.	1.9	30
813	Lenvatinib for the treatment of kidney cancer. Expert Review of Anticancer Therapy, 2018, 18, 511-518.	2.4	13
814	The role of surgery in the management of metastatic kidney cancer: an evidence-based collaborative review. Minerva Urology and Nephrology, 2018, 70, 109-125.	2.5	4
815	Body mass index as independent predictor of overall survival in patients with advanced renal cell carcinoma at start of systemic treatment—Analyses from the German clinical RCC-Registry. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 470.e1-470.e9.	1.6	7

#	Article	IF	CITATIONS
816	The association between facility case volume and overall survival in patients with metastatic renal cell carcinoma in the targeted therapy era. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 470.e19-470.e29.	1.6	4
817	Fourth-Line Therapy in Metastatic Renal Cell Carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC)1. Kidney Cancer, 2018, 2, 31-36.	0.4	10
818	Tumor infiltrating CD19 ⁺ B lymphocytes predict prognostic and therapeutic benefits in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors. Oncolmmunology, 2018, 7, 1-9.	4.6	93
819	Association of genetic polymorphisms in <i>VEGF</i> â€460, â€7 and â€583 and hematocrit level with the development of idiopathic recurrent pregnancy loss and a metaâ€analysis. Journal of Gene Medicine, 2018, 20, e3048.	2.8	8
820	Significance of introduction of alternative dosing schedule for sunitinib during first-line treatment of patients with metastatic renal cell carcinoma. Medical Oncology, 2018, 35, 133.	2.5	15
821	Effect of Switching Systemic Treatment After Stereotactic Radiosurgery for Oligoprogressive, Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2018, 16, 413-419.e1.	1.9	21
822	Epigenetics in renal cell cancer: mechanisms and clinical applications. Nature Reviews Urology, 2018, 15, 430-451.	3.8	115
823	The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma. Anti-Cancer Drugs, 2018, 29, 705-709.	1.4	2
824	Hyponatremia associates with poor outcome in metastatic renal cell carcinoma patients treated with everolimus: prognostic impact. Acta Oncológica, 2018, 57, 1580-1585.	1.8	8
825	Normalization of C-reactive protein levels following cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors is associated with improved overall survival. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 339.e9-339.e15.	1.6	14
826	An Empirical Approach Leveraging Tumorgrafts to Dissect the Tumor Microenvironment in Renal Cell Carcinoma Identifies Missing Link to Prognostic Inflammatory Factors. Cancer Discovery, 2018, 8, 1142-1155.	9.4	138
827	Inflammatory markers and overall survival in older adults with cancer. Journal of Geriatric Oncology, 2019, 10, 279-284.	1.0	16
828	Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncology, The, 2019, 20, 1370-1385.	10.7	594
829	Treatment of advanced renal cell carcinoma patients with cabozantinib, an oral multityrosine kinase inhibitor of MET, AXL and VEGF receptors. Future Oncology, 2019, 15, 2337-2348.	2.4	15
830	Baseline perfusion CT parameters as potential biomarkers in predicting long-term prognosis of localized clear cell renal cell carcinoma. Abdominal Radiology, 2019, 44, 3370-3376.	2.1	3
831	Serum Lactate Dehydrogenase Before Nivolumab Treatment Could Be a Therapeutic Prognostic Biomarker for Patients With Metastatic Clear Cell Renal Cell Carcinoma. Anticancer Research, 2019, 39, 4371-4377.	1.1	14
832	Time on Therapy for at Least Three Months Correlates with Overall Survival in Metastatic Renal Cell Carcinoma. Cancers, 2019, 11, 1000.	3.7	17
833	<p>Prognostic value of pretreatment neutrophil count in metastatic renal cell carcinoma: a systematic review and meta-analysis</p> . Cancer Management and Research, 2019, Volume 11, 5365-5374	1.9	6

#	Article	IF	CITATIONS
834	Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictive and prognostic markers in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiation. BMC Cancer, 2019, 19, 664.	2.6	40
835	Efficacy and safety of cytokines versus first-line sunitinib and second-line axitinib for patients with metastatic renal cell carcinoma (ESCAPE study): A study protocol for phase III randomized sequential open-label study. Contemporary Clinical Trials Communications, 2019, 15, 100403.	1.1	4
836	A Meta-Analysis Evaluating Clinical Outcomes of Patients with Renal Cell Carcinoma Harboring Chromosome 9P Loss. Molecular Diagnosis and Therapy, 2019, 23, 569-577.	3.8	9
837	Validation of the IMDC Prognostic Model in Patients With Metastatic Renal-Cell Carcinoma Treated With First-Line Axitinib: A Multicenter Retrospective Study. Clinical Genitourinary Cancer, 2019, 17, e1080-e1089.	1.9	10
838	Survival of patients receiving systematic therapy for metachronous or synchronous metastatic renal cell carcinoma: a retrospective analysis. BMC Cancer, 2019, 19, 688.	2.6	5
839	Predictive factors for toxicity and survival of second-line sunitinib in advanced gastrointestinal stromal tumours (GIST). Acta Oncológica, 2019, 58, 1648-1654.	1.8	11
840	Efficacy and safety of perioperative appliance of sunitinib in patients with metastatic or advanced renal cell carcinoma. Medicine (United States), 2019, 98, e15424.	1.0	7
841	Management of kidney cancer patients: 2018 guidelines of the Italian Medical Oncology Association (AIOM). Tumori, 2019, 105, 3-12.	1.1	10
842	Random Allocated Study of Wrapping Oblate for Prevention of Everolimus-associated Stomatitis in Patients With Metastatic Renal Cell Carcinoma. Anticancer Research, 2019, 39, 3937-3944.	1.1	0
843	Management of Advanced Kidney Cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2019. Canadian Urological Association Journal, 2019, 13, 343-54.	0.6	10
844	First-Line Systemic Therapy for Metastatic Clear-Cell Renal Cell Carcinoma: Critical Appraisal of Emerging Options. Targeted Oncology, 2019, 14, 639-645.	3.6	14
845	Brain Metastasis From Renal-Cell Carcinoma: An Institutional Study. Clinical Genitourinary Cancer, 2019, 17, e1163-e1170.	1.9	36
846	Complications associated with perioperative use of tyrosine kinase inhibitor in cytoreductive nephrectomy. Scientific Reports, 2019, 9, 15272.	3.3	3
847	Prognostic value of PD-L1 expression for surgically treated localized renal cell carcinoma: implications for risk stratification and adjuvant therapies. Therapeutic Advances in Urology, 2019, 11, 175628721988260.	2.0	14
849	Effect of third- and fourth-line systemic therapies for metastatic renal cell carcinoma. Scientific Reports, 2019, 9, 15451.	3.3	8
850	The Changing Therapeutic Landscape of Metastatic Renal Cancer. Cancers, 2019, 11, 1227.	3.7	49
851	First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium. European Urology, 2019, 76, 861-867.	1.9	71
852	Novel Predictive Models of Early Death Less Than 1 Year in Patients With Metastatic Renal Cell Carcinoma After Treatment With First-line Tyrosine Kinase Inhibitors. Clinical Genitourinary Cancer, 2019, 17, e1137-e1146.	1.9	3

#	Article	IF	CITATIONS
854	Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma. European Urology Oncology, 2019, 2, 505-514.	5.4	50
855	Tumor Microenvironment Dynamics in Clear-Cell Renal Cell Carcinoma. Cancer Discovery, 2019, 9, 1349-1357.	9.4	226
856	Pathologic response and surgical outcomes in patients undergoing nephrectomy following receipt of immune checkpoint inhibitors for renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 924-931.	1.6	42
857	Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial. Lancet Oncology, The, 2019, 20, 1544-1555.	10.7	86
858	Clinicopathologic features associated with survival after cytoreductive nephrectomy for nonclear cell renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 811.e9-811.e16.	1.6	6
859	Sorafenib Versus Observation Following Radical Metastasectomy for Clear-cell Renal Cell Carcinoma: Results from the Phase 2 Randomized Open-label RESORT Study. European Urology Oncology, 2019, 2, 699-707.	5.4	38
860	Impact of Disagreement Between Two Risk Group Models on Prognosis in Patients With Metastatic Renal-Cell Carcinoma. Clinical Genitourinary Cancer, 2019, 17, e440-e446.	1.9	17
861	Predictive genomic markers of response to VEGF targeted therapy in metastatic renal cell carcinoma. PLoS ONE, 2019, 14, e0210415.	2.5	8
862	The current treatment patterns of metastatic renal cell carcinoma: A national cancer database review, 2004–2015. Journal of Clinical Urology, 2019, 12, 266-273.	0.1	1
863	Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial. Journal of Hematology and Oncology, 2019, 12, 4.	17.0	27
864	Clinical Outcomes of 42 Renal Cell Carcinoma Patients With Metastases Solely to the Lung Who Received Sorafenib as Second-line Systemic Therapy. Anticancer Research, 2019, 39, 1067-1072.	1.1	3
865	Sarcomatoid Renal Cell Carcinoma: Population-Based Study of 879 Patients. Clinical Genitourinary Cancer, 2019, 17, e447-e453.	1.9	34
866	Metachronous Isolated Splenic Metastasis in a Young Patient With Renal Cell Carcinoma: Case Report and Literature Review. Urology, 2019, 127, 13-18.	1.0	7
867	A meta-analysis of efficacy and safety of sorafenib versus other targeted agents for metastatic renal cell carcinoma. Medicine (United States), 2019, 98, e13779.	1.0	9
868	Tivozanib for the treatment of renal cell carcinoma: patient selection and perspectives. International Journal of Nephrology and Renovascular Disease, 2019, Volume 12, 137-141.	1.8	0
869	Real-world Effectiveness and Safety of Pazopanib in Patients With Intermediate Prognostic Risk Advanced Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2019, 17, e526-e533.	1.9	9
870	Tumoral Pyruvate Kinase L/R as a Predictive Marker for the Treatment of Renal Cancer Patients with Sunitinib and Sorafenib. Journal of Cancer, 2019, 10, 3224-3231.	2.5	18
871	Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor. Cancers, 2019, 11, 830.	3.7	29

#	Article	IF	CITATIONS
872	Medical Science and Research. Advances in Experimental Medicine and Biology, 2019, , .	1.6	2
873	Clear-cell Renal Cell Carcinoma: Molecular Characterization of IMDC Risk Groups and Sarcomatoid Tumors. Clinical Genitourinary Cancer, 2019, 17, e981-e994.	1.9	34
874	Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1931-1939.	6.4	53
875	Does CARMENA mark the end of cytoreductive nephrectomy for metastatic renal cell carcinoma?. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 525-528.	1.6	0
876	Expression of PD-1 and CTLA-4 Are Negative Prognostic Markers in Renal Cell Carcinoma. Journal of Clinical Medicine, 2019, 8, 743.	2.4	29
877	Improved identification of patients with oligometastatic clearÂcell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET/CT. Annals of Nuclear Medicine, 2019, 33, 617-623.	2.2	40
878	PD-L1 detection using 89Zr-atezolizumab immuno-PET in renal cell carcinoma tumorgrafts from a patient with favorable nivolumab response. , 2019, 7, 144.		53
879	A Retrospective Analysis of the Impact of Metastasectomy on Prognostic Survival According to Metastatic Organs in Patients With Metastatic Renal Cell Carcinoma. Frontiers in Oncology, 2019, 9, 413.	2.8	22
880	Survival and clinical prognostic factors in metastatic nonâ€clear cell renal cell carcinoma treated with targeted therapy: A multiâ€institutional, retrospective study using the Korean metastatic renal cell carcinoma registry. Cancer Medicine, 2019, 8, 3401-3410.	2.8	13
881	Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors. European Journal of Cancer, 2019, 114, 67-75.	2.8	88
882	Reassessing the Role of Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma in 2019. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 276-283.	3.8	11
883	The use of cytoreductive nephrectomy in patients with renal cell carcinoma. Expert Review of Anticancer Therapy, 2019, 19, 405-411.	2.4	2
884	Sub-classification of patients with intermediate-risk metastatic renal cell carcinoma treated with targeted therapy. Japanese Journal of Clinical Oncology, 2019, 49, 780-785.	1.3	2
886	Targeting Tyrosine kinases in Renal Cell Carcinoma: "New Bullets against Old Guys― International Journal of Molecular Sciences, 2019, 20, 1901.	4.1	41
887	Metastasectomy in Advanced Renal Cell Carcinoma: A Systematic Review. Kidney Cancer, 2019, 3, 31-40.	0.4	2
888	Real-World Outcomes of Nivolumab and Cabozantinib in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Current Oncology, 2019, 26, 175-179.	2.2	23
889	Assessing Outcomes and Prognostic Factors for First-Line Therapy in Elderly Patients With Metastatic Renal Cell Carcinoma: Real-Life Data From a Single United Kingdom Institution. Clinical Genitourinary Cancer, 2019, 17, e658-e663.	1.9	4
890	Towards individualized therapy for metastatic renal cell carcinoma. Nature Reviews Clinical Oncology, 2019, 16, 621-633.	27.6	148

			0
#	ARTICLE	IF	CITATIONS
891	metastatic renal cell cancer (mRCC): data from the PROCLAIMSM registry. , 2019, 7, 84.		34
892	sE-cadherin is upregulated in serum of patients with renal cell carcinoma and promotes tumor cell dissemination in vitro. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 355.e1-355.e9.	1.6	1
893	Radiological Response and Neutrophil-to-Lymphocyte Ratio as Predictive Factors for Progression-Free and Overall Survival in Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib. Advances in Experimental Medicine and Biology, 2019, 1153, 31-45.	1.6	7
894	Prognostic significance of the dynamic changes of systemic inflammatory response in metastatic renal cell carcinoma. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2019, 45, 89-99.	1.5	8
895	Serum Alpha1-Globulin as a Novel Prognostic Factor in Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors. Targeted Oncology, 2019, 14, 187-195.	3.6	5
896	Current Status and Future Directions of Immunotherapy in Renal Cell Carcinoma. Current Oncology Reports, 2019, 21, 34.	4.0	37
897	Disagreement in risk groups for metastatic renal cancer. Nature Reviews Urology, 2019, 16, 332-333.	3.8	2
898	Resection of pancreatic metastatic renal cell carcinoma: experience and long-term survival outcome from a large center in China. International Journal of Clinical Oncology, 2019, 24, 686-693.	2.2	10
899	A Cost-Effectiveness Analysis of Nivolumab and Ipilimumab Versus Sunitinib in First-Line Intermediate- to Poor-Risk Advanced Renal Cell Carcinoma. Oncologist, 2019, 24, 366-371.	3.7	26
900	Upfront cytoreductive nephrectomy vs. upfront systemic therapy in metastatic kidney cancer. Canadian Urological Association Journal, 2019, 13, E377-E381.	0.6	3
901	Prognostic impact of neutrophil-to-lymphocyte ratio in renal cell carcinoma: a systematic review and meta-analysis. Immunotherapy, 2019, 11, 631-643.	2.0	38
902	Current status of prognostic factors in patients with metastatic renal cell carcinoma. International Journal of Urology, 2019, 26, 608-617.	1.0	19
903	Prognostic Markers for Refined Stratification of IMDC Intermediate-Risk Metastatic Clear Cell Renal Cell Carcinoma Treated with First-Line Tyrosine Kinase Inhibitor Therapy. Targeted Oncology, 2019, 14, 179-186.	3.6	14
904	Surgery for highâ€risk locally advanced (<scp>pT</scp> 3c) renal tumours: oncological outcomes and prognostic significance of a modified International Metastatic Renal Cell Cancer Database Consortium (<scp>IMDC</scp>) score. BJU International, 2019, 124, 462-468.	2.5	4
905	The Changing Landscape of Management of Metastatic Renal Cell Carcinoma: Current Treatment Options and Future Directions. Current Treatment Options in Oncology, 2019, 20, 41.	3.0	25
906	The effect of a treatment delay on outcome in metastatic renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 529.e1-529.e7.	1.6	5
907	Construction and Validation of a 9-Gene Signature for Predicting Prognosis in Stage III Clear Cell Renal Cell Carcinoma. Frontiers in Oncology, 2019, 9, 152.	2.8	19
908	External validation of nomograms for prediction of progression-free survival and liver toxicity in patients with advanced renal cell carcinoma treated with pazopanib. International Journal of Clinical Oncology, 2019, 24, 698-705.	2.2	6

#	Article	IF	CITATIONS
909	Real-world Experience of Cabozantinib as Second- or Subsequent Line Treatment in Patients With Metastatic Renal Cell Carcinoma: Data From the Polish Managed Access Program. Clinical Genitourinary Cancer, 2019, 17, e556-e564.	1.9	17
910	Overview of current and future systemic therapy for metastatic renal cell carcinoma. Japanese Journal of Clinical Oncology, 2019, 49, 395-403.	1.3	38
911	Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 2019, 380, 1103-1115.	27.0	1,824
912	Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 2019, 380, 1116-1127.	27.0	2,319
913	A new prognostic model for survival in second line for metastatic renal cell carcinoma: development and external validation. Angiogenesis, 2019, 22, 383-395.	7.2	5
914	Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma. Clinical Genitourinary Cancer, 2019, 17, e513-e521.	1.9	31
915	Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2019, 30, 706-720.	1.2	750
916	The Emerging Role of Combination Angiogenesis Inhibitors and Immune Checkpoint Inhibitors in the Treatment of Metastatic Renal Cell Cancer. Kidney Cancer, 2019, 3, 81-91.	0.4	1
917	The Current and Evolving Landscape of First-Line Treatments for Advanced Renal Cell Carcinoma. Oncologist, 2019, 24, 338-348.	3.7	34
918	An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma. Oncologist, 2019, 24, 202-210.	3.7	24
919	Surgical metastasectomy for renal cell carcinoma: which patients are the real candidates for surgery?. Annals of Translational Medicine, 2019, 7, S273-S273.	1.7	7
920	Role of immunotherapy in metastatic renal cell cancer: past, present and future. Annals of Translational Medicine, 2019, 7, S349-S349.	1.7	5
922	Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. European Urology Oncology, 2019, 2, 643-648.	5.4	31
923	PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma. BMC Cancer, 2019, 19, 1102.	2.6	17
924	Development and Validation of a Novel Prognostic Model for Predicting Overall Survival in Treatment-naÃ⁻ve Castration-sensitive Metastatic Prostate Cancer. European Urology Oncology, 2019, 2, 320-328.	5.4	39
925	Individualised Indications for Cytoreductive Nephrectomy: Which Criteria Define the Optimal Candidates?. European Urology Oncology, 2019, 2, 365-378.	5.4	47
926	The impact of postoperative inflammatory biomarkers on oncologic outcomes of bladder cancer. Progres En Urologie, 2019, 29, 270-281.	0.8	12
928	BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma. Journal of Translational Medicine, 2019, 17, 386.	4.4	32

#	Article	IF	CITATIONS
929	Treatment selection for firstâ€line metastatic renal cell carcinoma in Australia: Impact of new therapy options. Asia-Pacific Journal of Clinical Oncology, 2019, 15, 3-10.	1.1	3
930	The Interplay between Inflammation, Anti-Angiogenic Agents, and Immune Checkpoint Inhibitors: Perspectives for Renal Cell Cancer Treatment. Cancers, 2019, 11, 1935.	3.7	21
931	ls cytoreductive nephrectomy relevant in the immunotherapy era?. Current Opinion in Urology, 2019, 29, 526-530.	1.8	12
932	The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC). , 2019, 7, 354.		182
933	Renal cell carcinoma lung metastases treated by radiofrequency ablation integrated with systemic treatments: over 10 years of experience. BMC Cancer, 2019, 19, 1182.	2.6	22
934	Safety and Efficacy of Cabozantinib for Metastatic Nonclear Renal Cell Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 42-45.	1.3	20
935	Biomarkers of Prognosis and Efficacy of Anti-angiogenic Therapy in Metastatic Clear Cell Renal Cancer. Frontiers in Oncology, 2019, 9, 1400.	2.8	39
936	Active Smoking Is Associated With Worse Prognosis in Metastatic Renal Cell Carcinoma Patients Treated With Targeted Therapies. Clinical Genitourinary Cancer, 2019, 17, 65-71.	1.9	9
937	Urologic Malignancies. , 2019, , 115-133.		0
938	Bone metastases and age are associated with earlier dose reductions in metastatic clear-cell renal cell carcinoma patients treated with angiogenesis inhibitors. Acta Clinica Belgica, 2019, 74, 414-423.	1.2	1
939	Renal cell carcinoma and brain metastasis: Questioning the dogma of role for cytoreductive nephrectomy. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 182.e9-182.e15.	1.6	10
940	Fibroblast Growth Factor Receptor-2 Polymorphism rs2981582 is Correlated With Progression-free Survival and Overall Survival in Patients With Metastatic Clear-cell Renal Cell Carcinoma Treated With Sunitinib. Clinical Genitourinary Cancer, 2019, 17, e235-e246.	1.9	4
941	Improved Survival Outcomes for Kidney Cancer Patients With Brain Metastases. Clinical Genitourinary Cancer, 2019, 17, e263-e272.	1.9	19
942	Effects of Antiangiogenetic Drugs on Microcirculation and Macrocirculation in Patients with Advanced-Stage Renal Cancer. Cancers, 2019, 11, 30.	3.7	7
943	External validation of the systemic immune-inflammation index as a prognostic factor in metastatic renal cell carcinoma and its implementation within the international metastatic renal cell carcinoma database consortium model. International Journal of Clinical Oncology, 2019, 24, 526-532.	2.2	22
944	Impact of inflammatory marker levels one month after the first-line targeted therapy initiation on progression-free survival prediction in patients with metastatic clear cell renal cell carcinoma. Japanese Journal of Clinical Oncology, 2019, 49, 69-76.	1.3	4
945	Loss of BAP1 expression in metastatic tumor tissue is an event of poor prognosis in patients with metastatic clear cell renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 78-85.	1.6	12
946	Differential Expression of PD-L1 Between Sporadic and VHL-Associated Hereditary Clear-Cell Renal Cell Carcinoma and Its Correlation With Clinicopathological Features. Clinical Genitourinary Cancer, 2019, 17, 97-104.e1.	1.9	7

#	Article	IF	CITATIONS
947	Diagnosis and Surgical Management of Renal Tumors. , 2019, , .		1
948	Expert Consensus Document on Pulmonary Metastasectomy. Annals of Thoracic Surgery, 2019, 107, 631-649.	1.3	128
949	Update on the Biology and Management of Renal Cell Carcinoma. Journal of Investigative Medicine, 2019, 67, 1-10.	1.6	12
950	Transcriptomic Profiling of the Tumor Microenvironment Reveals Distinct Subgroups of Clear Cell Renal Cell Cancer: Data from a Randomized Phase III Trial. Cancer Discovery, 2019, 9, 510-525.	9.4	169
951	Phase 2 Multicenter Single-Arm Study of Second-Line Axitinib in Favorable Risk Patients with Metastatic Renal Cell Carcinoma: FavorAx. Targeted Oncology, 2019, 14, 33-38.	3.6	4
952	Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma. European Journal of Cancer, 2019, 108, 33-40.	2.8	96
953	Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration: analysis from a randomised, double-blind phase II study. BMC Cancer, 2019, 19, 17.	2.6	4
954	Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial. Lancet Oncology, The, 2019, 20, 297-310.	10.7	207
955	Survival outcome and prognostic model of patients with colorectal cancer on phase 1 trials. Investigational New Drugs, 2019, 37, 490-497.	2.6	4
956	Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions. European Urology, 2019, 75, 100-110.	1.9	178
957	Metastatic papillary renal cell carcinoma in the era of targeted therapy – a retrospective study from three European academic centres. Acta Oncológica, 2019, 58, 306-312.	1.8	3
958	Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib. JAMA Oncology, 2019, 5, 164.	7.1	329
959	Systemic therapy of metastatic renal cell carcinoma: Review of the current literature. Urologia, 2019, 86, 3-8.	0.7	12
960	Comparative Study of Different Classification Models in Renal-Cell Carcinoma. Pathology and Oncology Research, 2019, 25, 1357-1362.	1.9	0
961	Survival after Cytoreductive Nephrectomy in Metastatic Non-clear Cell Renal Cell Carcinoma Patients: A Population-based Study. European Urology Focus, 2019, 5, 488-496.	3.1	41
962	The Development of Brain Metastases in Patients with Renal Cell Carcinoma: Epidemiologic Trends, Survival, and Clinical Risk Factors Using a Population-based Cohort. European Urology Focus, 2019, 5, 474-481.	3.1	44
963	The Value of Neutrophil to Lymphocyte Ratio in Patients Undergoing Cytoreductive Nephrectomy with Thrombectomy. European Urology Focus, 2020, 6, 104-111.	3.1	18
964	Radiological Response Heterogeneity Is of Prognostic Significance in Metastatic Renal Cell Carcinoma Treated with Vascular Endothelial Growth Factor-targeted Therapy. European Urology Focus, 2020, 6,	3.1	5

#	Article	IF	CITATIONS
965	Survival outcomes associated with different sunitinib dosing regimens in metastatic renal cell carcinoma. Journal of Oncology Pharmacy Practice, 2020, 26, 67-73.	0.9	2
966	Cancer of the Kidney. , 2020, , 1361-1381.e4.		Ο
967	Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma: How to Apply New Evidence in Clinical Practice. Oncology, 2020, 98, 1-9.	1.9	10
968	Efficacy and safety profile of nivolumab for Japanese patients with metastatic renal cell cancer. International Journal of Clinical Oncology, 2020, 25, 151-157.	2.2	7
969	Improving IMDC Prognostic Prediction Through Evaluation of Initial Site of Metastasis in Patients With Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2020, 18, e83-e90.	1.9	17
970	Complete response to combination therapy with nivolumab and ipilimumab for metastatic collecting duct carcinoma of the kidney. International Cancer Conference Journal, 2020, 9, 32-35.	0.5	22
971	Feasibility of the ACL (albumin, C-reactive protein and lactate dehydrogenase) model as a novel prognostic tool in patients with metastatic renal cell carcinoma previously receiving first-line targeted therapy. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 6.e9-6.e16.	1.6	9
972	Lactate Dehydrogenase-to-Lymphocyte Ratio Represents a Powerful Prognostic Tool of Metastatic Renal Cell Carcinoma Patients Treated with Tyrosine Kinase Inhibitors. Pathology and Oncology Research, 2020, 26, 1319-1324.	1.9	5
973	Prognostic role of interleukin-6 in renal cell carcinoma: a meta-analysis. Clinical and Translational Oncology, 2020, 22, 835-843.	2.4	11
974	Long survival of patients with metastatic clear cell renal cell carcinoma. Results of real life study of 344 patients. International Journal of Cancer, 2020, 146, 1643-1651.	5.1	5
975	Using a Benefit–Risk Analysis Approach to Capture Regulatory Decision Making: Renal Cell Carcinoma. Clinical Pharmacology and Therapeutics, 2020, 107, 495-506.	4.7	4
976	Elevated neutrophil-lymphocyte ratio combined with hyponatremia indicate poor prognosis in renal cell carcinoma. Acta Oncológica, 2020, 59, 13-19.	1.8	4
977	The impact of neutrophil-lymphocyte ratio on risk reclassification of patients with advanced renal cell cancer to guide risk-directed therapy. Acta Oncológica, 2020, 59, 20-27.	1.8	3
978	Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features. Journal of Clinical Oncology, 2020, 38, 63-70.	1.6	109
979	The relationship between prognostic nutritional index and treatment response in patients with metastatic renal cell cancer. Journal of Oncology Pharmacy Practice, 2020, 26, 1110-1116.	0.9	19
980	PAK1 expression determines poor prognosis and immune evasion in metastatic renal cell carcinoma patients. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 293-304.	1.6	10
981	Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214. European Urology, 2020, 77, 449-453.	1.9	52
982	Novel Risk Scoring System for Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. Oncologist, 2020, 25, e484-e491.	3.7	29

#	Article	IF	CITATIONS
983	Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study. Lancet Oncology, The, 2020, 21, 95-104.	10.7	160
984	Prognostic and Predictive Value of PBRM1 in Clear Cell Renal Cell Carcinoma. Cancers, 2020, 12, 16.	3.7	72
985	Circulating Non-coding RNAs in Renal Cell Carcinoma—Pathogenesis and Potential Implications as Clinical Biomarkers. Frontiers in Cell and Developmental Biology, 2020, 8, 828.	3.7	22
986	Consensus paper: current state of first- and second-line therapy in advanced clear-cell renal cell carcinoma. Future Oncology, 2020, 16, 2307-2328.	2.4	17
987	A biobank analysis of prognostic biomarkers of the systemic inflammatory response in patients presenting with malignancy of undefined primary origin. European Journal of Cancer, 2020, 139, 1-9.	2.8	4
988	Association of preoperative serum De Ritis ratio with oncological outcomes in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 936.e7-936.e14.	1.6	3
989	Prognostic and Predictive Factors in Metastatic Renal Cell Carcinoma. Cancer Journal (Sudbury, Mass) Tj ETQq0 0	0.rgBT /O [.] 2.0	verlock 10 T
990	Cytoreductive Nephrectomy in Patients Presenting With Advanced Disease. Cancer Journal (Sudbury,) Tj ETQq1 1	0,784314 2.0	rgBT /Overl
991	Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncology, The, 2020, 21, 1563-1573.	10.7	466
992	Immunotherapy for Renal Cell Carcinoma. , 0, , .		Ο
993	Current Multimodality Treatments against Brain Metastases from Renal Cell Carcinoma. Cancers, 2020, 12, 2875.	3.7	14
994	Discontinuation of first-line molecular-targeted therapy and prognosis in patients with metastatic renal cell carcinoma: Impact of disease progression vs. adverse events. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 937.e19-937.e25.	1.6	2
995	<i>TYROBP</i> is a potential prognostic biomarker of clear cell renal cell carcinoma. FEBS Open Bio, 2020, 10, 2588-2604.	2.3	16
996	Baseline blood volume identified by dynamic contrast-enhanced computed tomography as a new independent prognostic factor in metastatic renal cell carcinoma. Translational Oncology, 2020, 13, 100829.	3.7	6
997	Significance of tumor microenvironment in acquiring resistance to vascular endothelial growth factorâ€ŧyrosine kinase inhibitor and recent advance of systemic treatment of clear cell renal cell carcinoma. Pathology International, 2020, 70, 712-723.	1.3	5
998	Understanding the role of salvage lymphadenectomy in node only recurrences after nephrectomy for renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 739.e1-739.e8.	1.6	1
999	Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis. Targeted Oncology, 2020, 15, 495-501.	3.6	28
1000	Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional Cohort. Frontiers in Oncology, 2020, 10, 581189.	2.8	11

#	Article	IF	CITATIONS
1001	Biomarker Development for Metastatic Renal Cell Carcinoma: Omics, Antigens, T-cells, and Beyond. Journal of Personalized Medicine, 2020, 10, 225.	2.5	7
1002	Prognostic Impact of Bone Metastasis on Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated by First Line Tyrosine Kinase Inhibitors: A Propensity-Score Matching Analysis. Journal of Cancer, 2020, 11, 7202-7208.	2.5	3
1003	Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open, 2020, 5, e001079.	4.5	343
1004	Pathologic Complete Response to Neoadjuvant Nivolumab/Ipilimumab in a Patient with Metastatic Renal Cell Carcinoma. Case Reports in Urology, 2020, 2020, 1-6.	0.3	3
1005	Prognostic Stratification of the IMDC Intermediate Risk Group After Treatment With First-line Molecular-targeted Therapy for Metastatic Renal Cell Carcinoma. Anticancer Research, 2020, 40, 4395-4400.	1.1	3
1006	Serum tumour associated trypsin inhibitor, as a biomarker for survival in renal cell carcinoma. Scandinavian Journal of Urology, 2020, 54, 413-419.	1.0	3
1007	Identification of a three-long noncoding RNA prognostic model involved competitive endogenous RNA in kidney renal clear cell carcinoma. Cancer Cell International, 2020, 20, 319.	4.1	25
1008	The role of income disparities on survival in metastatic clear cell renal cell carcinoma in the targeted therapy era. European Journal of Health Economics, 2020, 21, 1223-1233.	2.8	4
1009	Regulatory Considerations for Contribution of Effect of Drugs Used in Combination Regimens: Renal Cell Cancer Case Studies. Clinical Cancer Research, 2020, 26, 6406-6411.	7.0	5
1010	Cytoreductive nephrectomy for favorable risk metastatic renal cell carcinoma. Current Opinion in Urology, 2020, Publish Ahead of Print, 740-742.	1.8	1
1011	The Value of PD-L1 Expression as Predictive Biomarker in Metastatic Renal Cell Carcinoma Patients: A Meta-Analysis of Randomized Clinical Trials. Cancers, 2020, 12, 1945.	3.7	49
1012	Acrometastasis to the Hand in Renal Cell Carcinoma. Indian Journal of Surgery, 2021, 83, 1294-1296.	0.3	0
1013	Advanced Non–Clear Cell Kidney Cancer. Cancer Journal (Sudbury, Mass), 2020, 26, 441-447.	2.0	1
1014	Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE). Journal of Clinical Oncology, 2020, 38, 4240-4248.	1.6	69
1015	Development of a Model for Predicting Early Discontinuation of Adjuvant Chemotherapy in Stage III Colon Cancer. JCO Clinical Cancer Informatics, 2020, 4, 972-984.	2.1	4
1017	Faecal microbiota transplantation for the treatment of diarrhoea induced by tyrosine-kinase inhibitors in patients with metastatic renal cell carcinoma. Nature Communications, 2020, 11, 4333.	12.8	82
1019	Patient selection and risk factors in the changing treatment landscape of metastatic renal cell carcinoma. Expert Review of Anticancer Therapy, 2020, 20, 831-840.	2.4	3
1020	Association Between Immune-related Adverse Events and Clinical Outcome Following Nivolumab Treatment in Patients With Metastatic Renal Cell Carcinoma. In Vivo, 2020, 34, 2647-2652.	1.3	11

#	Article	IF	CITATIONS
1021	Treatment patterns, outcomes and clinical characteristics in advanced renal cell carcinoma: a real-world US study. Future Oncology, 2020, 16, 3045-3060.	2.4	7
1022	MicroRNA expression profiles in molecular subtypes of clear-cell renal cell carcinoma are associated with clinical outcome and repression of specific mRNA targets. PLoS ONE, 2020, 15, e0238809.	2.5	5
1023	Efficacy and safety of firstâ€line nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma: A multicenter retrospective study. International Journal of Urology, 2020, 27, 1095-1100.	1.0	20
1024	Immune-related myositis resulting from combination therapy of ipilimumab and nivolumab in patient with metastatic renal cell carcinoma. BMJ Case Reports, 2020, 13, e235199.	0.5	3
1025	Immunotherapy in metastatic sarcomatoid renal cell carcinoma: A single institution experience. Cancer Treatment and Research Communications, 2020, 25, 100251.	1.7	5
1026	Real-world Data of Nivolumab for Patients With Advanced Renal Cell Carcinoma in the Netherlands: An Analysis of Toxicity, Efficacy, and Predictive Markers. Clinical Genitourinary Cancer, 2021, 19, 274.e1-274.e16.	1.9	12
1027	Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade. Cancer Cell, 2020, 38, 803-817.e4.	16.8	262
1028	Development and validation of a nomogram to predict overall survival for patients with metastatic renal cell carcinoma. BMC Cancer, 2020, 20, 1066.	2.6	15
1029	Biomarkers Towards New Era of Therapeutics for Metastatic Renal Cell Carcinoma. Kidney Cancer, 2020, 4, 61-69.	0.4	1
1030	Skeletal-Related Events in Patients with Metastatic Renal Cell Carcinoma: A Systematic Review. Kidney Cancer, 2020, 4, 93-102.	0.4	1
1031	Efficacy of Nivolumab Plus Ipilimumab in a Patient With Renal Cell Carcinoma Concomitant With Cardiac Metastasis: A Case Report. In Vivo, 2020, 34, 1475-1480.	1.3	4
1032	The Impact of Age and Gender on Outcomes of Patients With Advanced Renal Cell Carcinoma Treated With Targeted Therapy. Clinical Genitourinary Cancer, 2020, 18, e598-e609.	1.9	11
1033	Advancing the Science and Management of Renal Cell Carcinoma: Bridging the Divide between Academic and Community Practices. Journal of Clinical Medicine, 2020, 9, 1508.	2.4	3
1034	Impact of concomitant acid suppressive therapy on pazopanib efficacy and dose reductions in patients with metastatic renal cell carcinoma. European Journal of Clinical Pharmacology, 2020, 76, 1273-1280.	1.9	7
1035	Elective Cytoreductive Nephrectomy After Checkpoint Inhibitor Immunotherapy in Patients With Initially Unresectable Metastatic Clear Cell Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2020, 18, 361-366.	1.9	13
1036	Contemporary Cytoreductive Nephrectomy Provides Survival Benefit in Clear-cell Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2020, 18, e730-e738.	1.9	9
1037	Bone metastasis is associated with poor prognosis in metastatic papillary renal cell carcinoma patients treated with first agent angiogenesis inhibitors. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 686.e1-686.e9.	1.6	2
1038	Advanced renal cell carcinoma (RCC) management: an expert panel recommendation from the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG). Journal of Cancer Research and Clinical Oncology, 2020, 146, 1829-1845.	2.5	3

#	Article	IF	CITATIONS
1039	Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study. , 2020, 8, e000538.		19
1040	Impact of Serum Î ³ -Glutamyltransferase on Overall Survival in Patients with Metastatic Renal Cell Carcinoma in the Era of Targeted Therapy. Targeted Oncology, 2020, 15, 347-356.	3.6	9
1041	Real-world use of temsirolimus in Japanese patients with unresectable or metastatic renal cell carcinoma: recent consideration based on the results of a post-marketing, all-case surveillance study. Japanese Journal of Clinical Oncology, 2020, 50, 940-947.	1.3	3
1042	Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nature Medicine, 2020, 26, 909-918.	30.7	488
1043	Anti-angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-Carcinoma. Journal of Clinical Medicine, 2020, 9, 1594.	2.4	49
1044	Immune Checkpoint Inhibitors in Genitourinary Malignancies. Current Oncology, 2020, 27, 69-77.	2.2	13
1045	Cytoreductive Nephrectomy in the Era of Tyrosine Kinase and Immuno-Oncology Checkpoint Inhibitors. Urologic Clinics of North America, 2020, 47, 359-370.	1.8	10
1046	Epidemiology, Risk Assessment, and Biomarkers for Patients with Advanced Renal Cell Carcinoma. Urologic Clinics of North America, 2020, 47, 293-303.	1.8	25
1047	Clinical outcomes of second-line treatment following prior targeted therapy in patients with metastatic renal cell carcinoma: a comparison of axitinib and nivolumab. International Journal of Clinical Oncology, 2020, 25, 1678-1686.	2.2	9
1048	Cytoreductive Nephrectomy in Metastatic Patients with Signs or Symptoms: Implications for Renal Cell Carcinoma Guidelines. European Urology, 2020, 78, 321-326.	1.9	25
1049	Systemic therapy in metastatic renal cell carcinoma: Emerging challenges in therapeutic choice. Critical Reviews in Oncology/Hematology, 2020, 152, 102971.	4.4	7
1050	<p>Optimal Management of First-Line Advanced Renal Cell Carcinoma: Focus on Pembrolizumab</p> . OncoTargets and Therapy, 2020, Volume 13, 4021-4034.	2.0	5
1051	Survival After Surgery for Renal Cell Carcinoma Metastatic to the Spine: Impact of Modern Systemic Therapies on Outcomes. Neurosurgery, 2020, 87, 1174-1180.	1.1	10
1052	C-reactive protein at 1Âmonth after treatment of nivolumab as a predictive marker of efficacy in advanced renal cell carcinoma. Cancer Chemotherapy and Pharmacology, 2020, 86, 75-85.	2.3	10
1053	Sequencing Therapies for Metastatic Renal Cell Carcinoma. Urologic Clinics of North America, 2020, 47, 305-318.	1.8	14
1054	The Evolving Role of Metastasectomy for Patients with Metastatic Renal Cell Carcinoma. Urologic Clinics of North America, 2020, 47, 379-388.	1.8	12
1055	Impact of the systemic immune-inflammation index for the prediction of prognosis and modification of the risk model in patients with metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitors. Canadian Urological Association Journal, 2020, 14, E582-E587.	0.6	11
1056	Neoadjuvant Cabozantinib in Renal-Cell Carcinoma: A Brief Review. Clinical Genitourinary Cancer, 2020, 18, e688-e691.	1.9	11

#	Article	IF	CITATIONS
1057	Renal cell carcinoma revealed by sternal tumefaction: A rare case report and literature review. Urology Case Reports, 2020, 31, 101137.	0.3	3
1058	Perioperative therapies for urological cancers. Japanese Journal of Clinical Oncology, 2020, 50, 357-367.	1.3	3
1059	Real-world Experience With Sunitinib Treatment in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to Risk Score. Clinical Genitourinary Cancer, 2020, 18, e588-e597.	1.9	11
1060	Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II AXIPAP trial. European Journal of Cancer, 2020, 129, 107-116.	2.8	35
1061	New prognostic model for synchronous metastatic renal cell carcinoma. International Journal of Urology, 2020, 27, 448-456.	1.0	4
1062	A New Therapeutic Era for Metastatic Renal Cell Carcinoma. JAMA Oncology, 2020, 6, 633.	7.1	10
1063	The role of active surveillance and cytoreductive nephrectomy in metastatic renal cell carcinoma. Cancer Treatment and Research Communications, 2020, 23, 100169.	1.7	6
1064	Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma. European Journal of Cancer, 2020, 135, 203-210.	2.8	50
1065	Efficacy and Prognostic Factors of Sunitinib as First-Line Therapy for Patients With Metastatic Renal Cell Carcinoma in an Arab Population. JCO Global Oncology, 2020, 6, 19-26.	1.8	8
1066	Prognostic Value of Systemic Inflammatory Biomarkers in Patients with Metastatic Renal Cell Carcinoma. Pathology and Oncology Research, 2020, 26, 2489-2497.	1.9	6
1067	Prognostic Effect of Comorbid Disease and Immune Gene Expression on Mortality in Kidney Cancer—A Population Based Study. Cancers, 2020, 12, 1654.	3.7	3
1068	Survival following cytoreductive nephrectomy: a comparison of existing prognostic models. BJU International, 2020, 126, 745-753.	2.5	20
1069	New First Line Treatment Options of Clear Cell Renal Cell Cancer Patients with PD-1 or PD-L1 Immune-Checkpoint Inhibitor-Based Combination Therapies. Journal of Clinical Medicine, 2020, 9, 565.	2.4	35
1070	Clinical and histological response to combination nivolumab and ipilimumab in metastatic renal cell carcinoma. Baylor University Medical Center Proceedings, 2020, 33, 258-260.	0.5	2
1071	Outcomes in Black and White Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors: Insights From Two Large Cohorts. JCO Global Oncology, 2020, 6, 293-306.	1.8	4
1072	Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcome—Results from the International Metastatic Renal Cell Carcinoma Database Consortium. European Urology Oncology, 2020, 3, 530-539.	5.4	29
1073	Results of the ADAPT Phase 3 Study of Rocapuldencel-T in Combination with Sunitinib as First-Line Therapy in Patients with Metastatic Renal Cell Carcinoma. Clinical Cancer Research, 2020, 26, 2327-2336.	7.0	49
1074	A new scenario in metastatic renal cell carcinoma: a SOG-GU consensus. Clinical and Translational Oncology, 2020, 22, 1565-1579.	2.4	1

#	Article	IF	CITATIONS
1075	Neutrophil–lymphocyte ratio as a prognostic factor for survival in patients with advanced renal cell carcinoma (Turkish Oncology Group Study). Journal of Oncology Pharmacy Practice, 2020, 26, 1583-1589.	0.9	6
1076	Real-World Assessment of Clinical Outcomes Among First-Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium Risk Group. Oncologist, 2020, 25, 422-430.	3.7	12
1077	Interleukin-2 chronotherapy for metastatic renal cell carcinoma: Results of a phase I-II study. Cytokine, 2020, 128, 154984.	3.2	16
1078	A historical turning point for the treatment of advanced renal cell carcinoma: inhibition of immune checkpoint. Current Medical Research and Opinion, 2020, 36, 625-635.	1.9	4
1079	Expression signature of sixâ€snoRNA serves as novel nonâ€invasive biomarker for diagnosis and prognosis prediction of renal clear cell carcinoma. Journal of Cellular and Molecular Medicine, 2020, 24, 2215-2228.	3.6	32
1080	SEOM clinical guideline for treatment of kidney cancer (2019). Clinical and Translational Oncology, 2020, 22, 256-269.	2.4	18
1081	Clinical and economic outcomes of treatment sequences for intermediate- to poor-risk advanced renal cell carcinoma. Immunotherapy, 2020, 12, 37-51.	2.0	10
1082	Racial and ethnic differences in survival in contemporary metastatic renal cell carcinoma patients, according to alternative treatment modalities. Cancer Causes and Control, 2020, 31, 263-272.	1.8	9
1083	Outcomes of patients with spinal metastases from renal cell carcinoma treated with conventionally-fractionated external beam radiation therapy. Medicine (United States), 2020, 99, e19838.	1.0	2
1084	Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma. European Urology, 2020, 78, 615-623.	1.9	44
1085	Sunitinib Versus Sorafenib as Initial Targeted Therapy for mCC-RCC With Favorable/Intermediate Risk: Multicenter Randomized Trial CROSS-J-RCC. Clinical Genitourinary Cancer, 2020, 18, e374-e385.	1.9	12
1087	Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era: An analysis of the National Cancer Database. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 604.e9-604.e17.	1.6	77
1088	Atezolizumab for the treatment of renal cell carcinoma. Expert Opinion on Biological Therapy, 2020, 20, 679-686.	3.1	0
1089	On the Shoulders of Giants: The Evolution of Renal Cell Carcinoma Treatment—Cytokines, Targeted Therapy, and Immunotherapy. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, 418-435.	3.8	16
1090	Prediction of Immune checkpoint inhibitors benefit from routinely measurable peripheral blood parameters. Chinese Clinical Oncology, 2020, 9, 19-19.	1.2	6
1092	Whole-body diffusion-weighted magnetic resonance imaging for the detection of bone metastases and their prognostic impact in metastatic renal cell carcinoma patients treated with angiogenesis inhibitors. Acta OncolÅ ³ gica, 2020, 59, 818-824.	1.8	5
1093	Avelumab and axitinib in the treatment of renal cell carcinoma: safety and efficacy. Expert Review of Anticancer Therapy, 2020, 20, 343-354.	2.4	0
1094	Challenges and opportunities in the management of metastatic renal cell carcinoma: combination therapy and the role of cytoreductive surgery. Current Opinion in Oncology, 2020, 32, 240-249.	2.4	15

#	Article	IF	CITATIONS
1095	Tumor endothelial ELTD1 as a predictive marker for treatment of renal cancer patients with sunitinib. BMC Cancer, 2020, 20, 339.	2.6	7
1096	Addition of Primary Metastatic Site on Bone, Brain, and Liver to IMDC Criteria in Patients With Metastatic Renal Cell Carcinoma: A Validation Study. Clinical Genitourinary Cancer, 2021, 19, 32-40.	1.9	17
1097	Clear cell renal cell carcinoma ontogeny and mechanisms of lethality. Nature Reviews Nephrology, 2021, 17, 245-261.	9.6	278
1098	Systemic therapy for metastatic renal cell carcinoma in the first-line setting: a systematic review and network meta-analysis. Cancer Immunology, Immunotherapy, 2021, 70, 265-273.	4.2	44
1099	Firstâ€line pazopanib in intermediate†and poorâ€risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial. International Journal of Cancer, 2021, 148, 950-960.	5.1	5
1100	Complete response of hereditary leiomyomatosis and renal cell cancer (HLRCC)-associated renal cell carcinoma to nivolumab and ipilimumab combination immunotherapy by: a case report. Familial Cancer, 2021, 20, 75-80.	1.9	17
1101	PD-L1 and VEGFR-2 expression in synchronous metastatic renal cell carcinoma treated with targeted therapy following cytoreductive nephrectomy. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 78.e9-78.e16.	1.6	4
1102	Prognostic impact of systemic therapy change in metastatic renal cell carcinoma treated with cytoreductive nephrectomy. Japanese Journal of Clinical Oncology, 2021, 51, 296-304.	1.3	4
1103	Comparison of nivolumab plus ipilimumab with tyrosine kinase inhibitors as first-line therapies for metastatic renal-cell carcinoma: a multicenter retrospective study. International Journal of Clinical Oncology, 2021, 26, 154-162.	2.2	11
1104	Modest efficacy of nivolumab plus ipilimumab in patients with papillary renal cell carcinoma. Japanese Journal of Clinical Oncology, 2021, 51, 646-653.	1.3	22
1105	Mast cell density in metastatic renal cell carcinoma: Association with prognosis and tumourâ€infiltrating lymphocytes. Scandinavian Journal of Immunology, 2021, 93, e13006.	2.7	9
1107	Prospect and adversity of artificial intelligence in urology. , 2021, , 309-337.		1
1108	Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 134.e9-134.e16.	1.6	9
1109	Role of circulating tumor cells in patients with metastatic clear-cell renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 135.e9-135.e15.	1.6	5
1110	The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis. European Urology, 2021, 79, 783-792.	1.9	46
1111	The need for new algorithms of treatment sequencing in clear-cell metastatic renal cell carcinoma. Expert Review of Anticancer Therapy, 2021, 21, 401-412.	2.4	8
1112	Reconnaissance of tumor immune microenvironment spatial heterogeneity in metastatic renal cell carcinoma and correlation with immunotherapy response. Clinical and Experimental Immunology, 2021, 204, 96-106.	2.6	23
1113	Prognostic impact of metastasectomy in renal cell carcinoma in the postcytokine therapy era. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 77.e17-77.e25.	1.6	16

#	Article	IF	CITATIONS
1114	Development of novel ACN (albumin, C-reactive protein and neutrophil-to-lymphocyte ratio) prognostication model for patients with metastatic renal cell carcinoma receiving first-line molecular-targeted therapy. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 78.e1-78.e8.	1.6	8
1115	Metastatic renal cell carcinoma to the brain: optimizing patient selection for gamma knife radiosurgery. Acta Neurochirurgica, 2021, 163, 333-342.	1.7	4
1116	Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint Inhibitors. European Urology Oncology, 2021, 4, 102-111.	5.4	26
1117	Are tyrosine kinase inhibitors fit for purpose in the treatment of metastatic papillary renal cell carcinoma?. Journal of Clinical Urology, 0, , 205141582098766.	0.1	0
1118	Novel risk scoring system for metastatic renal cell carcinoma patients treated with cabozantinib. Cancer Treatment and Research Communications, 2021, 28, 100393.	1.7	2
1119	Surgical Management of Genitourinary Cancer Liver Metastases. Surgical Oncology Clinics of North America, 2021, 30, 89-102.	1.5	1
1120	Toxicities of axitinib, sunitinib and temsirolimus: implications for progression-free and overall survival in metastatic renal cell cancer. Future Oncology, 2021, 17, 45-56.	2.4	2
1121	Identification of DNA methylation signatures associated with poor outcome in lower-risk Stage, Size, Grade and Necrosis (SSIGN) score clear cell renal cell cancer. Clinical Epigenetics, 2021, 13, 12.	4.1	8
1122	New approaches to first-line treatment of advanced renal cell carcinoma. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110347.	3.2	25
1123	Impact of Primary Tumor Size on Prognosis in Patients With Metastatic Renal Cell Carcinoma Receiving Cytoreductive Nephrectomy: A Population Study of a Chinese Center and the US SEER Database. Technology in Cancer Research and Treatment, 2021, 20, 153303382110195.	1.9	5
1124	Transdiaphragmatic nephrectomy with synchronous pulmonary and anterior thoracic wall mass metastasectomy in a young male with metastatic renal cell carcinoma; a single.incision approach. Urology Annals, 2021, 13, 190.	0.6	0
1125	External validation of the albumin, C-reactive protein and lactate dehydrogenase model in patients with metastatic renal cell carcinoma receiving second-line axitinib therapy in a Japanese multi-center cohort. Japanese Journal of Clinical Oncology, 2021, 51, 810-818.	1.3	0
1126	Assessment of prognosis by established prognosis scores and physicians' judgement in mRCC patients: an analysis of the STAR-TOR registry. Translational Andrology and Urology, 2021, 10, 0-0.	1.4	3
1127	Pembrolizumab plus axitinib and nivolumab plus ipilimumab as first-line treatments of advanced intermediate- or poor-risk renal-cell carcinoma: a number needed to treat analysis from the Brazilian private perspective. Journal of Medical Economics, 2021, 24, 291-298.	2.1	4
1128	Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival. JAMA Network Open, 2021, 4, e2021869.	5.9	104
1129	Comorbidity and frailty assessment in renal cell carcinoma patients. World Journal of Urology, 2021, 39, 2831-2841.	2.2	7
1130	Prognostic effect of preoperative serum albumin to globulin ratio in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma. Translational Andrology and Urology, 2021, 10, 609-619.	1.4	5
1131	Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. Nature Communications, 2021, 12, 808.	12.8	84

#	Article	IF	CITATIONS
1132	Current role of cytoreductive nephrectomy in metastatic renal cell carcinoma. Turkish Journal of Urology, 2021, 47, S79-S84.	1.3	10
1133	Dissecting Outcomes: Should Cytoreductive Nephrectomy Be Performed for Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid Dedifferentiation?. Frontiers in Oncology, 2020, 10, 627025.	2.8	6
1134	Safety and Efficacy of Robotic Radiosurgery for Visceral and Lymph Node Metastases of Renal Cell Carcinoma: A Retrospective, Single Center Analysis. Cancers, 2021, 13, 680.	3.7	2
1137	Sex-specific hormone changes during immunotherapy and its influence on survival in metastatic renal cell carcinoma. Cancer Immunology, Immunotherapy, 2021, 70, 2805-2817.	4.2	13
1138	Impact of C-reactive protein flare-response on oncological outcomes in patients with metastatic renal cell carcinoma treated with nivolumab. , 2021, 9, e001564.		34
1139	Next Steps: Sequencing Therapies in Metastatic Kidney Cancer in the Contemporary Era. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, 187-197.	3.8	11
1140	Sarcopenia and modified Glasgow Prognostic Score predict postsurgical outcomes in localized renal cell carcinoma. Cancer, 2021, 127, 1974-1983.	4.1	26
1141	Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 2021, 384, 829-841.	27.0	961
1142	Impact of albumin to globulin ratio on survival outcomes of patients with metastatic renal cell carcinoma. Turkish Journal of Urology, 2021, 47, 113-119.	1.3	5
1143	Predictive value of De Ritis ratio in metastatic renal cell carcinoma treated with tyrosine-kinase inhibitors. World Journal of Urology, 2021, 39, 2977-2985.	2.2	6
1144	MicroRNAs Possibly Involved in the Development of Bone Metastasis in Clear-Cell Renal Cell Carcinoma. Cancers, 2021, 13, 1554.	3.7	9
1145	Elucidating the Efficacy of Pancreatectomy for Renal Cell Metastases Remains Problematic. Annals of Surgical Oncology, 2021, 28, 2946-2948.	1.5	0
1146	Pazopanib in patients with metastatic renal cell carcinoma: a single-center, real-world, retrospective Chinese study. Translational Andrology and Urology, 2021, 10, 1321-1331.	1.4	1
1147	Finding predictive factors for immunotherapy in metastatic renal-cell carcinoma: What are we looking for?. Cancer Treatment Reviews, 2021, 94, 102157.	7.7	16
1148	Site-specific Response to Nivolumab in Renal Cell Carcinoma. Anticancer Research, 2021, 41, 1539-1545.	1.1	14
1149	Can Systemic Immune-Inflammation Index Create a New Perspective for the IMDC Scoring System in Patients with Metastatic Renal Cell Carcinoma?. Urologia Internationalis, 2021, 105, 666-673.	1.3	6
1150	Management of advanced kidney cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2021. Canadian Urological Association Journal, 2020, 15, 84-97.	0.6	11
1151	Stereotactic body radiotherapy (SBRT) in combination with drugs in metastatic kidney cancer: A systematic review. Critical Reviews in Oncology/Hematology, 2021, 159, 103242.	4.4	7

#	Article	IF	CITATIONS
1152	Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC). Cancer, 2021, 127, 2204-2212.	4.1	32
1153	Tumour Evolution and Seed and Soil Mechanism in Pancreatic Metastases of Renal Cell Carcinoma. Cancers, 2021, 13, 1342.	3.7	8
1154	A qualitative framework of non-selection factors for cytoreductive nephrectomy. World Journal of Urology, 2021, 39, 3359-3365.	2.2	3
1157	Outcomes of patients with intermediateâ€risk or poorâ€risk metastatic renal cell carcinoma who received their first cycle of nivolumab and ipilimumab in the hospital because of symptomatic disease: The MD Anderson Cancer Center experience. International Journal of Cancer, 2021, 149, 387-393.	5.1	6
1158	Atypical Response Patterns in Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors—Navigating the Radiologic Potpourri. Cancers, 2021, 13, 1689.	3.7	7
1159	Study of Treatment Outcome in Adults with TFE-Related RCC. South Asian Journal of Cancer, 2021, 10, 92-96.	0.6	0
1160	Modified Glasgow Prognostic Score as a Predictor of Prognosis in Metastatic Renal Cell Carcinoma Treated With Nivolumab. Clinical Genitourinary Cancer, 2021, 19, e78-e83.	1.9	8
1161	Development of a Novel Risk Score to Select the Optimal Candidate for Cytoreductive Nephrectomy Among Patients with Metastatic Renal Cell Carcinoma. Results from a Multi-institutional Registry (REMARCC). European Urology Oncology, 2021, 4, 256-263.	5.4	24
1162	The platelet to lymphocyte ratio predicts overall survival better than the neutrophil to lymphocyte ratio in metastatic renal cell carcinoma. Turkish Journal of Medical Sciences, 2021, 51, 757-765.	0.9	8
1163	Immunology and Immunotherapeutic Approaches for Advanced Renal Cell Carcinoma: A Comprehensive Review. International Journal of Molecular Sciences, 2021, 22, 4452.	4.1	13
1164	Efficacy and Safety of Nivolumab and Ipilimumab for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Cohort Study. Current Oncology, 2021, 28, 1402-1411.	2.2	11
1165	IL13Rα2 Is Involved in the Progress of Renal Cell Carcinoma through the JAK2/FOXO3 Pathway. Journal of Personalized Medicine, 2021, 11, 284.	2.5	4
1166	Metastatic Renal Cell Carcinoma Management: From Molecular Mechanism to Clinical Practice. Frontiers in Oncology, 2021, 11, 657639.	2.8	18
1167	Platelet transfusion for cancer secondary thrombocytopenia: Platelet and cancer cell interaction. Translational Oncology, 2021, 14, 101022.	3.7	12
1169	Frequency of pre-treatment may not increase the immune-related adverse events of RCC patients treated with nivolumab. Medicine (United States), 2021, 100, e25402.	1.0	2
1170	Prognostic Significance of Pancreatic Metastases in Patients With Advanced Renal Cell Carcinoma Treated With Systemic Therapy. Clinical Genitourinary Cancer, 2021, 19, e367-e373.	1.9	4
1171	C-reactive protein and neutrophil-lymphocyte ratio are prognostic in metastatic clear-cell renal cell carcinoma patients treated with nivolumab. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 239.e17-239.e25.	1.6	13
1172	Association Between Systemic Therapy and/or Cytoreductive Nephrectomy and Survival in Contemporary Metastatic Non–clear Cell Renal Cell Carcinoma Patients. European Urology Focus, 2021, 7, 598-607.	3.1	10

#	Article	IF	CITATIONS
1173	Prognostic Factors in De Novo Metastatic Renal Cell Carcinoma: A Report From the Latin American Renal Cancer Group. JCO Global Oncology, 2021, 7, 671-685.	1.8	3
1174	Prognostic and predictive role of intra-tumoral CXCR1 expression in patients receiving tyrosine kinase inhibitors for metastatic clear-cell renal cell carcinoma. Journal of Clinical Urology, 2023, 16, 113-120.	0.1	0
1175	Thrombospondin-2 and LDH Are Putative Predictive Biomarkers for Treatment with Everolimus in Second-Line Metastatic Clear Cell Renal Cell Carcinoma (MARC-2 Study). Cancers, 2021, 13, 2594.	3.7	2
1176	Clinical outcomes and prognostic factors following the surgical resection of renal cell carcinoma spinal metastases. Cancer Science, 2021, 112, 2416-2425.	3.9	11
1177	The prognostic value of galactosylceramide-sulfotransferase (Gal3ST1) in human renal cell carcinoma. Scientific Reports, 2021, 11, 10926.	3.3	7
1178	Combining anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) and -programmed cell death protein 1 (PD-1) agents for cancer immunotherapy. Expert Opinion on Biological Therapy, 2021, 21, 1623-1634.	3.1	10
1179	Active Surveillance in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System. Clinical Genitourinary Cancer, 2021, 19, 521-530.	1.9	8
1180	Prognostic significance of the controlling nutritional status score in patients with metastatic renal cell carcinoma diagnosed before an era of first-line immune-oncology combination therapies. Japanese Journal of Clinical Oncology, 2021, 51, 1570-1576.	1.3	1
1181	Real-world symptoms, disease burden, resource use and quality of life in US patients with advanced renal cell cancer. Future Oncology, 2021, 17, 2169-2182.	2.4	3
1182	Pulmonary metastasectomy in renal cell carcinoma: Predictive and prognostic elements from paired histopathological analysis of primary tumors and respective metastases. Journal of Onco-Nephrology, 2021, 5, 96-104.	0.6	0
1183	On-treatment C-reactive protein control could predict response to subsequent anti-PD-1 treatment in metastatic renal cell carcinoma. International Journal of Clinical Oncology, 2021, 26, 1500-1505.	2.2	2
1184	Prognostic Role of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma: A Large, Multicenter, Prospective Trial. Oncologist, 2021, 26, 740-750.	3.7	19
1185	Biomarkers in renal cell carcinoma: Are we there yet?. Asian Journal of Urology, 2021, 8, 362-375.	1.2	15
1186	Influence of treatment access on survival of metastatic renal cell carcinoma in brazilian cancer center. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2021, 47, 566-573.	1.5	2
1187	Outcomes based on age in patients with metastatic renal cell carcinoma treated with first line targeted therapy or checkpoint immunotherapy: Older patients more prone to toxicity. Journal of Geriatric Oncology, 2021, 12, 827-833.	1.0	14
1188	Real-world outcomes in patients with metastatic renal cell carcinoma according to risk factors: the STAR-TOR registry. Future Oncology, 2021, 17, 2325-2338.	2.4	3
1189	Making Patient-Specific Treatment Decisions Using Prognostic Variables and Utilities of Clinical Outcomes. Cancers, 2021, 13, 2741.	3.7	23
1190	Validation of the updated renal graded prognostic assessment (GPA) for patients with renal cancer brain metastases treated with gamma knife radiosurgery. Journal of Neuro-Oncology, 2021, 153, 527-536.	2.9	3

#	Article	IF	CITATIONS
1191	Immune Checkpoint Inhibition in Advanced Bladder and Kidney Cancer: Responses and Further Management. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, e182-e189.	3.8	7
1192	Renal cancer: Key studies for FRCS (Urol). Journal of Clinical Urology, 0, , 205141582110264.	0.1	0
1193	Detection of von Hippelâ€Lindau gene mutation in circulating cellâ€free DNA for clear cell renal cell carcinoma. Cancer Science, 2021, 112, 3363-3374.	3.9	10
1194	MicroRNAs Targeting HIF-2α, VEGFR1 and/or VEGFR2 as Potential Predictive Biomarkers for VEGFR Tyrosine Kinase and HIF-2α Inhibitors in Metastatic Clear-Cell Renal Cell Carcinoma. Cancers, 2021, 13, 3099.	3.7	16
1195	Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC) – an International mRCC Database Consortium (IMDC) analysis. Journal of Geriatric Oncology, 2021, 12, 820-826.	1.0	10
1196	Prognosis of Japanese metastatic renal cell carcinoma patients in the targeted therapy era. International Journal of Clinical Oncology, 2021, 26, 1947-1954.	2.2	4
1197	Prognostic Factors Affecting Survival after Pulmonary Resection of Metastatic Renal Cell Carcinoma: A Multicenter Experience. Cancers, 2021, 13, 3258.	3.7	5
1198	Platelet-to-lymphocyte ratio is not a predictor of clinically significant prostate cancer at the prostate biopsy: A large cohort study. Scientific Reports, 2021, 11, 14240.	3.3	4
1199	Prognostic value of programmed death-ligand 1 status in Japanese patients with renal cell carcinoma. International Journal of Clinical Oncology, 2021, 26, 2073-2084.	2.2	4
1200	Stereotactic Ablative Radiation (SAbR) for Oligometastatic RCC. Seminars in Radiation Oncology, 2021, 31, 227-234.	2.2	9
1201	Insight on a new indolinone derivative as an orally bioavailable lead compound against renal cell carcinoma. Bioorganic Chemistry, 2021, 112, 104985.	4.1	13
1202	Development of a Metastatic Uveal Melanoma Prognostic Score (MUMPS) for Use in Patients Receiving Immune Checkpoint Inhibitors. Cancers, 2021, 13, 3640.	3.7	4
1203	Pathological eradication of recurrent metastatic renal cell carcinoma with sarcomatoid component by nivolumab plus ipilimumab combination therapy. International Cancer Conference Journal, 2021, 10, 285-289.	0.5	2
1204	Role of Radioembolization in the Management of Liver-Dominant Metastatic Renal Cell Carcinoma: A Single-Center, Retrospective Study. CardioVascular and Interventional Radiology, 2021, 44, 1755-1762.	2.0	4
1205	Prognostic value of DCE-CT-derived blood volume and flow compared to core biopsy microvessel density in patients with metastatic renal cell carcinoma. European Radiology Experimental, 2021, 5, 32.	3.4	2
1206	Tumor Growth Rate Decline despite Progressive Disease May Predict Improved Nivolumab Treatment Outcome in mRCC: When RECIST Is Not Enough. Cancers, 2021, 13, 3492.	3.7	3
1207	Survival Outcomes of Patients in Advanced Non-Clear Renal Cell Carcinoma Treated with Pazopanib: A Retrospective Single Institution Experience. UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi, 2021, 31, 170-177.	0.1	0
1208	Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors. , 2021, 9, e002851.		12

#	Article	IF	CITATIONS
1209	Evolution of risk stratification systems is critical for improving patient selection for cytoreductive nephrectomy. Cancer, 2021, 127, 3920-3923.	4.1	2
1210	Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation. BJU International, 2022, 129, 610-620.	2.5	22
1211	Development of a mechanically matched silk scaffolded 3D clear cell renal cell carcinoma model. Materials Science and Engineering C, 2021, 126, 112141.	7.3	8
1212	Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials. European Journal of Cancer, 2021, 151, 115-125.	2.8	22
1213	Prognostic role of hematologic parameters of metastatic renal cell carcinoma treated with sunitinib. Tumori, 2021, , 030089162110339.	1.1	2
1214	Impact of Body Mass Index on Survival of Metastatic Renal Cancer. Journal of Kidney Cancer and VHL, 2021, 8, 49-54.	1.0	3
1215	Renal cell carcinoma (RCC): fatter is better? A review on the role of obesity in RCC. Endocrine-Related Cancer, 2021, 28, R207-R216.	3.1	14
1216	What is the role of real-world data in metastatic renal cell cancer?. Future Oncology, 2021, 17, 3905-3909.	2.4	1
1217	A Contemporary Review of Immune Checkpoint Inhibitors in Advanced Clear Cell Renal Cell Carcinoma. Vaccines, 2021, 9, 919.	4.4	9
1218	Prognostic factors for overall survival in patients with clear cell metastatic renal cell carcinoma. Medicine (United States), 2021, 100, e26826.	1.0	2
1219	First-Line Immuno-Oncology Combinations for Metastatic Clear Cell Renal Cell Carcinoma (mRCC): A Systematic Review of Phase III Clinical Trials. Kidney Cancer, 2021, 5, 207-217.	0.4	3
1220	Immune checkpoint inhibitor-induced myocarditis in cancer patients: a case report and review of reported cases. Cardio-Oncology, 2021, 7, 27.	1.7	17
1221	Does sunitinib still have a place in the current recommendations for the systemic treatment of advanced renal cell carcinoma?. Meditsinskiy Sovet, 2021, , 89-94.	0.5	2
1222	Interactive Data Visualization Tool for Patient-Centered Decision Making in Kidney Cancer. JCO Clinical Cancer Informatics, 2021, 5, 912-920.	2.1	0
1223	Immune Checkpoint Inhibitor in First-Line Treatment of Metastatic Renal Cell Carcinoma: A Review of Current Evidence and Future Directions. Frontiers in Oncology, 2021, 11, 707214.	2.8	26
1224	Cabozantinib and nivolumab as first-line treatment in advanced renal cell carcinoma. Expert Review of Anticancer Therapy, 2021, 21, 1183-1192.	2.4	Ο
1225	Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma. BMC Cancer, 2021, 21, 904.	2.6	10
1226	A 25-year perspective on evaluation and understanding of biomarkers in urologic cancers. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 602-617.	1.6	3

#	Article	IF	Citations
1227	Treatment Options for De Novo Metastatic Clear-cell Renal Cell Carcinoma: Current Recommendations and Future Insights. European Urology Oncology. 2022. 5. 125-133.	5.4	10
1228	Complete response and renal cell carcinoma in the immunotherapy era: The paradox of good news. Cancer Treatment Reviews, 2021, 99, 102239.	7.7	13
1229	Clinical Review on the Management of Metastatic Renal Cell Carcinoma. JCO Oncology Practice, 2022, 18, 187-196.	2.9	62
1230	A 25-year perspective on advances in the study of the epidemiology, disparities, and outcomes of urologic cancers. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 595-601.	1.6	1
1231	Association of tumor burden with outcome in first-line therapy with nivolumab plus ipilimumab for previously untreated metastatic renal cell carcinoma. Japanese Journal of Clinical Oncology, 2021, 51, 1751-1756.	1.3	7
1232	RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse. Contemporary Clinical Trials, 2021, 108, 106482.	1.8	33
1233	Hypopituitarism in patients with metastatic renal cell carcinoma treated with ipilimumab and nivolumab combination therapy. Japanese Journal of Clinical Oncology, 2021, 51, 1744-1750.	1.3	2
1234	Renal Cell Carcinoma—Lessons in Diversity, Breakthroughs, and Challenges. JCO Oncology Practice, 2022, 18, 197-199.	2.9	3
1235	Prediction of early progression of metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitor. Current Urology, 2021, 15, 187-192.	0.6	3
1236	THSD7A expression: a novel immunohistochemical determinant in predicting overall survival of metastatic renal cell carcinoma treated with targeted therapy. Irish Journal of Medical Science, 2021, , 1.	1.5	4
1237	Prognostic significance of hemoglobin-to-red cell distribution width ratio in patients with metastatic renal cancer. Future Oncology, 2021, 17, 3853-3864.	2.4	17
1238	Sunitinib Alone or After Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Is There Still a Role for Cytoreductive Nephrectomy?. European Urology, 2021, 80, 417-424.	1.9	67
1239	Efficacy of VEGFR-TKIs plus immune checkpoint inhibitors in metastatic renal cell carcinoma patients with favorable IMDC prognosis. Cancer Treatment Reviews, 2021, 100, 102295.	7.7	20
1240	Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study). Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110196.	3.2	36
1241	Development and validation of nomogram based on a novel platelet index score to predict prognosis in patients with renal cell carcinoma. Journal of Cancer, 2021, 12, 6301-6309.	2.5	4
1242	Sorafenib as a second-line treatment in metastatic renal cell carcinoma in Mexico: a prospective cohort study. BMC Cancer, 2021, 21, 16.	2.6	5
1243	The Predictive Value of Red Blood Cell Distribution Width for Survival Outcomes of Metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapy. Nutrition and Cancer, 2021, 73, 1957-1963.	2.0	7
1244	Prognostic Value of Plasma hPG80 (Circulating Progastrin) in Metastatic Renal Cell Carcinoma. Cancers, 2021, 13, 375.	3.7	9

#	Article	IF	CITATIONS
1245	Cabozantinib realâ€world effectiveness in the firstâ€through fourthâ€line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Cancer Medicine, 2021, 10, 1212-1221.	2.8	22
1246	Development and Clinical Validation of a Seven-Gene Prognostic Signature Based on Multiple Machine Learning Algorithms in Kidney Cancer. Cell Transplantation, 2021, 30, 096368972096917.	2.5	9
1247	Testosterone for Managing Treatment-related Fatigue in Patients With Metastatic Renal Cell Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2021, 44, 137-142.	1.3	3
1248	Laboratory Parameters are Possible Prognostic Markers in Patients with Advanced-stage NSCLC Treated with Bevacizumab plus Chemotherapy. Journal of Cancer, 2021, 12, 5753-5759.	2.5	3
1249	Spontaneous regression of multiple pulmonary metastases accompanied by normalization of serum immune markers following cytoreductive nephrectomy in a patient with clearâ€cell renal cell carcinoma. IJU Case Reports, 2021, 4, 95-99.	0.3	5
1250	Current Landscape of Immunotherapy in Genitourinary Malignancies. Advances in Experimental Medicine and Biology, 2020, 1244, 107-147.	1.6	3
1251	Treatment Overview. , 2017, , 177-207.		2
1252	Prognostic role of pretreatment lactate dehydrogenase in patients with metastatic renal cell carcinoma: A systematic review and meta-analysis. International Journal of Surgery, 2020, 79, 66-73.	2.7	10
1253	Fatal hyperprogression induced by nivolumab in metastatic renal cell carcinoma with sarcomatoid features: a case report. Anti-Cancer Drugs, 2021, 32, 222-225.	1.4	3
1254	Oncological outcomes of a multicenter cohort treated with axitinib for metastatic renal cell carcinoma. Cancer Science, 2020, 111, 2460-2471.	3.9	7
1255	Uncommon side effect with a commonly used targeted agent: sunitinib-induced nephrotic syndrome in a patient with metastatic renal cell carcinoma. BMJ Case Reports, 2014, 2014, bcr2013201183-bcr2013201183.	0.5	9
1256	Pancreatic tropism of metastatic renal cell carcinoma. JCI Insight, 2020, 5, .	5.0	55
1257	DNA hypomethylation promotes transposable element expression and activation of immune signaling in renal cell cancer. JCI Insight, 2020, 5, .	5.0	41
1258	Prolonged survival with personalized immunotherapy (ACS-003) in combination with sunitinib in unfavorable risk metastatic RCC (mRCC) Journal of Clinical Oncology, 2013, 31, 357-357.	1.6	13
1259	Disease-Specific Survival in De Novo Metastatic Renal Cell Carcinoma in the Cytokine and Targeted Therapy Era. PLoS ONE, 2013, 8, e63341.	2.5	62
1260	Initial Hyperleukocytosis and Neutrophilia in Nasopharyngeal Carcinoma: Incidence and Prognostic Impact. PLoS ONE, 2015, 10, e0136752.	2.5	19
1261	Nivolumab versus Cabozantinib: Comparing Overall Survival in Metastatic Renal Cell Carcinoma. PLoS ONE, 2016, 11, e0155389.	2.5	23
1262	The Evolving Landscape of Metastatic Renal Cell Carcinoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 299-302.	3.8	10

#	Article	IF	CITATIONS
1263	Predictors of Progression-Free Survival and Overall Survival in Metastatic Non-Clear Cell Renal Cell Carcinoma: A Single-Center Experience. World Journal of Oncology, 2019, 10, 101-111.	1.5	12
1264	Interleukin-2 in Renal Cell Carcinoma: A Has-Been or a Still-Viable Option?. Journal of Kidney Cancer and VHL, 2014, 1, 74-83.	1.0	25
1265	Management of metastatic renal cell carcinoma – mini review. Journal of Kidney Cancer and VHL, 2015, 2, 75-83.	1.0	5
1266	Review of the Interaction Between Body Composition and Clinical Outcomes in Metastatic Renal Cell Cancer Treated with Targeted Therapies. Journal of Kidney Cancer and VHL, 2016, 3, 12-22.	1.0	6
1267	Sequential Therapy in Metastatic Renal Cell Carcinoma. Journal of Kidney Cancer and VHL, 2016, 3, 23-35.	1.0	5
1268	Exploration of IMDC model in patients with metastatic renal cell carcinoma using targeted agents: a meta-analysis. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2020, 46, 328-340.	1.5	2
1269	Cabozantinib: from studies to clinical practice. Onkourologiya, 2019, 15, 28-41.	0.3	6
1270	Eosinophil percentage elevation as a prognostic factor for overall survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor. Oncotarget, 2016, 7, 68943-68953.	1.8	6
1271	Low CCL-21 expression associates with unfavorable postoperative prognosis of patients with metastatic renal cell carcinoma. Oncotarget, 2017, 8, 25650-25659.	1.8	6
1272	Meta-analysis on the association of <i>VEGFR1</i> genetic variants with sunitinib outcome in metastatic renal cell carcinoma patients. Oncotarget, 2017, 8, 1204-1212.	1.8	6
1273	Immunotherapy: incorporation in the evolving paradigm of renal cancer management and future prospects. Oncotarget, 2017, 8, 17313-17327.	1.8	31
1274	Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: a multicenter retrospective analysis. Oncotarget, 2017, 8, 100708-100716.	1.8	32
1275	Inherent characteristics of metachronous metastatic renal cell carcinoma in the era of targeted agents. Oncotarget, 2017, 8, 78825-78837.	1.8	6
1276	A retrospective comparative study of progression-free survival and overall survival between metachronous and synchronous metastatic renal cell carcinoma in intermediate- or poor-risk patients treated with VEGF-targeted therapy. Oncotarget, 2017, 8, 93633-93643.	1.8	13
1277	The clinical use of the platelet to lymphocyte ratio and lymphocyte to monocyte ratio as prognostic factors in renal cell carcinoma: a systematic review and meta-analysis. Oncotarget, 2017, 8, 84506-84514.	1.8	23
1278	Survival outcomes of double- and triple-sequential targeted therapy in patients with metastatic renal cell carcinoma: a retrospective comparison. Oncotarget, 2017, 8, 100056-100065.	1.8	5
1279	Patient derived renal cell carcinoma xenografts exhibit distinct sensitivity patterns in response to antiangiogenic therapy and constitute a suitable tool for biomarker development. Oncotarget, 2018, 9, 30946-30961.	1.8	9
1280	Identification of international metastatic renal cell carcinoma database consortium (IMDC) intermediate-risk subgroups in patients with metastatic clear-cell renal cell carcinoma. Oncotarget, 2020, 11, 4582-4592.	1.8	14

#	Article	IF	CITATIONS
1281	Metastatic renal cell carcinoma: the first report of unilateral fundus hemorrhage induced by sorafenib. Oncotarget, 2016, 7, 35181-35187.	1.8	11
1282	Meta-analysis of the efficacy of the pretreatment neutrophil-to-lymphocyte ratio as a predictor of prognosis in renal carcinoma patients receiving tyrosine kinase inhibitors. Oncotarget, 2016, 7, 44039-44046.	1.8	32
1283	ls active surveillance an option for metachronous metastatic renal cell carcinoma?. Annals of Translational Medicine, 2019, 7, 84-84.	1.7	3
1284	Cytoreductive nephrectomy for metastatic renal cell carcinoma, the ultimate urologic †Choosing Wisely' campaign: a narrative review. Translational Cancer Research, 2020, 9, 7337-7349.	1.0	13
1285	Prognostic Significance of Pancreatic Metastases from Renal Cell Carcinoma in Patients Treated with Tyrosine Kinase Inhibitors. Anticancer Research, 2018, 38, 359-365.	1.1	15
1286	Elevated Neutrophil–to–Lymphocyte Ratio Predicts Survival in Patients with Advanced Gastric Cancer Treated with Trastuzumab Combination Chemotherapy. Anticancer Research, 2018, 38, 3151-3156.	1.1	7
1287	Axitinib, cabozantinib, everolimus, nivolumab, sunitinib and best supportive care in previously treated renal cell carcinoma: a systematic review and economic evaluation. Health Technology Assessment, 2018, 22, 1-278.	2.8	24
1288	Methods for the evaluation of biomarkers in patients with kidney and liver diseases: multicentre research programme including ELUCIDATE RCT. Programme Grants for Applied Research, 2018, 6, 1-528.	1.0	3
1289	Complete metastasectomy in renal cell carcinoma: a propensity-score matched by the International Metastatic RCC Database Consortium prognostic model. Ecancermedicalscience, 2019, 13, 967.	1.1	6
1290	Relapse of aseptic meningitis induced by ipilimumab and nivolumab therapy for metastatic renal cell carcinoma: A case report. Molecular and Clinical Oncology, 2019, 11, 590-594.	1.0	8
1291	Does preoperative neutrophil/lymphocyte rate have an effect on survival of the bladder cancer patients who received radical cystectomy?. Journal of Cancer Research and Therapeutics, 2018, 14, 432-436.	0.9	2
1292	Saudi Oncology Society and Saudi Urology Association combined clinical management guidelines for renal cell carcinoma. Urology Annals, 2016, 8, 136.	0.6	5
1293	Saudi oncology society and Saudi urology association combined clinical management guidelines for renal cell carcinoma 2017. Urology Annals, 2018, 10, 123.	0.6	5
1294	Development of the clinical calculator for mortality of patients with metastatic clear cell type renal cell carcinoma: An analysis of patients from Korean Renal Cancer Study Group database. Investigative and Clinical Urology, 2020, 61, 260.	2.0	5
1295	The platelet-to-lymphocyte ratio as a significant prognostic factor to predict survival outcomes in patients with synchronous metastatic renal cell carcinoma. Investigative and Clinical Urology, 2020, 61, 475.	2.0	7
1296	Efficacy and Safety of Everolimus in Korean Patients with Metastatic Renal Cell Carcinoma Following Treatment Failure with a Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor. Cancer Research and Treatment, 2014, 46, 339-347.	3.0	5
1297	Systemic Treatments for Metastatic Renal Cell Carcinoma: 10-Year Experience of Immunotherapy and Targeted Therapy. Cancer Research and Treatment, 2016, 48, 1092-1101.	3.0	24
1298	Application of the International Metastatic Renal Cell Carcinoma Database Consortium and Memorial Sloan Kettering Cancer Center Risk Models in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma: A Multi-Institutional Retrospective Study Using the Korean Metastatic Renal Cell Carcinoma Registry, Cancer Research and Treatment, 2019, 51, 758-768.	3.0	9

		CITATION RE	PORT	
#	Article		IF	CITATIONS
1299	Cross-talk between tumors can affect responses to therapy. Oncolmmunology, 2015, 4	4, e975572.	4.6	7
1300	Combination drug regimens for metastatic clear cell renal cell carcinoma. World Journa Oncology, 2020, 11, 541-562.	l of Clinical	2.3	19
1301	A simple prognostic model for overall survival in metastatic renal cell carcinoma. Canac Urological Association Journal, 2016, 10, 113.	lian	0.6	9
1302	NCCN Guidelines Insights: Kidney Cancer, Version 2.2020. Journal of the National Com Cancer Network: JNCCN, 2019, 17, 1278-1285.	prehensive	4.9	185
1303	Prognostic Factors for Overall Survival in Patients With Metastatic Colorectal Carcinon With Vascular Endothelial Growth Factor-Targeting Agents. Asian Pacific Journal of Car Prevention, 2012, 13, 1059-1063.	na Treated Icer	1.2	24
1304	Prognostic and Predictive Value of Hematologic Parameters in Patients with Metastatic Carcinoma: Second Line Sunitinib Treatment Following IFN-alpha. Asian Pacific Journal Prevention, 2013, 14, 2101-2105.	c Renal Cell of Cancer	1.2	27
1305	Prognostic Value of Hematologic Parameters in Patients with Metastatic Renal Cell Car Tyrosine Kinase Inhibitors. Asian Pacific Journal of Cancer Prevention, 2014, 15, 3801-3	rcinoma Using 1804.	1.2	16
1306	Factors Prognostic for Survival in Japanese Patients Treated with Sunitinib as First-line Metastatic Clear Cell Renal Cell Cancer. Asian Pacific Journal of Cancer Prevention, 201	Therapy for 5, 16, 5687-5690.	1.2	8
1307	Thrombotic Thrombocytopenic Purpura Induced by Immune Checkpoint Inhibitiors: A C Review of the Literature. Cureus, 2020, 12, e11246.	ase Report and	0.5	14
1308	Prognostic significance of pseudocapsule status in patients with metastatic renal cell o treated with tyrosine kinase inhibitors. Translational Andrology and Urology, 2021, 10,	arcinoma 0-0.	1.4	1
1309	Association between prior nephrectomy and efficacy of immune checkpoint inhibitor the metastatic renal cell carcinoma - A systematic review and meta-analysis. Urologic Onco and Original Investigations, 2022, 40, 64.e17-64.e24.	herapy in Nogy: Seminars	1.6	3
1310	Blood Volume as a new functional image-based biomarker of progression inÂmetastati carcinoma. Scientific Reports, 2021, 11, 19659.	c renal cell	3.3	0
1311	Predictive impact of early changes in serum C-reactive protein levels in nivolumab plus therapy for metastatic renal cell carcinoma. Clinical Genitourinary Cancer, 2021, , .	ipilimumab	1.9	6
1312	Crosstalk Between the Tumor Microenvironment and Cancer Cells: A Promising Predict for Immune Checkpoint Inhibitors. Frontiers in Cell and Developmental Biology, 2021,	ive Biomarker 9, 738373.	3.7	15
1313	Efficacy of nivolumab plus ipilimumab as first-line therapy for primary tumors in patient cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 13.	s with renal e19-13.e27.	1.6	4
1314	Invited commentary: When and how to initiate systemic therapy in treating favorable r renal cell carcinoma. Current Urology, 2021, 15, 185-186.	isk metastatic	0.6	1
1315	Emerging Agents in Renal Cell Carcinoma. , 2012, , 285-301.			0
1316	Metastasectomy 2012 123-140			0

		CITATION RE	PORT	
#	Article		IF	CITATIONS
1317	Renal Cell Carcinoma: Clinical Presentation, Staging, and Prognostic Factors. , 2012, ,	69-88.		1
1318	Comparative efficacy of sunitinib versus sorafenib as the first-line treatment for patien metastatic renal cell carcinoma Journal of Clinical Oncology, 2012, 30, e15080-e1508	its with 80.	1.6	Ο
1319	Sustained long-term clinical and radiological response with sunitinib for metastatic rer carcinoma (RCC). Case Reports in Clinical Medicine, 2013, 02, 29-31.	nal-cell	0.2	0
1320	Systemic Therapy of Advanced Renal Cell Carcinoma—Summary of Main Presentation ASCO-GU and ESMO 2012 Annual Meetings. Open Journal of Urology, 2013, 03, 5-11.	ns at the ASCO,	0.1	0
1321	Molecular Targeted Therapies for Patients with Metastatic Renal Cell Cancer. Translati (Sunnyvale, Calif), 2013, 01, .	onal Medicine	0.4	0
1322	Signaling Pathways and Biomarkers in Renal Tumors. , 0, , .			0
1323	Nierenzellkarzinom. , 2014, , 347-397.			0
1324	Kidney Cancer. , 2014, , 309-323.			1
1325	Cancer of the Kidney. , 2014, , 1416-1444.e5.			1
1326	Clinical Prognostic Factors in Metastatic Renal Cell Carcinoma. , 2015, , 555-567.			0
1327	Is thrombocytosis a useful prognostic marker in renal cell carcinoma? Results of a sing retrospective analysis. Indian Journal of Urology, 2015, 31, 42.	le-center	0.6	1
1328	Independent Predictors of Clinical Outcomes and Prediction Models for Renal Tumor F 2015, , 355-371.	athology. ,		2
1329	Renal Cell Carcinoma: Clinical Presentation, Staging, and Prognostic Factors. , 2015, ,	105-121.		1
1330	Emerging Agents in Renal Cell Carcinoma. , 2015, , 385-402.			0
1331	Surgical and Medical Options in the Management of Renal Cell Carcinoma. , 2015, , 18	33-208.		0
1332	Metastasectomy. , 2015, , 173-194.			0
1333	Metastatic renal cell cancer and hypercalcaemia. , 2015, , 143-154.			0
1334	Nierenzellkarzinom. , 2016, , 55-66.			0
#	Article	IF	Citations	
------	---	-----	-----------	
1335	Forthcoming Drugs for Metastatic Renal Cell Carcinoma Therapy. , 2017, , 333-349.		0	
1336	Nierenzellkarzinom beim alten und geriatrischen Patienten. , 2017, , 1-15.		Ο	
1337	Poor risk advanced renal cell carcinoma: Outcomes from a registry in a tertiary cancer center. Indian Journal of Medical and Paediatric Oncology, 2017, 38, 311.	0.2	0	
1338	A Three-Variable Model Predicts Short Survival in Patients With Newly Diagnosed Metastatic Renal Cell Carcinoma. Journal of Clinical Medicine Research, 2017, 9, 281-288.	1.2	Ο	
1339	Comparison of Tyrosine Kinase Inhibitor Versus Mammalian Target of Rapamycin Inhibitor as Second-line Molecular-targeted Therapy for Patients with Poor-risk Metastatic Renal Cell Carcinoma. Anticancer Research, 2017, 37, 1523-1528.	1.1	2	
1340	Initial computed tomography imaging details during first-line systemic therapy is of significant prognostic value in patients with naĂ̄ve, unresectable metastatic renal cell carcinoma. PLoS ONE, 2017, 12, e0177975.	2.5	2	
1341	Yüksek nötrofil- lenfosit oranının renal hücreli karsinomda preoperatif ve postoperatif dönemde sağkalıma etkisi. Kırıkkale Üniversitesi Tıp Fakültesi Dergisi, 0, , 73-77.	0.3	1	
1342	Nierenzellkarzinom beim alten und geriatrischen Patienten. , 2018, , 447-460.		0	
1343	Changing Paradigms in the Treatment of Renal Cancer. Oncology & Hematology Review, 2018, 14, 20.	0.2	0	
1344	Adult Kidney Neoplastic Pathology. , 2018, , 1-119.		0	
1345	Kidney Cancer in Older Adults. , 2018, , 1-11.		0	
1346	Management of Older Patients With Metastatic Renal Cell Carcinoma Receiving Sunitinib: A Hypothetical, Illustrative Case Scenario. Journal of the Advanced Practitioner in Oncology, 2018, 9, .	0.4	Ο	
1347	Neutrophil-lymphocyte ratio in the management and prediction of outcomes in renal cell carcinoma. World Journal of Clinical Urology, 2018, 7, 1-6.	0.0	0	
1349	Pre-surgical Treatment of Renal Cell Carcinoma. , 2019, , 247-262.		0	
1350	Cytoreductive Nephrectomy and Metastasectomy for Renal Cell Carcinoma. , 2019, , 299-311.		0	
1351	Kidney Cancer: From Basics to Immunotherapy. , 2019, , 625-657.		0	
1352	Therapeutic effects of pazopanib treatment in patients with metastatic kidney cancer in real clinical practice. Onkourologiya, 2019, 14, 37-47.	0.3	0	
1353	Metastatic Surgery in Advanced Renal Cell Carcinoma. , 2019, , 615-640.		0	

#	Article	IF	CITATIONS
1354	Prognostic and Predictive Markers, and Stratifications Tables, for the Detection and Treatment of Renal Cell Carcinoma. , 2019, , 511-528.		0
1355	The power of meta-analysis in therapeutic decision making for advanced kidney cancer. Translational Cancer Research, 2019, 8, 7-10.	1.0	0
1356	Photodynamic diagnosis and urinary porphyrin measurements after 5-aminolevulinic acid (5-ALA) administration in patients with renal cell carcinoma. Nippon Laser Igakkaishi, 2019, 40, 93-103.	0.0	0
1357	Metachronous metastasis of renal cell carcinoma to the urinary bladder. Urologie Pro Praxi, 2019, 20, 133-135.	0.1	0
1358	Therapy Management Using Modified 2-Weeks-On/1-Week-Off Dosing Schedule in Patients With Metastatic Renal Cell Carcinoma Receiving Sunitinib: A Hypothetical, Illustrative Case Scenario. Journal of the Advanced Practitioner in Oncology, 2019, 10, 483-493.	0.4	0
1359	Early Experiences with Nivolumab in Patients with Metastatic Renal Cell Carcinoma and Failed Target Therapy. The Korean Journal of Urological Oncology, 2019, 17, 96-102.	0.1	0
1360	Defining an Individualized Treatment Strategy for Metastatic Renal Cancer. , 2020, , 437-452.		0
1361	Role of Surgery in Locally Recurrent and Metastatic Renal Cancer. , 2020, , 295-305.		0
1362	No paradigm changes with checkpoint inhibitor monotherapy in patients with metastatic renal cell carcinoma and brain metastases. Annals of Translational Medicine, 2019, 7, 612-612.	1.7	0
1364	Kidney Cancer in Older Adults. , 2020, , 689-699.		0
1365	Tumors: Urologic Cancer. , 2020, , 1-11.		0
1366	Prognostic value of maximum standard uptake value, metabolic tumor volume, and total lesion glycolysis of 18F-FDG PET/CT in patients with renal carcinoma. Medicine (United States), 2020, 99, e19988.	1.0	7
1368	The Impact of Hypertension on the Clinicopathological Outcome and Progression of Renal Cell Carcinoma. Anticancer Research, 2020, 40, 4087-4093.	1.1	7
1369	Medical Management of Renal Cell Cancer. , 0, , .		0
1370	Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma. Cancer Cell, 2021, 39, 1497-1518.e11.	16.8	126
1371	Overall survival improvement in patients with metastatic clear-cell renal cell carcinoma between 2000 and 2020: a retrospective cohort study. Acta OncolÃ ³ gica, 2022, 61, 22-29.	1.8	17
1372	Immune Checkpoint Inhibitors for Genitourinary Cancers: Treatment Indications, Investigational Approaches and Biomarkers. Cancers, 2021, 13, 5415.	3.7	13
1373	Development and internal validation of nomograms for the prediction of postoperative survival of patients with grade 4 renal cell carcinoma (RCC). Translational Andrology and Urology, 2020, 9, 2629-2639.	1.4	4

# 1374	ARTICLE Prognostic and predictive factors to nivolumab in patients with metastatic renal cell carcinoma: a single center study. Anti-Cancer Drugs, 2021, 32, 74-81.	IF 1.4	CITATIONS
1375	The role of open radical nephrectomy in contemporary management of renal cell carcinoma. Translational Andrology and Urology, 2020, 9, 3123-3139.	1.4	6
1377	Urological Cancer. , 2021, , 77-93.		0
1378	Prognostic value of tumor growth rate and biomarker dynamics in patients with renal cell carcinoma. Urologicheskie Vedomosti, 2020, 10, 281-291.	0.3	1
1379	Novel survival nomograms for patients with lung metastatic clear cell renal cell carcinoma. Medicine (United States), 2020, 99, e23465.	1.0	5
1380	Cáncer renal avanzado, perfiles para los nuevos tratamientos. Medicina Clinica Practica, 2022, 5, 100277.	0.3	0
1381	Survival prognoses of Heng intermediate-risk patients with metastatic renal cell carcinoma treated with immunotherapy or targeted therapy: A real-world, single-center retrospective study. Investigative and Clinical Urology, 2020, 61, 146.	2.0	0
1382	Comparison of three risk stratification models for non-clear cell renal cell carcinoma patients treated with temsirolimus as first-line therapy. Korean Journal of Internal Medicine, 2020, 35, 185-193.	1.7	1
1383	News in the treatment of metastatic renal cancer. Onkologie (Czech Republic), 2020, 14, 26-31.	0.1	0
1384	Selection and evaluation of preoperative systemic inflammatory response biomarkers model prior to cytoreductive nephrectomy using a machine-learning approach. World Journal of Urology, 2022, 40, 747-754.	2.2	4
1386	The role of stereotactic body radiation therapy and its integration with systemic therapies in metastatic kidney cancer: a multicenter study on behalf of the AIRO (Italian Association of) Tj ETQq0 0 0 rgBT /Ov 2021 38 527-537	verlogck 10	Tf 50 342 To
1387	Comparative clinical and economic analysis of using cabozantinib as second-line therapy for adult patients with advanced renal cell carcinoma. Onkourologiya, 2020, 16, 52-64.	0.3	0
1388	Nierenzellkarzinom. , 2014, , 347-397.		0
1391	Cytoreductive surgery in the era of targeted molecular therapy. Translational Andrology and Urology, 2015, 4, 301-9.	1.4	3
1392	Management of metastatic renal cell carcinoma in patients with poor prognosis. Cancer Management and Research, 2010, 2, 123-32.	1.9	11
1393	Critical appraisal of pazopanib as treatment for patients with advanced metastatic renal cell carcinoma. Cancer Management and Research, 2011, 3, 273-85.	1.9	2
1394	Cutaneous metastasis of renal cell carcinoma: a report of two cases. International Journal of Clinical and Experimental Pathology, 2012, 5, 175-8.	0.5	7
1395	Renal cell carcinoma metastatic to the nasal cavity. International Journal of Clinical and Experimental Pathology, 2012, 5, 588-91.	0.5	16

#	Article	IF	Citations
1396	Pazopanib and anti-VECF therapy. Open Access Journal of Urology, 2010, 2, 35-40.	0.3	0
1397	Outcomes of Patients With Late-Relapse Metastatic Renal Cell Carcinoma Treated With Targeted Therapies: A Single Institution Experience. Ochsner Journal, 2017, 17, 331-334.	1.1	5
1398	Management of Older Patients With Metastatic Renal Cell Carcinoma Receiving Sunitinib: A Hypothetical, Illustrative Case Scenario. Journal of the Advanced Practitioner in Oncology, 2018, 9, 67-76.	0.4	0
1399	Experience of Sorafenib as First-Line Treatment in Metastatic Renal Cell Carcinoma in a Tertiary Care Centre. International Journal of Hematology-Oncology and Stem Cell Research, 2018, 12, 197-203.	0.3	0
1400	Next Generation Sequencing in Renal Cell Carcinoma: Towards Precision Medicine. Kidney Cancer Journal: Official Journal of the Kidney Cancer Association, 2019, 17, 94-104.	0.1	0
1401	Laparoscopic cytoreductive nephrectomy is associated with significantly improved survival compared with open cytoreductive nephrectomy or targeted therapy alone. Molecular and Clinical Oncology, 2020, 13, 71.	1.0	Ο
1402	Adrenal Metastases as Sanctuary Sites in Advanced Renal Cancer. Journal of Kidney Cancer and VHL, 2020, 7, 1-7.	1.0	1
1403	Prognostic models in papillary renal cell carcinoma. Annals of Translational Medicine, 2020, 8, 1334.	1.7	0
1404	The current role of cytoreductive nephrectomy for metastatic renal cell carcinoma. Indian Journal of Urology, 2021, 37, 13-19.	0.6	1
1405	Albumin levels predict prognosis in advanced renal cell carcinoma treated with tyrosine kinase inhibitors: a systematic review and meta-analysis. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 12.e13-12.e22.	1.6	6
1406	Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial. Clinical Cancer Research, 2021, 27, 6687-6695.	7.0	25
1407	Cabozantinib plus immunotherapy combinations in metastatic renal cell and urothelial carcinoma. Future Oncology, 2022, 18, 21-33.	2.4	5
1408	Antiangiogenic Therapy in Clear Cell Renal Carcinoma (CCRC): Pharmacological Basis and Clinical Results. Cancers, 2021, 13, 5896.	3.7	15
1410	Risk Stratification and Treatment Algorithm of Metastatic Renal Cell Carcinoma. Journal of Clinical Medicine, 2021, 10, 5339.	2.4	5
1411	Multimodal Deep Learning for Prognosis Prediction in Renal Cancer. Frontiers in Oncology, 2021, 11, 788740.	2.8	35
1412	Novel cutâ€off values of time from diagnosis to systematic therapy predict the overall survival and the efficacy of targeted therapy in renal cell carcinoma: A longâ€term, followâ€up, retrospective study. International Journal of Urology, 2021, , .	1.0	1
1413	Assessment of prognostic factors in previously treated Japanese patients with metastatic renal cell carcinoma who received nivolumab: An observational multi‑institute study. Molecular and Clinical Oncology, 2021, 16, 17.	1.0	2
1414	Stereotactic Radiosurgery Results for Brain Metastasis Patients with Renal Cancer: A Validity Study of Renal Graded Prognostic Assessment and Proposal of a New Grading Index (JLGK2101 Study). Clinical and Translational Radiation Oncology, 2021, 32, 69-75.	1.7	1

ARTICLE IF CITATIONS # Immune Checkpoint Inhibitor Therapy for Bone Metastases: Specific Microenvironment and Current 1415 2.2 21 Situation. Journal of Immunology Research, 2021, 2021, 1-18. A renal cell carcinoma tumorgraft platform to advance precision medicine. Cell Reports, 2021, 37, 1416 6.4 110055. A Multicentre Retrospective Study of Nivolumab Plus Ipilimumab for Untreated Metastatic Renal Cell 1417 7 1.1 Carcinoma. Anticancer Research, 2021, 41, 6199-6209. Association of cabozantinib pharmacokinetics, progression and toxicity in metastatic renal cell carcinoma patients: results from a pharmacokinetics/pharmacodynamics study. ESMO Open, 2021, 6, 1420 4.5 100312. Thyrotoxic Goiter and Asymptomatic Thyroid Nodule as an Initial Presentation of Clear Cell Renal Cell 1421 0.6 0 Carcinoma. Urological Science, 2019, 30, 238-240. Current and Future Aspect of Immunotherapy for Advanced Renal Cell Carcinoma. Urological Science, 0.6 2020, 31, 8-14. Landscape of Immunotherapy in Genitourinary Malignancies. Advances in Experimental Medicine and 1423 1.6 2 Biology, 2021, 1342, 143-192. Combination therapies in clinical trials for renal cell carcinoma: how could they impact future 1424 4.1 treatments?. Expert Opinion on Investigational Drugs, 2021, , 1-9. First-Line Treatments for Metastatic Clear Cell Renal Cell Carcinoma: An Ever-Enlarging Landscape. 1425 3.7 9 Oncologist, 2022, 27, 125-134. Biomarkers of tumor microenvironment of malignant neoplasms of kidneys, urinary bladder, and 1426 0.2 prostate gland (literature review). Medical Alphabet, 2022, , 41-46. Laparoscopic cytoreductive nephrectomy is associated with significantly improved survival compared with open cytoreductive nephrectomy of targeted therapy alone. Molecular and Clinical Oncology, 1428 3 1.0 2020, 13, 1-1. Adrenal Metastases as Sanctuary Sites in Advanced Renal Cancer. Journal of Kidney Cancer and VHL, 1429 1.0 2020, 7, 1-7. Prognostic models in papillary renal cell carcinoma. Annals of Translational Medicine, 2020, 8, 1430 1.7 2 1334-1334. Tumors: Urologic Cancer., 2021, , 5291-5301. 1431 Novel emerging biomarkers to immunotherapy in kidney cancer. Therapeutic Advances in Medical 1432 3.2 12 Oncology, 2021, 13, 175883592110593. Prognostic effect of preoperative systemic immune-inflammation index in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma. Minerva Urology and Nephrology, 1433 2022, 74, . Prognostic Immunophenotyping Clusters of Clear Cell Renal Cell Carcinoma Defined by the Unique 1434 3.7 12 Tumor Immune Microenvironment. Frontiers in Cell and Developmental Biology, 2021, 9, 785410. Improvement of Medical Treatment in Japanese Patients With Metastatic Renal Cell Carcinoma. Cancer 1436 Diagnosis & Prognosis, 2022, 2, 25-30.

#	Article	IF	Citations
1437	Integrative clinical and molecular characterization of translocation renal cell carcinoma. Cell Reports, 2022, 38, 110190.	6.4	40
1438	Editorial Comment to Novel cutâ€off values of time from diagnosis to systematic therapy predict the overall survival and the efficacy of targeted therapy in renal cell carcinoma: A longâ€term, followâ€up, retrospective study. International Journal of Urology, 2022, 29, 220-221.	1.0	0
1439	Outcomes of sorafenib treatment of advanced renal cell carcinoma according to International Metastatic Renal Cell Carcinoma Data Consortium risk criteria: analysis of Japanese real-world data from postmarketing all-patient surveillance of sorafenib. Future Oncology, 2022, , .	2.4	1
1440	The Value of Metastasectomy in Renal Cell Carcinoma in 2021. Indian Journal of Surgery, 0, , 1.	0.3	0
1441	Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 71-90.	4.9	248
1442	Immunotherapy: A new standard in the treatment of metastatic clear cell renal cell carcinoma. World Journal of Clinical Oncology, 2022, 13, 28-38.	2.3	10
1443	Reviewing Treatment Options for Advanced Renal Cell Carcinoma: Is There Still a Place for Tyrosine Kinase Inhibitor (TKI) Monotherapy?. Advances in Therapy, 2022, 39, 1107-1125.	2.9	10
1444	A Cost-effectiveness Analysis Comparing Pembrolizumab-Axitinib, Nivolumab-Ipilimumab, and Sunitinib for Treatment of Advanced Renal Cell Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2022, 45, 66-73.	1.3	6
1446	Selection of Optimal Candidates for Cytoreductive Nephrectomy in Patients with Metastatic Clear Cell Renal Cell Carcinoma: A Predictive Model Based on SEER Database. Frontiers in Oncology, 2022, 12, 814512.	2.8	6
1447	2021 Updated European Association of Urology Guidelines on the Use of Adjuvant Pembrolizumab for Renal Cell Carcinoma. European Urology, 2022, 81, 134-137.	1.9	29
1448	OUP accepted manuscript. Oncologist, 2022, , .	3.7	2
1449	Surgical management of renal cancer metastasis in the humerus: novel use of a trabecular metal spacer. BMJ Case Reports, 2022, 15, e244313.	0.5	0
1450	Immune-Related Thyroiditis as a Predictor for Survival in Metastatic Renal Cell Carcinoma. Cancers, 2022, 14, 875.	3.7	3
1451	Predictors of Survival in Favorable Risk Patients with Metastatic Renal Cell Carcinoma Treated with a Single-Agent First-Line Therapy. Urologia Internationalis, 2022, , 1-5.	1.3	1
1452	Advanced Hepatocellular Cancer Treated with Sorafenib and Novel Inflammatory Markers. Journal of Gastrointestinal Cancer, 2022, , 1.	1.3	2
1453	Substratification of patients with highestâ€risk nonâ€muscle invasive bladder cancer helps to identify the candidates for immediate radical cystectomy: A twoâ€center study. International Journal of Urology, 2022, , .	1.0	3
1455	Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210795.	3.2	10
1456	Immune Checkpoint Inhibitor Combination Therapy for Renal Cell Carcinomas With Concomitant Inferior Vena Cava Thrombi. In Vivo, 2022, 36, 1030-1034.	1.3	11

	Сітатіс	on Report	
#	Article	IF	CITATIONS
1457	c-Met and EPHA7 Receptor Tyrosine Kinases Are Related to Prognosis in Clear Cell Renal Cell Carcinoma: Focusing on the Association with Myoferlin Expression. Cancers, 2022, 14, 1095.	3.7	2
1458	Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World Comparison. Clinical Genitourinary Cancer, 2022, 20, 285-295.	1.9	5
1459	Small renal mass with large lymph nodal metastasis and inferior vena cava thrombus: an exceptional amalgamation. Annals of the Royal College of Surgeons of England, 2022, , .	0.6	0
1460	Case Study: A Japanese patient with metastatic renal cell carcinoma who achieved longâ€ŧerm treatmentâ€free survival with pembrolizumab and axitinib in the KEYNOTEâ€426 phase III trial of pembrolizumab and axitinib versus sunitinib. IJU Case Reports, 2022, 5, 149-152.	0.3	1
1461	The Role of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: A Real-World Multi-Institutional Analysis. Journal of Urology, 2022, 208, 71-79.	0.4	24
1462	Diagnostics and prognostic evaluation in renal cell tumors: the German S3 guidelines recommendations. World Journal of Urology, 2022, , 1.	2.2	0
1463	Oncological outcomes of surgery for isolated retroperitoneal recurrence in renal cancer patients after radical nephrectomy. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 111.e27-111.e34.	1.6	0
1464	Reshaping Treatment Paradigms for Advanced Renal Cell Cancer Patients and Improving Patient Management. Current Treatment Options in Oncology, 2022, 23, 609-629.	3.0	1
1465	Improving Brain Metastases Outcomes Through Therapeutic Synergy Between Stereotactic Radiosurgery and Targeted Cancer Therapies. Frontiers in Oncology, 2022, 12, 854402.	2.8	12
1466	Approaches to First-Line Therapy for Metastatic Clear Cell Renal Cell Carcinoma. Current Oncology Reports, 2022, 24, 695-702.	4.0	9
1467	Treatment Equity in the Immunotherapy Era: Options for Patients with Both Autoimmune Disease and GU Cancers. Life, 2022, 12, 360.	2.4	1
1468	Immune Checkpoint Inhibitor Combination Therapy versus Sunitinib as First-Line Treatment for Favorable-IMDC-Risk Advanced Renal Cell Carcinoma Patients: A Meta-Analysis of Randomized Clinical Trials. Biomedicines, 2022, 10, 577.	3.2	5
1469	Prognostic model of upfront cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors and/or targeted agents. International Urology and Nephrology, 2022, 54, 1225-1232.	1.4	8
1470	Prognostic Utility of Parameters Derived From Pretreatment Dual-Layer Spectral-Detector CT in Patients With Metastatic Renal Cell Carcinoma. American Journal of Roentgenology, 2022, 218, 867-876.	2.2	6
1471	Real-World Metastatic Renal Cell Carcinoma Treatment Patterns and Clinical Outcomes in The Netherlands. Frontiers in Pharmacology, 2022, 13, 803935.	3.5	8
1472	Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma. Journal of Translational Medicine, 2022, 20, 159.	4.4	12
1473	Efficacy of second-line ICIs combined with TKIs among patients with metastatic renal cell carcinoma: a real-world study. Immunotherapy, 2022, 14, 309-320.	2.0	0
1474	Impact of Body Mass Index on Survival Outcomes of Patients with Metastatic Renal Cell Carcinoma in the Immuno-oncology Era: A Systematic Review and Meta-analysis. European Urology Open Science, 2022, 39, 62-71.	0.4	9

#	Article	IF	CITATIONS
1475	A largeâ€scale assay library for targeted protein quantification in renal cell carcinoma tissues. Proteomics, 2022, 22, 2100228.	2.2	0
1476	AXL targeting by a specific small molecule or monoclonal antibody inhibits renal cell carcinoma progression in an orthotopic mice model. Physiological Reports, 2021, 9, e15140.	1.7	5
1477	Real-World Data on the Use of Nivolumab Monotherapy in the Treatment of Advanced Renal Cell Carcinoma after Prior Therapy: Interim Results from the Noninterventional NORA Study. European Urology Focus, 2022, 8, 1289-1299.	3.1	4
1478	Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance). Clinical Cancer Research, 2022, 28, 2771-2778.	7.0	8
1479	Metastatic Clear Renal-Cell Carcinoma Mimicking Anaplastic Thyroid Cancer: A Case Report. Ear, Nose and Throat Journal, 2021, , 014556132110655.	0.8	0
1483	Front-Line Therapy for Metastatic Renal Cell Carcinoma: A Perspective on the Current Algorithm and Future Directions. Cancers, 2022, 14, 2049.	3.7	7
1487	Critical appraisal of pazopanib as treatment for patients with advanced metastatic renal cell carcinoma. Cancer Management and Research, 2011, 3, 273.	1.9	5
1488	The current role of cytoreductive nephrectomy for metastatic renal cell carcinoma. Indian Journal of Urology, 2021, 37, 13.	0.6	4
1489	Impact of the Discordance Between Scales of Memorial Sloan-Kettering Cancer Center and International Metastatic Renal Cell Carcinoma Database Consortium in Patients' Prognosis With Metastatic Renal Cancer. World Journal of Oncology, 2022, 13, 53-58.	1.5	1
1490	Practice-changing publications: Kidney cancer. Canadian Urological Association Journal, 2021, 16, E237-9.	0.6	0
1491	A Retrospective Study of First-Line Therapy Involving Immune Checkpoint Inhibitors in Patients With Poor Risk Metastatic Renal Cell Carcinoma. Frontiers in Oncology, 2022, 12, 874385.	2.8	0
1492	Radiogenomics in Clear Cell Renal Cell Carcinoma: A Review of the Current Status and Future Directions. Cancers, 2022, 14, 2085.	3.7	7
1493	Association between cognitive impairment and oral anticancer agent use in older patients with metastatic renal cell carcinoma. Journal of the American Geriatrics Society, 2022, 70, 2330-2343.	2.6	0
1495	Systemic therapy in metastatic renal cell carcinoma (mRCC): an evidence-based recommendation of the German interdisciplinary RCC guidelines group. World Journal of Urology, 2022, 40, 2381-2386.	2.2	3
1496	Complementary roles of surgery and systemic treatment in clear cell renal cell carcinoma. Nature Reviews Urology, 2022, 19, 391-418.	3.8	20
1497	Compassionate Use Program of Ipilimumab and Nivolumab in Intermediate or Poor Risk Metastatic Renal Cell Carcinoma: A Large Multicenter Italian Study. Cancers, 2022, 14, 2293.	3.7	4
1498	Early reduction in spectral dual-layer detector CT parameters as favorable imaging biomarkers in patients with metastatic renal cell carcinoma. European Radiology, 2022, 32, 7323-7334.	4.5	5
1499	A Positive Feedback Loop between Inactive VHL-Triggered Histone Lactylation and PDGFRÎ ² Signaling Drives Clear Cell Renal Cell Carcinoma Progression. International Journal of Biological Sciences, 2022, 18, 3470-3483.	6.4	40

#	ARTICLE The relationship between pan-immune-inflammation value and survival outcomes in patients with	IF	CITATIONS
1500	metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: a Turkish oncology group kidney cancer consortium (TKCC) study. Journal of Cancer Research and Clinical Oncology, 2022, 148, 3537-3546.	2.5	9
1501	Real-world data on the efficacy and safety of pazopanib in IMDC favorable- and intermediate-risk metastatic renal cell carcinoma: a multicenter retrospective cohort study of Chinese patients. Translational Andrology and Urology, 2022, 11, 694-709.	1.4	2
1502	Efficacy of Cabozantinib for Papillary Compared With Clear-cell Renal Cell Carcinoma Following Immune Checkpoint Inhibitor Treatment. Anticancer Research, 2022, 42, 3151-3158.	1.1	4
1503	Micro-RNAs Predict Response to Systemic Treatments in Metastatic Renal Cell Carcinoma Patients: Results from a Systematic Review of the Literature. Biomedicines, 2022, 10, 1287.	3.2	10
1504	Immune-Associated Gene Signatures Serve as a Promising Biomarker of Immunotherapeutic Prognosis for Renal Clear Cell Carcinoma. Frontiers in Immunology, 0, 13, .	4.8	10
1505	Comprehensive assessments of immunoâ€oncology drugâ€based combination therapies as firstâ€line treatment for advanced renal cell carcinoma. International Journal of Urology, 2022, 29, 816-822.	1.0	1
1506	First-line therapy for metastatic renal cell carcinoma. Journal of Clinical Urology, 0, , 205141582210929.	0.1	0
1507	An Evaluation of Cabozantinib for the Treatment of Renal Cell Carcinoma: Focus on Patient Selection and Perspectives. Therapeutics and Clinical Risk Management, 0, Volume 18, 619-632.	2.0	5
1508	Renal and urinary bladder cancer. , 2023, , 327-335.		0
1509	A single-sample mRNA molecular classification of bladder cancer predicting prognosis and response to immunotherapy. Translational Andrology and Urology, 2021, .	1.4	Ο
1510	Imaging Response to Contemporary Immuno-oncology Combination Therapies in Patients With Metastatic Renal Cell Carcinoma. JAMA Network Open, 2022, 5, e2216379.	5.9	10
1511	Targeting hypoxia-inducible factor pathways in sporadic and Von Hippel-Lindau syndrome-related kidney cancers. Critical Reviews in Oncology/Hematology, 2022, 176, 103750.	4.4	8
1512	Construction and validation of an autophagy-related long non-coding RNA signature to predict the prognosis of kidney renal papillary cell carcinoma. Journal of Investigative Medicine, 2022, 70, 1536-1544.	1.6	4
1513	A Molecularly Characterized Preclinical Platform of Subcutaneous Renal Cell Carcinoma (RCC) Patient-Derived Xenograft Models to Evaluate Novel Treatment Strategies. Frontiers in Oncology, 0, 12, .	2.8	2
1514	Genome-Wide Meta-Analysis Identifies Variants in DSCAM and PDLIM3 That Correlate with Efficacy Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib. Cancers, 2022, 14, 2838.	3.7	1
1515	Role of the Systemic Immune-Inflammation Index in Patients with Metastatic Renal Cell Carcinoma Treated with First-Line Ipilimumab plus Nivolumab. Cancers, 2022, 14, 2972.	3.7	13
1516	An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma. Ca-A Cancer Journal for Clinicians, 2022, 72, 454-489.	329.8	13
1517	Metastatic Clear-Cell Renal Cell Carcinoma in the Era of Immune Checkpoint Inhibitors: Therapies and Ongoing Trials. Cancers, 2022, 14, 2867.	3.7	10

#	Article	IF	CITATIONS
1518	In the phase III IMmotion151 trial of metastatic renal cell carcinoma the easy-to-implement modified Glasgow prognostic score predicts outcome more accurately than the IMDC score. Annals of Oncology, 2022, 33, 982-984.	1.2	8
1519	Targeting Cardiovascular Adverse EventsÂof Metastatic Renal Cell Carcinoma Therapies. JACC: CardioOncology, 2022, 4, 235-237.	4.0	1
1520	Prognostic and predictive significance of VEGF, CD31, and Ang-1 in patients with metastatic clear cell renal cell carcinoma treated with first-line sunitinib. Bosnian Journal of Basic Medical Sciences, 0, , .	1.0	2
1521	Up-front Nivolumab With or Without Salvage Ipilimumab Across International Metastatic Database Consortium Risk Groups in Metastatic Clear Cell Renal Cell Carcinoma. Journal of Clinical Oncology, 0, , .	1.6	0
1522	Primary Tumor Shrinkage and the Effect on Metastatic Disease and Outcomes in Patients With Advanced Kidney Cancer With Intermediate or Poor Prognosis Treated With Nivolumab Plus Ipilimumab or Cabozantinib. Clinical Genitourinary Cancer, 2022, 20, 498.e1-498.e9.	1.9	3
1523	RCC Real-World Data: Prognostic Factors and Risk Stratification in the Immunotherapy Era. Cancers, 2022, 14, 3127.	3.7	5
1524	Cabozantinib in the treatment of patients with advanced renal cell carcinoma. Journal of Modern Oncology, 2022, 24, 184-190.	0.3	0
1525	External Validation of a Novel Risk Model in Patients With Favorable Risk Renal Cell Carcinoma Defined by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC): Results From the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database. Clinical Genitourinary Cancer. 2023, 21, 175-182.	1.9	2
1526	Does the Time to Start First-Line Treatment Influence the Survival of Favorable-Risk Patients With Metastatic Renal Cell Carcinoma? Results of the MetaSurv–UroCCR 79 Study. Clinical Genitourinary Cancer, 2023, 21, 194-202.	1.9	0
1527	The unique genomic landscape and prognostic mutational signature of Chinese clear cell renal cell carcinoma. Journal of the National Cancer Center, 2022, 2, 162-170.	7.4	7
1528	VHL and DNA damage repair pathway alterations as potential clinical biomarkers for first-line TKIs in metastatic clear cell renal cell carcinomas. Cellular Oncology (Dordrecht), 0, , .	4.4	2
1529	Facts and Hopes for Immunotherapy in Renal Cell Carcinoma. Clinical Cancer Research, 2022, 28, 5013-5020.	7.0	8
1530	Long-term outcome of renal cell carcinoma in patients with HIV who undergo surgery. BMC Infectious Diseases, 2022, 22, .	2.9	3
1531	Prognostic value of the ratio of maximum to minimum diameter of primary tumor in metastatic clear cell renal cell carcinoma. BMC Urology, 2022, 22, .	1.4	2
1532	Impact of modified Glasgow prognostic score on predicting prognosis and modification of risk model for patients with metastatic renal cell carcinoma treated with first line tyrosine kinase inhibitor. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 455.e11-455.e18.	1.6	2
1533	Clinicopathological characteristics and prognosis of metastatic collecting duct carcinoma. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 385.e1-385.e8.	1.6	1
1534	Renal Tumors. , 2023, , 285-308.		0
1535	Two case reports of immune checkpoint therapy on chromophobe renal cell carcinoma with sarcomatoid differentiation. International Cancer Conference Journal, 0, , .	0.5	1

#	Article	IF	CITATIONS
1536	CABOSEQ: The Effectiveness of Cabozantinib in Patients With Treatment Refractory Advanced Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). Clinical Genitourinary Cancer, 2023, 21, 106.e1-106.e8.	1.9	7
1537	Pancreatic metastases after surgery for renal cell carcinoma: survival and pathways of progression. World Journal of Urology, 0, , .	2.2	2
1538	Role of metastasectomy in the management of renal cell carcinoma. Frontiers in Surgery, 0, 9, .	1.4	6
1539	Other-cause mortality and access to care in metastatic renal cell carcinoma according to race/ethnicity. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 493.e9-493.e16.	1.6	5
1540	C-reactive protein and immune-related adverse events as prognostic biomarkers in immune checkpoint inhibitor treated metastatic renal cell carcinoma patients. Acta Oncológica, 2022, 61, 1240-1247.	1.8	4
1541	Perirenal Fat Thickness Significantly Associated with Prognosis of Metastatic Renal Cell Cancer Patients Receiving Anti-VECF Therapy. Nutrients, 2022, 14, 3388.	4.1	1
1543	The expanding role of BAP1 in clear cell renal cell carcinoma. Human Pathology, 2023, 133, 22-31.	2.0	6
1544	The Association between a Decrease in On-Treatment Neutrophil-to-Eosinophil Ratio (NER) at Week 6 after Ipilimumab Plus Nivolumab Initiation and Improved Clinical Outcomes in Metastatic Renal Cell Carcinoma. Cancers, 2022, 14, 3830.	3.7	5
1545	Deep learning can predict survival directly from histology in clear cell renal cell carcinoma. PLoS ONE, 2022, 17, e0272656.	2.5	9
1546	C-reactive protein provides superior prognostic accuracy than the IMDC risk model in renal cell carcinoma treated with Atezolizumab/Bevacizumab. Frontiers in Oncology, 0, 12, .	2.8	4
1547	2021 Consensus Statements on the Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma From the Korean Renal Cancer Study Group (KRoCS). The Korean Journal of Urological Oncology, 2022, 20, 151-162.	0.1	1
1548	Real-world effectiveness of nivolumab plus ipilimumab and second-line therapy in Japanese untreated patients with metastatic renal cell carcinoma: 2-year analysis from a multicenter retrospective clinical study (J-cardinal study). Japanese Journal of Clinical Oncology, 0, , .	1.3	1
1549	Efficacy of Cabozantinib in Metastatic MiT Family Translocation Renal Cell Carcinomas. Oncologist, 2022, 27, 1041-1047.	3.7	10
1551	Coexpression of lymphocyte-activation gene 3 and programmed death ligand-1 in tumor infiltrating immune cells predicts worse outcome in renal cell carcinoma. International Journal of Immunopathology and Pharmacology, 2022, 36, 039463202211255.	2.1	6
1552	The role of gut microbiome in immune modulation in metastatic renal cell carcinoma. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211227.	3.2	7
1553	Biomarkers in Urological Cancers. , 2022, , 37-76.		0
1554	Logical Imputation to Optimize Prognostic Risk Classification in Metastatic Renal Cell Cancer. Kidney Cancer, 2022, , 1-10.	0.4	0
1555	Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trial. BMJ Open, 2022, 12, e058396.	1.9	2

#	Article	IF	CITATIONS
1556	Real World Data of Diagnosis, Survival, and Treatment Outcomes in Patients With Metastatic Non Clear Cell Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2023, 21, e35-e43.	1.9	1
1557	Neutrophilia and post-radiation thrombocytopenia predict for poor prognosis in radiation-treated glioma patients. Frontiers in Oncology, 0, 12, .	2.8	4
1558	Thrombocytosis predicts poor prognosis of Asian patients with colorectal cancer: A systematic review and meta-analysis. Medicine (United States), 2022, 101, e30275.	1.0	2
1559	Development and validation of a novel immunotype for prediction of overall survival in patients with clear cell renal cell carcinoma. Frontiers in Oncology, 0, 12, .	2.8	0
1560	Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma. JAMA Oncology, 2022, 8, 1411.	7.1	37
1562	Case report: Complete remission of bone metastasis from renal cell carcinoma in histopathological examination after treatment with immune checkpoint inhibitors. Frontiers in Immunology, 0, 13, .	4.8	1
1563	Molecular analysis and favorable clinical outcomes in real-world patients with metastatic renal cell carcinoma. Acta Oncológica, 2022, 61, 1268-1277.	1.8	2
1564	The prognostic value of baseline and early variations of peripheral blood inflammatory ratios and their cellular components in patients with metastatic renal cell carcinoma treated with nivolumab: The Δ-Meet-URO analysis. Frontiers in Oncology, 0, 12, .	2.8	4
1565	Clinical implications of the tumor microenvironment using multiplexed immunohistochemistry in patients with advanced or metastatic renal cell carcinoma treated with nivolumab plus ipilimumab. Frontiers in Oncology, 0, 12, .	2.8	3
1566	CDCA3 Predicts Poor Prognosis and Affects CD8+ T Cell Infiltration in Renal Cell Carcinoma. Journal of Oncology, 2022, 2022, 1-12.	1.3	2
1567	Elevated neutrophilâ€toâ€lymphocyte ratio (<scp>NLR</scp>) is associated with poorer progressionâ€free survival in unresectable stage <scp>III NSCLC</scp> treated with consolidation durvalumab. Thoracic Cancer, 2022, 13, 3058-3062.	1.9	4
1568	Associations between Pretreatment Body Composition Features and Clinical Outcomes among Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Blockade. Clinical Cancer Research, 2022, 28, 5180-5189.	7.0	9
1569	The relationship between systemic immune inflammation index and survival in patients with metastatic renal cell carcinomatreated withtyrosine kinase inhibitors. Scientific Reports, 2022, 12, .	3.3	7
1571	Rechallenging nivolumab following immune checkpoint inhibitor–induced pericarditis. Baylor University Medical Center Proceedings, 0, , 1-2.	0.5	0
1572	Initial active surveillance for patients with metastatic renal cell carcinoma: 10 years' experience at a regional cancer Centre. Cancer Medicine, 2023, 12, 5255-5264.	2.8	3
1573	Effectiveness of immune checkpoint inhibitors in combination with stereotactic radiosurgery for patients with brain metastases from renal cell carcinoma: inverse probability of treatment weighting using propensity scores. Journal of Neurosurgery, 2022, , 1-9.	1.6	4
1574	Phase I/ <scp>II</scp> study of multipeptide cancer vaccine <scp>IMA901</scp> after singleâ€dose cyclophosphamide in Japanese patients with advanced renal cell cancer with longâ€ŧerm follow up. International Journal of Urology, 0, , .	1.0	1
1576	Contemporary vs historical survival rates in metastatic clear cell renal carcinoma according to race/ethnicity. World Journal of Urology, 0, , .	2.2	0

ARTICLE

IF CITATIONS

Avelumab plus axitinib combination in treating metastatic renal cell carcinoma. Onkologie (Czech) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50

1578	Hot topics in renal cancer pathology: implications for clinical management. Expert Review of Anticancer Therapy, 2022, 22, 1275-1287.	2.4	4
1579	Progression-free Survival After Second Line of Therapy for Metastatic Clear Cell Renal Cell Carcinoma in Patients Treated with First-line Immunotherapy Combinations. European Urology, 2023, 83, 195-199.	1.9	5
1580	French AFU Cancer Committee Guidelines - Update 2022-2024: management of kidney cancer. Progres En Urologie, 2022, 32, 1195-1274.	0.8	11
1581	Serum C-reactive Protein Level Predicts Overall Survival for Clear Cell and Non-Clear Cell Renal Cell Carcinoma Treated with Ipilimumab plus Nivolumab. Cancers, 2022, 14, 5659.	3.7	4
1582	[89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma. Clinical Cancer Research, 2023, 29, 592-601.	7.0	7
1583	Therapeutic sequencing in advanced renal cell carcinoma: How to choose considering clinical and biological factors. Critical Reviews in Oncology/Hematology, 2023, 181, 103881.	4.4	3
1584	Can Molecular Classifications Help Tailor First-line Treatment of Metastatic Renal Cell Carcinoma? A Systematic Review of Available Models. European Urology Open Science, 2023, 47, 12-19.	0.4	1
1585	Frontline immune checkpoint inhibitor-based combination therapy in metastatic renal cell carcinoma patients with poor performance status. European Journal of Cancer, 2023, 180, 21-29.	2.8	2
1586	Current and Future Biomarkers in the Management of Renal Cell Carcinoma. Urologic Clinics of North America, 2023, 50, 151-159.	1.8	2
1587	Guiding treatment selection with immunotherapy compared to targeted therapy agents in patients with metastatic kidney cancer. Expert Review of Precision Medicine and Drug Development, 2022, 7, 131-149.	0.7	3
1588	The impact of proton-pump inhibitors administered with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma. Anti-Cancer Drugs, 2023, 34, 178-186.	1.4	4
1589	Prognostic significance of 18F-FDG PET/CT indices in metastatic renal cell cancer and evaluation of revised IMDC risk model by including 18F-FDG PET-CT parameters. Acta Radiologica, 2023, 64, 2040-2049.	1.1	2
1590	A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03). Tumori, 2023, 109, 129-137.	1.1	16
1591	Association of neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, and De Ritis ratio with mortality in renal cell carcinoma: A multicenter analysis. Frontiers in Oncology, 0, 12, .	2.8	0
1592	Geriatric Nutritional Risk Index as a Predictor of Prognosis in Metastatic Renal Cell Carcinoma Treated with Nivolumab. Nutrition and Cancer, 2023, 75, 670-677.	2.0	3
1593	Impact of low and high body mass index on predicting therapeutic efficacy and prognosis in patients with metastatic renal cell carcinoma treated with firstâ€ine tyrosine kinase inhibitors. International Journal of Urology, 0, , .	1.0	1
1594	Clinical outcomes of nivolumab plus ipilimumab in patients with metastatic nonâ€clear cell renal cell carcinoma: Realâ€world data from a Japanese multicenter retrospective study. International Journal of Urology, 2023, 30, 714-721.	1.0	3

#	Article	IF	Citations
1595	Optimization of firstâ€line systemic therapy in patients with advanced clear cell renal cell carcinoma. International Journal of Urology, 2023, 30, 705-713.	1.0	1
1596	Effect of M2-like macrophages of the injured-kidney cortex on kidney cancer progression. Cell Death Discovery, 2022, 8, .	4.7	3
1597	Prognostic significance of sarcopenia and systemic inflammation for patients with renal cell carcinoma following nephrectomy. Frontiers in Oncology, 0, 12, .	2.8	2
1599	Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program. ESMO Open, 2022, 7, 100634.	4.5	5
1600	Neutrophil interactions with T cells, platelets, endothelial cells, and of course tumor cells. Immunological Reviews, 2023, 314, 13-35.	6.0	14
1601	Body Composition to Define Prognosis of Cancers Treated by Anti-Angiogenic Drugs. Diagnostics, 2023, 13, 205.	2.6	2
1602	CÃ _i ncer renal. Descripci $ ilde{A}^3$ n poblacional en una instituci $ ilde{A}^3$ n acad $ ilde{A}$ ©mica. , 2016, 21, .		0
1603	Biomarkers of Inflammation and Progression During Immunotherapy in Patients With Metastatic Renal Cell Carcinoma. In Vivo, 2023, 37, 393-399.	1.3	0
1604	Sunitinib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers. Drug Resistance Updates, 2023, 67, 100929.	14.4	23
1605	The Emerging Role of PET/CT with PSMA-Targeting Radiopharmaceuticals in Clear Cell Renal Cancer: An Updated Systematic Review. Cancers, 2023, 15, 355.	3.7	9
1606	The value of the multidisciplinary team in metastatic renal cell carcinoma: Paving the way for precision medicine in toxicities management. Frontiers in Oncology, 0, 12, .	2.8	3
1607	Differences in overall survival between clear cell metastatic renal cell carcinoma patients versus population-based controls according to race/ethnicity in the United States. Annals of Epidemiology, 2023, 79, 65-70.	1.9	2
1609	Clear Cell Renal Cell Carcinoma: From Biology to Treatment. Cancers, 2023, 15, 665.	3.7	11
1610	Renal cancer. InnovAiT, 0, , 175573802211487.	0.0	0
1611	The Association Between Cytoreductive Nephrectomy and Overall Survival in Metastatic Renal Cell Carcinoma with Primary Tumor Size â‰ 4 Âcm. European Urology Focus, 2023, , .	3.1	2
1612	Prognostic Value of Serum Soluble PD-L1 in Metastatic Renal Cell Carcinoma Patients Treated With Nivolumab. Anticancer Research, 2023, 43, 841-847.	1.1	1
1613	Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma. European Urology, 2023, 84, 109-116.	1.9	15
1614	Differential treatment responses to immune checkpoint inhibitor (ICI) therapy in a case of multiple primary malignancies: the programmed death ligand-1 (PD-L1) negative ureteral and lung metastasis from a clear cell renal cell carcinoma appearing after robotic-assisted partial nephrectomy progressed after ICI therapy, while synchronous PD-L1-positive primary lung squamous cell carcinoma	1.9	0

#	Article	IF	CITATIONS
1615	LITESPARK-011: belzutifan plus lenvatinib vs cabozantinib in advanced renal cell carcinoma after anti-PD-1/PD-L1 therapy. Future Oncology, 2023, 19, 113-121.	2.4	7
1616	Cost-Effectiveness of Nivolumab Plus Ipilimumab for the First-Line Treatment of Intermediate/Poor-Risk Advanced and/or Metastatic Renal Cell Carcinoma in Switzerland. PharmacoEconomics - Open, 2023, 7, 567-577.	1.8	1
1617	Development and validation of a nomogram to evaluate the therapeutic effects of second-line axitinib in patients with metastatic renal cell carcinoma. Frontiers in Oncology, 0, 13, .	2.8	0
1618	Artificial intelligence-based prediction of overall survival in metastatic renal cell carcinoma. Frontiers in Oncology, 0, 13, .	2.8	2
1619	Fat Loss in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. International Journal of Molecular Sciences, 2023, 24, 3994.	4.1	0
1620	Urine supernatant reveals a signature that predicts survival in clearâ€cell renal cell carcinoma. BJU International, 2023, 132, 75-83.	2.5	2
1621	The role of cytoreductive nephrectomy and systemic therapy in the management of tumour thrombus in patients with metastatic renal cell carcinoma. British Journal of Cancer, 2023, 128, 1888-1896.	6.4	3
1622	Management of Metastatic Renal Cell Carcinoma in a Tertiary Care Hospital. Cureus, 2023, , .	0.5	1
1623	Imaging Recommendations for Diagnosis, Staging, and Management of Renal Tumors. Indian Journal of Medical and Paediatric Oncology, 2023, 44, 084-092.	0.2	1
1624	Kidney cancer treatment in the aging population. Japanese Journal of Geriatrics, 2023, 60, 20-24.	0.1	0
1625	Pseudoprogression and Mixed Responses in Metastatic Renal Cell Carcinoma Patients Treated With Nivolumab: A Retrospective Analysis. Clinical Genitourinary Cancer, 2023, 21, 442-451.	1.9	0
1626	Is It Time to Integrate Frailty Assessment in Onconephrology?. Cancers, 2023, 15, 1674.	3.7	0
1627	Navigating and adapting care integrating immunotherapy, antiangiogenic therapy, and combinations in patients with advanced renal cell carcinoma. , 2023, 11, e006361.		1
1628	Secondary Neoplasms. , 2023, , 493-506.		0
1629	A New Signature That Predicts Progression-Free Survival of Clear Cell Renal Cell Carcinoma with Anti-PD-1 Therapy. International Journal of Molecular Sciences, 2023, 24, 5332.	4.1	1
1630	Advanced CT Imaging, Radiomics, and Artificial Intelligence to Evaluate Immune Checkpoint Inhibitors' Effects on Metastatic Renal Cell Carcinoma. Applied Sciences (Switzerland), 2023, 13, 3779.	2.5	1
1631	Expression of RSUME is Associated With Poor Prognosis in Clear Cell Renal Carcinoma: Involvement of ROS Related Metabolism. Clinical Genitourinary Cancer, 2023, 21, 393-402.e5.	1.9	0
1632	Impact of sex on prognosis in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitors. Japanese Journal of Clinical Oncology, 0, , .	1.3	0

#	Article	IF	CITATIONS
1633	Tailoring treatment with cabozantinib or pazopanib in patients with metastatic renal cell carcinoma: does it affect outcome?. Expert Review of Anticancer Therapy, 2023, 23, 545-554.	2.4	1
1634	Pembrolizumab plus lenvatinib for radically unresectable or metastatic renal cell carcinoma in the Japanese population. Expert Review of Anticancer Therapy, 2023, 23, 461-469.	2.4	1
1635	Cytoreductive Nephrectomy and Metastatic Renal Cell Carcinoma: State of the Art and Future Perspectives. Medicina (Lithuania), 2023, 59, 767.	2.0	7
1636	Update on combined immunotherapy for the treatment of advanced renal cell carcinoma. Human Vaccines and Immunotherapeutics, 2023, 19, .	3.3	4
1637	Hemoglobin and neutrophil levels stratified according to International Metastatic Renal Cell Carcinoma Database Consortium risk predict the effectiveness of ipilimumab plus nivolumab in patients with advanced metastatic renal cell carcinoma. International Journal of Urology, 2023, 30, 754-761.	1.0	1
1638	Triplet Strategies in Metastatic Clear Cell Renal Cell Carcinoma: A Worthy Option in the First-Line Setting?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2023, , .	3.8	2
1639	Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma. ESMO Open, 2023, 8, 101210.	4.5	11
1640	Realâ€world effectiveness of nivolumab and subsequent therapy in Japanese patients with metastatic renal cell carcinoma (POSTâ€NIVO study): 36â€month followâ€up results of a clinical chart review. International Journal of Urology, 2023, 30, 762-771.	1.0	0
1641	Nieren- und Harnwegstumore. , 2023, , 163-169.		0
1642	Prognostic Models in Metastatic Renal Cell Carcinoma. Hematology/Oncology Clinics of North America, 2023, , .	2.2	0
1643	A U.S. Food and Drug Administration–pooled Analysis of Frontline Combination Treatment Survival Benefits by Risk Groups in Metastatic Renal Cell Carcinoma. European Urology, 2023, 84, 373-378.	1.9	2
1644	The role of radiation therapy for de novo metastatic bladder and renal cancers. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2024, 28, 56-65.	1.4	0
1645	Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma. Cancer Immunology Research, 2023, 11, 1114-1124.	3.4	5
1646	Are markers of survival associated with perioperative outcomes for tumor thrombectomy patients?. Urologic Oncology: Seminars and Original Investigations, 2023, 41, 358.e17-358.e24.	1.6	0
1647	Prognostic impact of the radiological infiltrative feature of primary renal tumor in metastatic renal cell carcinoma. International Journal of Urology, 0, , .	1.0	0
1648	Efficacy and safety of pembrolizumab and axitinib as firstâ€line treatment for patients with advanced renal cell carcinoma: Realâ€world experience in Japan. International Journal of Urology, 2023, 30, 772-777.	1.0	2
1649	The 5-item frailty index predicts 30-day morbidity and mortality in radical nephrectomy patients: A propensity matched analysis. Urologic Oncology: Seminars and Original Investigations, 2023, 41, 329.e1-329.e7.	1.6	0
1650	Clinical significance of prognostic nutritional index (PNI)-monocyte-to-lymphocyte ratio (MLR)-platelet (PLT) score on postoperative outcomes in non-metastatic clear cell renal cell carcinoma. BMC Surgery, 2023, 23, .	1.3	2

#	Article	IF	CITATIONS
1651	The impact of nutritional status and changes of body composition on the prognosis of metastatic renal cell carcinoma patients. Journal of Medical Investigation, 2023, 70, 80-87.	0.5	2
1652	Efficacy and Safety of First-Line Cytokines Versus Sunitinib and Second-Line Axitinib for Patients with Metastatic Renal Cell Carcinoma (ESCAPE Study): A Phase III, Randomized, Sequential Open-Label Study. Cancers, 2023, 15, 2745.	3.7	0
1653	Gut and urinary microbiota: the causes and potential treatment measures of renal cell carcinoma. Frontiers in Immunology, 0, 14, .	4.8	1
1655	Evaluation of the role of inflammatory blood markers in predicting the pathological response after neoadjuvant chemoradiation in patients with locally advanced rectal cancer. Radiation Oncology Journal, 2023, 41, 81-88.	1.5	0
1656	A review of the clinical experience with CMN-001, a tumor RNA loaded dendritic cell immunotherapy for the treatment of metastatic renal cell carcinoma. Human Vaccines and Immunotherapeutics, 2023, 19, .	3.3	0
1657	Computational textural mapping harmonises sampling variation and reveals multidimensional histopathological fingerprints. British Journal of Cancer, 2023, 129, 683-695.	6.4	2
1658	A CT-based deep learning radiomics nomogram outperforms the existing prognostic models for outcome prediction in clear cell renal cell carcinoma: a multicenter study. European Radiology, 2023, 33, 8858-8868.	4.5	4
1659	First-line ICIs in renal cell carcinoma. Human Vaccines and Immunotherapeutics, 2023, 19, .	3.3	1
1660	Understanding and integrating cytoreductive nephrectomy with immune checkpoint inhibitors in the management of metastatic RCC. Nature Reviews Urology, 2023, 20, 654-668.	3.8	2
1661	Extracellular vesicles in renal cell carcinoma: challenges and opportunities coexist. Frontiers in Immunology, 0, 14, .	4.8	1
1663	Challenges in conducting fractional polynomial and standard parametric network meta-analyses of immune checkpoint inhibitors for first-line advanced renal cell carcinoma. Journal of Comparative Effectiveness Research, 2023, 12, .	1.4	1
1664	The Selection for Cytoreductive Nephrectomy (SCREEN) Score: Improving Surgical Risk Stratification by Integrating Common Radiographic Features. European Urology Oncology, 2023, , .	5.4	5
1665	Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial. Lancet Oncology, The, 2023, 24, 881-891.	10.7	17
1666	Sarcopenia assessments as predictors of overall survival in patients with metastatic renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2023, , .	1.6	0
1667	Comprehensive investigation of clinicopathological and immunological features to determine prognostic impact in metastatic renal cell carcinoma: The <scp>JEWEL</scp> study. International Journal of Urology, 0, , .	1.0	0
1668	Optimizing Treatment Selection in Advanced Renal Cell Carcinoma via IMDC Risk Group Stratification. European Urology, 2023, , .	1.9	0
1669	Proteogenomics of clear cell renal cell carcinoma response to tyrosine kinase inhibitor. Nature Communications, 2023, 14, .	12.8	3
1670	Tyrosine kinase and immune checkpoints inhibitors in favorable risk metastatic renal cell carcinoma: Trick or treat?. , 2023, 249, 108499.		2

#	Article	IF	CITATIONS
1671	Analysis of the effect of clinical and laboratory parameters on survival in patients with metastatic renal cell cancer with intermediate prognosis according to IMDC (International mRCC Database) Tj ETQq0 0 0 i	gBTøØverl	ock010 Tf 50 7
1672	Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?. European Urology Oncology. 2024, 7, 102-111.	5.4	5
1673	Second-Line Treatment of Metastatic Renal Cell Carcinoma in the Era of Predictive Biomarkers. Diagnostics, 2023, 13, 2430.	2.6	2
1674	The role of mean corpuscular volume and red cell distribution width in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: the MARECAP retrospective study. Therapeutic Advances in Urology, 2023, 15, .	2.0	4
1675	Medikamentöse Therapie des metastasierten Nierenzellkarzinoms. Springer Reference Medizin, 2023, , 551-559.	0.0	0
1676	Prognostic value of preoperative microscopic hematuria in patients with non-metastatic renal cell carcinoma who underwent nephrectomy. Journal of Cancer Research and Clinical Oncology, 0, , .	2.5	Ο
1678	Case–control study assessing the impact of COVID19 in advanced kidney cancer patients treated with antiangiogenics or immunotherapy: the COVID-REN study. Clinical and Translational Oncology, 2024, 26, 732-738.	2.4	1
1679	SEOM SOGUG clinical guideline for treatment of kidney cancer (2022). Clinical and Translational Oncology, 2023, 25, 2732-2748.	2.4	1
1680	Adult genitourinary cancer: Renal and testicular. , 2024, , 635-670.e2.		0

1681	Advanced Non-Clear Cell Renal Cell Carcinoma Treatments and Survival: A Real-World Single-Centre Experience. Cancers, 2023, 15, 4353.	3.7	1
1682	Clinical factors for tumor response, progression, and survival in nivolumab for advanced renal cell carcinoma in the SNiPâ€RCC study. International Journal of Urology, 2023, 30, 788-796.	1.0	1
1683	Preoperative prognostic model for localized and locally advanced renal cell carcinoma: Michinoku Japan Urological Cancer Study Group. International Journal of Clinical Oncology, 2023, 28, 1538-1544.	2.2	0
1684	A Neurosurgical Perspective on Brain Metastases from Renal Cell Carcinoma: Multi-Institutional, Retrospective Analysis. Biomedicines, 2023, 11, 2485.	3.2	1
1685	PNI as a Potential Add-On Biomarker to Improve the IMDC Intermediate Prognostic Score. Journal of Clinical Medicine, 2023, 12, 6420.	2.4	0
1686	Sunitinib in the treatment of advanced renal cell carcinoma. Meditsinskiy Sovet, 2023, , 178-182.	0.5	0

1687	Primary and acquired resistance to first-line therapy for clear cell renal cell carcinoma. Cancer Drug Resistance (Alhambra, Calif), 0, , 517-46.	2.1	3
1688	Characterization of papillary and clear cell renal cell carcinoma through imaging mass cytometry reveals distinct immunologic profiles. Frontiers in Immunology, 0, 14, .	4.8	0
1690	Contemporary Patients Have Better Perioperative Outcomes Following Cytoreductive Nephrectomy: A Multi-institutional Analysis of 1272 Consecutive Patients. Urology, 2023,	1.0	0

#	Article	IF	CITATIONS
1691	Assessing the prognostic value of IMDC risk score for nivolumab-treated patients with renal cancer and malignant melanoma. Cancer Biomarkers, 2023, , 1-11.	1.7	0
1692	Survival of patients with clear cell renal carcinoma according to number and location of organ-specific metastatic sites. Urologic Oncology: Seminars and Original Investigations, 2024, 42, 22.e23-22.e31.	1.6	0
1693	Prognostic Impact of Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab: A Multicenter Retrospective Study. Clinical Genitourinary Cancer, 2024, 22, 76-83.	1.9	1
1694	Efficacy and safety of axitinib for metastatic renal cell carcinoma: Real-world data on patients with renal impairment. Urologic Oncology: Seminars and Original Investigations, 2023, 41, 458.e9-458.e19.	1.6	0
1695	Prognostic Stratification by the Meet-URO Score in Real-World Older Patients With Metastatic Renal Cell Carcinoma (mRCC) Receiving Cabozantinib: A Subanalysis of the Prospective ZEBRA Study (Meet-URO 9). Clinical Genitourinary Cancer, 2024, 22, 126-133.e2.	1.9	0
1696	Management of Metastatic Renal Cell Carcinoma. , 2023, , 41-52.		0
1698	Immunotherapy in renal cell carcinoma. Lancet Oncology, The, 2023, , .	10.7	0
1699	Clinical Study of Peripheral Blood Inflammatory Indicators in Triple-Negative Breast Cancer after Neoadjuvant Chemotherapy. Advances in Clinical Medicine, 2023, 13, 16223-16230.	0.0	0
1700	転移性èŽç™Œã«å⁻¾ã⊷ã┥Pembrolizumab+Axitinibã,'投ä,Žå¾Œã«éţè¦−ä,‹èŽéƒ¨å^†å^‡é™₿,'æ−½è¡(Eã i ¼Œ0	CRã,'ç¶æŒã
1701	Efficacy of avelumab plus axitinib versus sunitinib by numbers of IMDC risk factors and target tumor sites at baseline in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101. ESMO Open, 2023, 8, 102034.	4.5	0
1702	Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study. Annals of Oncology, 2024, 35, 190-199.	1.2	3
1703	Cine magnetic resonance imaging predicts thrombus adhesion in metastatic renal cell carcinoma with an inferior vena cava tumor thrombus: A case of pathological complete response with pembrolizumab plus lenvatinib. IJU Case Reports, 2024, 7, 60-63.	0.3	0
1704	Special Issue Editorial: Emerging Therapies in Renal Cell Carcinoma: The Road to a Cure?. Cancers, 2023, 15, 5262.	3.7	0
1705	Observational study on the evolution of systemic treatments for advanced renal cell carcinoma in Southwest Finland between 2010 and 2021. Therapeutic Advances in Urology, 2023, 15, .	2.0	0
1706	Impact of healthcare inequities on survival in Mexican patients with metastatic renal cell carcinoma. Frontiers in Oncology, 0, 13, .	2.8	0

1709	Management of Renal Cell Carcinoma with IVC Thrombus, Nodal Involvement, and T4 Disease. , 2023, , 143-181.	0

1710 Prognostic Factors in Advanced Renal Cell Carcinoma. , 2023, , 233-250.

1711	First-Line S	ystemic Treatment O	ptions for Advanced	Renal Cell Carcinoma,	, 2023, , 269-292.
------	--------------	---------------------	---------------------	-----------------------	--------------------

#	Article	IF	CITATIONS
1713	Detection of factors related to treatment reduction in docetaxel and ramucirumab for non-small cell lung cancer treatment. Scientific Reports, 2023, 13, .	3.3	0
1715	Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM). Journal of Clinical Oncology, 0, , .	1.6	0
1716	Trends of Utilization of Systemic Therapies for Metastatic Renal Cell Carcinoma in the Canadian Health Care System. JCO Global Oncology, 2023, , .	1.8	0
1718	Predicting recurrence and survival in patients with non-metastatic renal-cell carcinoma after nephrectomy: a prospective population-based study with multicenter validation. International Journal of Surgery, 2024, 110, 820-831.	2.7	0
1720	Neutrophil extracellular traps in relationship to efficacy of systemic therapy for metastatic renal cell carcinoma. Cancer Medicine, 0, , .	2.8	0
1721	Association between time from diagnosis to initiation of systemic therapy of metastatic renal cell carcinoma with treatment outcome. Medicinski Podmladak, 2023, 74, 64-68.	0.0	0
1722	Combination therapies in patients with favorable risk metastatic renal cell Carcinoma: A Systematic Review and Meta-Analysis. Cancer Treatment Reviews, 2024, 122, 102667.	7.7	1
1723	LITESPARK-012: pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab for advanced renal cell carcinoma. Future Oncology, 2023, 19, 2631-2640.	2.4	0
1724	Characterization of Patients with Metastatic Renal Cell Carcinoma Undergoing Deferred, Upfront, or No Cytoreductive Nephrectomy in the Era of Combination Immunotherapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. European Urology Oncology, 2023,	5.4	1
1725	Predictive and prognostic biomarkers in urological tumours. Pathology, 2024, 56, 228-238.	0.6	1
1726	Current status and future perspective of immunotherapy for renal cell carcinoma. International Journal of Clinical Oncology, 0, , .	2.2	0
1727	The plateletâ€toâ€lymphocyte ratio is a complementary prognostic factor to tumor markers in predicting early recurrence of hepatocellular carcinoma after hepatectomy. Journal of Surgical Oncology, 2024, 129, 765-774.	1.7	0
1728	Risk–benefit trade-offs and precision utilities in phase I-II clinical trials. Clinical Trials, 0, , .	1.6	0
1729	The Effect of Treatment Intensification on Other-Cause Mortality in Clear-Cell Metastatic Renal Cell Carcinoma Patients. Clinical Genitourinary Cancer, 2024, 22, 420-425.	1.9	0
1730	Treatment Landscape of Renal Cell Carcinoma. Current Treatment Options in Oncology, 0, , .	3.0	0
1731	Novel voice of targeted therapy combination with immunotherapy for advanced renal cell carcinoma from China. Chinese Science Bulletin, 2024, 69, 968-970.	0.7	Ο
1732	Anemia in patients ≥ 75 years with metastatic clear cell renal cell carcinoma: an important poor prognostic factor in the international metastatic renal cell carcinoma database consortium model. BMC Urology, 2024, 24, .	1.4	0
1733	Navigating the ICI Combination Treatment Journey: Patterns of Response and Progression to First-Line ICI-Based Combination Treatment in Metastatic Renal Cell Carcinoma. Journal of Clinical Medicine, 2024, 13, 307.	2.4	0

#	Article	IF	CITATIONS
1734	Understanding Factors that Influence Prognosis and Response to Therapy in Clear Cell Renal Cell Carcinoma. Advances in Anatomic Pathology, 2024, 31, 96-104.	4.3	0
1735	Prognostic value of immunological components of tumor microenvironment of oncourological tumors. Urologicheskie Vedomosti, 2024, 13, 323-337.	0.3	0
1736	Beyond the knife: strategic patient selection for cytoreductive nephrectomy. Current Opinion in Urology, 2024, 34, 210-216.	1.8	0
1737	A promising natural killer cell-based model and a nomogram for the prognostic prediction of clear-cell renal cell carcinoma. European Journal of Medical Research, 2024, 29, .	2.2	0
1738	Adverse Events of Cabozantinib as a Potential Prognostic Factor in Metastatic Renal Cell Carcinoma Patients: Real-World Experience in a Single-Center Retrospective Study. Biomedicines, 2024, 12, 413.	3.2	0
1739	Linear Muscle Segmentation for Metastatic Renal Cell Carcinoma: Changes in Clinic-Friendly Estimation Predict Survival Following Cytoreductive Nephrectomy. Clinical Genitourinary Cancer, 2024, , 102056.	1.9	0
1740	External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations. Clinical and Experimental Metastasis, 2024, 41, 117-129.	3.3	0
1741	Analysis of Factors Contributing to Adverse Events and Evaluation of Their Impact on Prognosis in Metastatic Renal Cell Carcinoma Patients—Real-World Experience in a Single-Center Retrospective Study and Narrative Review. Medicina (Lithuania), 2024, 60, 398.	2.0	0
1743	The incidence, pathogenesis, and management of non-clear cell renal cell carcinoma. Therapeutic Advances in Urology, 2024, 16, .	2.0	0
1744	RENO Study: Clinical characteristics, treatment patterns and survival results in patients with metastatic renal cell carcinoma in Northern Spain. Seminars in Oncology, 2024, , .	2.2	0
1745	The impact of metastasectomy on survival of patients with synchronous metastatic renal cell cancer in Finland: A nationwide study. Scandinavian Journal of Surgery, 0, , .	2.6	0
1746	NLR Outperforms Low Hemoglobin and High Platelet Count as Predictive and Prognostic Biomarker in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. Clinical Genitourinary Cancer, 2024, 22, 102072.	1.9	0
1748	Association of lung immune prognostic index with survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab. Japanese Journal of Clinical Oncology, 0, , .	1.3	0
1749	Real-world patterns of treatment and response in metastatic renal cell carcinoma: a multicentre UK-wide review with UK Renal Oncology Collaborative (UK ROC). , 2024, 3, 100027.		0
1750	Management of treatment-related adverse effects in renal cell carcinoma. Urologie Pro Praxi, 2024, 25, 32-37.	0.1	0